Methods, compositions and components for CRISPR-CAS9 editing of TGFBR2 in T cells for immunotherapy

Editing the TGFBR2 gene in T cells through CRISPR/Cas9 technology solves the problem of TGF-β inhibiting T cell function, improves the response stability and T cell function of immunotherapy, and achieves effective resistance to TGF-β.

CN111527209BActive Publication Date: 2024-11-12EDITAS MEDICINE INC +1
View PDF 43 Cites 0 Cited by

Patent Information

Application Number
CN201880084188.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-11-01
Filing Date
2018-11-01
Publication Date
2024-11-12
Estimated Expiration
2039-01-17

AI Technical Summary

Technical Problem

The prior art is difficult to effectively solve the problem that TGF-β inhibits T cell function through TGFBR2, resulting in unstable response of immunotherapy in solid tumor patients and lacks effective strategies to reduce or eliminate the inhibitory effect of TGF-β on T cells.

Method used

Using the CRISPR/Cas9 genome editing system, the targeted editing of the TGFBR2 gene is induced by RNA-guided nucleases to change the expression of TGFBR2, for example, inducing downregulation of TGFBR2 in T cells through RNP complexes, resulting in altered TGFBR2 expression, including knockout Or knock down.

Benefits of technology

Through the changes in TGFBR2 expression, the lytic activity of T cells on target cancer cells is enhanced, the response stability and efficiency of immunotherapy is improved, the proliferation and survival ability of T cells are improved, and the inhibitory effect of TGF-β is reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002556467540000171
    Figure BDA0002556467540000171
  • Figure BDA0002556467540000251
    Figure BDA0002556467540000251
  • Figure BDA0002556467540000261
    Figure BDA0002556467540000261
Patent Text Reader

Abstract

Provided are CRISPR / CAS-associated genome editing systems, compositions and methods for targeting the TGFBR2 locus, and cells edited using these systems, compositions and methods.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 580,320, filed November 1, 2017, which is incorporated herein by reference in its entirety. Technical Field

[0003] The present disclosure relates to CRISPR / Cas9-related methods and components for editing a target nucleic acid sequence (e.g., the transforming growth factor beta receptor II (TGFBR2) gene) or modulating the expression of a target nucleic acid sequence (e.g., the TGFBR2 gene). Background Art

[0004] Adoptive T cell transfer using genetically modified T cells has entered clinical testing as a treatment method for solid and hematological malignancies. In Phase I and II trials involving hematological malignancies (e.g., lymphomas, chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL), many patients showed at least partial responses, and some showed complete responses (Kochenderfer, JN et al., 2012 Blood 119, 2709-2720). However, the responses observed in solid tumor types (including melanoma, renal cell carcinoma, and colorectal cancer) are not always so stable (Johnson, LA et al., 2009 Blood 114, 535-546; Lamers, CH et al., 2013 Mol. Ther. 21, 904-912; Warren, RS et al., 1998 Cancer Gene Ther. 5, S1-S2).

[0005] Although not wishing to be bound by any particular theory, the efficacy of adoptive T cell therapy in patients with solid tumors may be affected by a variety of factors, such as: (1) T cell proliferation, such as limited proliferation of T cells after adoptive transfer; (2) T cell survival, such as induction of T cell apoptosis by factors in the environment of target cells (e.g., cancer cells); and (3) T cell function, such as inhibition of cytotoxic T cell function by inhibitory factors secreted by host immune cells and target cells (e.g., cancer cells). These factors, in turn, may be affected by the activity of transforming growth factor β (TGF-β), which is a cytokine produced by a variety of tumor types that has been shown to directly inhibit tumor infiltrating lymphocytes and to induce and promote the function of regulatory T cells (Tregs) that can prevent anti-tumor immunity.

[0006] TGFBR2 is a receptor for TGF-β, which is expressed on a large number of cell types (including immune cells). It has been shown that TGF-β is bound by TGFBR2 and down-regulates T cell activation, proliferation and differentiation. Since severe autoimmune phenotypes are observed in mice containing T cells engineered to conditionally lack TGFBR2, the lack of preclinical mouse models has complicated the development of TGFBR2 inhibitors that can improve TGFBR2 activity on tumor-reactive T cells. Therefore, there is a need for effective strategies that can reduce or eliminate the inhibitory effects of TGF-β on T cells, including in the context of T cell-mediated immunotherapy.

[0007] CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) evolved as an adaptive immune system in bacteria and archaea to defend against viral attacks. Once exposed to a virus, a short segment of viral DNA is integrated into the CRISPR locus. RNA is transcribed from a portion of the CRISPR locus containing the viral sequence. RNA containing a sequence complementary to the viral genome mediates RNA-guided nucleases targeting target sequences in the viral genome. RNA-guided nucleases in turn cut the viral target and thus silence the viral target.

[0008] Recently, the CRISPR / Cas9 system has been adapted for genome editing in eukaryotic cells. The introduction of site-specific double-strand breaks (DSBs) allows the target sequence to be altered by endogenous DNA repair mechanisms such as non-homologous end joining (NHEJ) or homology-directed repair (HDR). CRISPR / Cas9 represents a promising approach to address TGF-β-mediated T cell suppression in the context of tumor therapy, but to date, no viable solution to this problem has been identified in T cells for tumor therapy. Summary of the invention

[0009] In some aspects, the genome editing system and related compositions and methods for the targeted editing of the nucleotide sequence for TGFBR2 are provided herein. In certain embodiments, this targeted editing causes a change (e.g., downward regulation) of TGFBR2 expression. In certain embodiments, this expression change occurs in T cells. In certain embodiments, the change in TGFBR2 expression in T cells relates to the use of ribonucleoprotein (RNP) complex as a genome editing system, and the genome editing system includes the nuclease protein guided by the RNA compounded with the gRNA of the TGFBR2 gene targeted. In certain embodiments, due to the double-strand break induced by the RNP and the subsequent imperfect repair and the change of TGFBR2 expression, the subsequent imperfect repair causes the insertion and deletion (indel) at the TGFBR2 sequence of the targeting and / or the vicinity.

[0010] In certain embodiments, the disclosure relates to a genome editing system comprising a guide RNA having a targeting domain complementary to a target sequence of a TGFBR2 gene, and wherein the RNA-guided nuclease is a Cas9 nuclease. The targeting domain can be 70%, 80%, 85%, 90%, 95% or 100% complementary.

[0011] In certain embodiments, the targeting domain is 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleotides in length.

[0012] In certain embodiments, the targeting domain has at least 18 contiguous nucleotides that are complementary to the TGFBR2 gene.

[0013] In certain embodiments, the targeting domain comprises a nucleotide sequence that is identical to or differs by no more than 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096. In certain embodiments, the targeting domain is configured to form a double-strand break or a single-strand break within about 500 bp, about 450 bp, about 400 bp, about 350 bp, about 300 bp, about 250 bp, about 200 bp, about 150 bp, about 100 bp, about 50 bp, about 25 bp, or about 10 bp of the TGFBR2 target position.

[0014] In certain embodiments disclosed herein, the genome editing system is capable of altering the TGFBR2 gene by knocking out the expression of the TGFBR2 gene or knocking down the expression of the TGFBR2 gene.

[0015] In certain embodiments, the genome editing system disclosed herein incorporates a gRNA comprising a targeting domain, which is configured to target the coding region or non-coding region of the TGFBR2 gene, wherein the non-coding region comprises a promoter region, an enhancer region, an intron, a 3'UTR, a 5'UTR or a polyadenylation signal region of the TGFBR2 gene; and the coding region comprises, for example, an early coding region of the TGFBR2 gene.

[0016] In certain embodiments, the genome editing system disclosed herein has a target sequence of the TGFBR2 gene, and the target sequence of the TGFBR2 gene comprises a sequence selected from SEQ ID NO: 1, 2 and 3.

[0017] In certain embodiments, the genome editing system disclosed herein has a target sequence of the TGFBR2 gene, and the target sequence of the TGFBR2 gene comprises a sequence selected from SEQ ID NOs: 4 to 10.

[0018] In certain embodiments, the genome editing system disclosed herein incorporates a targeting domain comprising a nucleotide sequence that is identical to or differs by no more than 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096. In certain embodiments, the targeting domain comprises a nucleotide sequence that is identical to or differs by no more than 3 nucleotides from a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO: 5041; (b) SEQ ID NO: 5042; (c) SEQ ID NO: 5047; (d) SEQ ID NO: 5050; (e) SEQ ID NO: 5052; (f) SEQ ID NO: 5092; and (g) SEQ ID NO: 5093. In certain embodiments, the genome editing system incorporates a gRNA molecule pair, including, for example, a gRNA pair having a target sequence of SEQ ID NOs: 5042 and 5041, or 5042 and 5092, or SEQ ID NOs: 5042 and 5093, or SEQ ID NOs: 5093 and 5041.

[0019] In certain embodiments, the present disclosure relates to a composition comprising a gRNA molecule comprising a targeting domain complementary to a target sequence of a TGFBR2 gene. In certain embodiments, the composition comprises one, two, three or four gRNA molecules. In certain embodiments, the composition further comprises an RNA-guided nuclease, such as a Cas9 molecule. In certain embodiments, the targeting domain incorporated into such a composition comprises a nucleotide sequence that is identical to or differs from a nucleotide sequence selected from SEQ ID NO: 5036 to 5096 by no more than 3 nucleotides. In certain embodiments, the targeting domain comprises a nucleotide sequence that is identical to or differs from a nucleotide sequence selected from the following by no more than 3 nucleotides: (a) SEQ ID NO: 5041; (b) SEQ ID NO: 5042; (c) SEQ ID NO: 5047; (d) SEQ ID NO: 5050; (e) SEQ ID NO: 5052; (f) SEQ ID NO: 5092; and (g) SEQ ID NO: 5093. In certain embodiments, the composition incorporates a pair of gRNA molecules, including, for example, a pair of gRNA molecules having target sequences SEQ ID NO: 5042 and 5041, or 5042 and 5092, or SEQ ID NO: 5042 and 5093, or SEQ ID NO: 5093 and 5041.

[0020] In certain embodiments, the disclosure relates to a vector encoding a gRNA molecule comprising a targeting domain complementary to a target sequence of a TGFBR2 gene. In certain embodiments, the vector further encodes an RNA-guided nuclease, such as a Cas9 molecule. In certain embodiments, the targeting domain of the gRNA encoded by the vector comprises a nucleotide sequence that is identical to or differs by no more than 3 nucleotides from a nucleotide sequence selected from SEQ ID NO: 5036 to 5096. In certain embodiments, the targeting domain comprises a nucleotide sequence that is identical to or differs by no more than 3 nucleotides from a nucleotide sequence selected from the following: (a) SEQ ID NO: 5041; (b) SEQ ID NO: 5042; (c) SEQ ID NO: 5047; (d) SEQ ID NO: 5050; (e) SEQ ID NO: 5052; (f) SEQ ID NO: 5092; and (g) SEQ ID NO: 5093. In certain embodiments, the vector is a viral vector. In certain embodiments, the vector is an adeno-associated virus (AAV) vector or a lentivirus (LV) vector.

[0021] In certain embodiments, the present disclosure relates to a method for altering a TGFBR2 gene in a cell, the method comprising administering to the cell one of: (i) a genome editing system comprising a gRNA molecule and a Cas9 molecule, the gRNA molecule comprising a targeting domain complementary to a target sequence of the TGFBR2 gene; (ii) a vector comprising a polynucleotide encoding a gRNA molecule and a polynucleotide encoding a Cas9 molecule, the gRNA molecule comprising a targeting domain complementary to a target sequence of the TGFBR2 gene; or (iii) a composition comprising a gRNA molecule and a Cas9 molecule, the gRNA molecule comprising a targeting domain complementary to a target sequence of the TGFBR2 gene.

[0022] In certain embodiments, the disclosure relates to cells comprising a genome editing system as described herein, a gRNA composition as described herein, or a vector as described herein. In certain embodiments, the cell expresses TGFBR2. In certain embodiments, the cell is a T cell.

[0023] In certain embodiments, the disclosure relates to a ribonucleoprotein (RNP) complex comprising a gRNA and an RNA-guided nuclease.

[0024] In certain embodiments, the disclosure relates to administering to a cell two or more RNP complexes comprising gRNAs with different targeting domains.

[0025] In certain embodiments, the present disclosure relates to RNP complexes comprising an enzymatically active Cas9 (eaCas9) nuclease.

[0026] In certain embodiments, the disclosure relates to an RNP complex comprising an eaCas9 nuclease that forms a double-strand break in a target nucleic acid or a single-strand break in a target nucleic acid.

[0027] In certain embodiments, the present disclosure relates to two RNP complexes comprising different gRNAs for forming offset single-strand breaks in a TGFBR2 gene in a cell.

[0028] In certain embodiments, the disclosure relates to a cell, which is a T cell or a natural killer (NK) cell. In certain embodiments, the cell further comprises an engineered T cell receptor (eTCR) or a chimeric antigen receptor (CAR).

[0029] In certain embodiments, the disclosure relates to a method for RNA-guided nuclease-mediated alteration of TGFBR2 gene expression in a cell, the method comprising: a) contacting the cell with a sufficient amount of a gRNA targeting TGFBR2 and an RNA-guided nuclease; and b) forming a first DNA double-strand break near a TGFBR2 target position in the TGFBR2 gene of the cell, wherein the first DNA double-strand break is repaired by NHEJ, wherein the repair alters the expression of the TGFBR2 gene.

[0030] In certain embodiments, the disclosure relates to forming a second DNA double-strand break near the TGFBR2 target position. In certain embodiments, the first double-strand break is formed within about 500bp, about 450bp, about 400bp, about 350bp, about 300bp, about 250bp, about 200bp, about 150bp, about 100bp, about 50bp, about 25bp, or about 10bp of the TGFBR2 target position. In certain embodiments, the first and second double-strand breaks are formed within about 500bp, about 450bp, about 400bp, about 350bp, about 300bp, about 250bp, about 200bp, about 150bp, about 100bp, about 50bp, about 25bp, or about 10bp of the TGFBR2 target position. In certain embodiments, the first double-strand break is formed in the coding region or non-coding region of the TGFBR2 gene, wherein the non-coding region comprises a promoter region, an enhancer region, an intron, a 3'UTR, a 5'UTR, or a polyadenylation signal region of the TGFBR2 gene. In certain embodiments, the first and second double-strand breaks are formed in the coding region or non-coding region of the TGFBR2 gene, wherein the non-coding region comprises a promoter region, an enhancer region, an intron, a 3'UTR, a 5'UTR, or a polyadenylation signal region of the TGFBR2 gene.

[0031] In certain embodiments, the coding region is selected from exon 3, exon 4, and exon 5.

[0032] In certain embodiments, the targeting domain comprises a nucleotide sequence that is identical to or differs by no more than about 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096.

[0033] In certain embodiments, the RNA-guided nuclease is a Streptococcus pyogenes Cas9 nuclease, and the targeting domain comprises a nucleotide sequence that is identical to, or differs by no more than about 3 nucleotides from, a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO: 5041; (b) SEQ ID NO: 5042; (c) SEQ ID NO: 5047; (d) SEQ ID NO: 5050; (e) SEQ ID NO: 5052; (f) SEQ ID NO: 5092; and (g) SEQ ID NO: 5093.

[0034] In certain embodiments, the RNA-guided nuclease is Staphylococcus aureus (S. aureus) Cas9 nuclease.

[0035] In certain embodiments, the RNA-guided nuclease is a mutant Cas9 nuclease.

[0036] In certain embodiments, the NHEJ repair produces an indel with a frequency greater than or equal to 20%.

[0037] In certain embodiments, the insertion or deletion frequency is greater than or equal to 30%, 40% or 50%.

[0038] In certain embodiments, the disclosure relates to a genomically engineered cell comprising an insertion or deletion at or near a target position of the TGFBR2 gene, wherein the target position comprises a nucleotide sequence that is complementary to or differs by no more than about 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096.

[0039] In certain embodiments, the insertion or deletion is within about 500bp, about 450bp, about 400bp, about 350bp, about 300bp, about 250bp, about 200bp, about 150bp, about 100bp, about 50bp, about 25bp, or about 10bp of the TGFBR2 target position.

[0040] In certain embodiments, the cell is a T cell or a NK cell. In certain embodiments, the cell further comprises an eTCR or a CAR.

[0041] In certain embodiments, the present disclosure relates to a composition comprising: a) a population of genomically engineered cells containing an insertion or deletion at or near a target location of a TGFBR2 gene, wherein the target location comprises a nucleotide sequence that is complementary to or differs by no more than about 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096; and b) a pharmaceutically acceptable buffer.

[0042] In certain embodiments, the cell colony comprises T cells or NK cells. In certain embodiments, the cell further comprises eTCR or CAR.

[0043] In certain embodiments, the disclosure relates to a method of treating cancer in a subject, comprising administering to the subject an engineered immune cell, wherein the engineered immune cell has reduced expression of TGFBR2 and optionally expresses an engineered T cell receptor (eTCR) or a chimeric antigen receptor (CAR), wherein the engineered immune cell has an insertion or deletion at or near a target location of the TGFBR2 gene.

[0044] In certain embodiments, the engineered immune cells include T cells or NK cells. In certain embodiments, the cells further include eTCR or CAR.

[0045] In certain embodiments, the cancer is selected from the group consisting of: leukemia, lymphoma such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, refractory follicular lymphoma, mantle cell lymphoma, indolent B-cell lymphoma, B-cell malignancies, colon cancer, lung cancer, liver cancer, breast cancer, prostate cancer, ovarian cancer, skin cancer, melanoma, bone cancer and brain cancer, ovarian cancer, epithelial cancer, renal cell carcinoma, pancreatic adenocarcinoma, Hodgkin's lymphoma, cervical cancer, colorectal cancer, glioblastoma, neuroblastoma, Ewing's sarcoma, medulloblastoma, osteosarcoma, synovial sarcoma, mesothelioma and / or any cancer type expressing TGF-β.

[0046] In certain embodiments, the T cells are CD4+ and / or CD8+ T cells.

[0047] In certain embodiments, the engineered immune cells maintain or have enhanced lytic activity against target cancer cells relative to non-engineered immune cells.

[0048] In certain embodiments, the engineered immune cells maintain or have increased expression of granzyme B and / or interferon gamma relative to non-engineered immune cells in the presence of TGFβ.

[0049] In certain embodiments, the engineered immune cells maintain or have improved persistence in response to repeated antigenic stimulation relative to non-engineered immune cells.

[0050] In certain embodiments, the engineered immune cells maintain or have increased expression of CD25 relative to non-engineered immune cells.

[0051] In certain embodiments, the engineered immune cells maintain or have reduced expression of PD-1 relative to non-engineered immune cells.

[0052] In certain embodiments, the engineered immune cells maintain or have increased proliferation relative to non-engineered immune cells.

[0053] In certain embodiments, the disclosure relates to a composition comprising a plurality of engineered T cells, wherein the engineered T cells exhibit reduced expression of the TGFBR2 gene relative to non-engineered T cells.

[0054] In certain embodiments, the engineered T cells exhibit a TGFBR2 gene expression level that is about 50%, about 40%, about 30%, about 20%, about 10%, or about 5% of the TGFBR2 expression level in non-engineered T cells.

[0055] In certain embodiments, the engineered T cells further comprise expression of an eTCR or CAR.

[0056] In certain embodiments, the T cells are CD4+ T cells and / or CD8+ T cells.

[0057] In certain embodiments, the engineered T cells are further characterized by having: a) enhanced lytic activity against target cancer cells relative to non-engineered T cells; b) maintained or increased expression of granzyme B and / or interferon γ relative to non-engineered T cells in the presence of TGFβ; c) maintained or increased persistence against repeated antigenic stimulation relative to non-engineered T cells; d) maintained or increased expression of CD25 relative to non-engineered T cells; e) maintained or decreased expression of PD-1 relative to non-engineered T cells; and / or f) maintained or increased proliferation relative to non-engineered T cells.

[0058] In certain embodiments, the present disclosure relates to a composition comprising a plurality of engineered T cells, wherein the engineered T cells exhibit reduced expression of a TGFBR2 gene relative to non-engineered T cells, the engineered T cells being generated by contacting non-engineered T cells with a genome editing system comprising: a gRNA containing a targeting domain complementary to a target sequence of a TGFBR2 gene; and an RNA-guided nuclease.

[0059] In certain embodiments, the engineered T cells are further transduced with a vector expressing eTCR or CAR. In certain embodiments, the vector is a viral vector. In certain embodiments, the viral vector is an adeno-associated virus (AAV) vector or a lentivirus (LV) vector.

[0060] In certain embodiments, the RNA-guided nuclease is a Streptococcus pyogenes Cas9 nuclease, and the targeting domain comprises a nucleotide sequence that is identical to, or differs by no more than about 3 nucleotides from, a nucleotide sequence selected from the group consisting of: (a) SEQ ID NO: 5041; (b) SEQ ID NO: 5042; (c) SEQ ID NO: 5047; (d) SEQ ID NO: 5050; (e) SEQ ID NO: 5052; (f) SEQ ID NO: 5092; and (g) SEQ ID NO: 5093.

[0061] In certain embodiments, the disclosure relates to compositions comprising a plurality of engineered T cells, wherein the engineered T cells are defective in TGFBR2 signaling.

[0062] In certain embodiments, the defective TGFBR2 signaling is mediated by expressing a dominant negative (DN) form of the TGFBR2 in the engineered T cells.

[0063] In certain embodiments, the engineered T cells are further transduced with a vector expressing eTCR or CAR. In certain embodiments, the vector is a viral vector. In certain embodiments, the viral vector is an adeno-associated virus (AAV) vector or a lentivirus (LV) vector.

[0064] In certain embodiments, the T cells are CD4+ T cells and / or CD8+ T cells.

[0065] In certain embodiments, the engineered T cells are further characterized by having: a) enhanced lytic activity against target cancer cells relative to non-engineered T cells; b) maintained or increased expression of granzyme B and / or interferon γ relative to non-engineered T cells in the presence of TGFβ; c) maintained or increased persistence against repeated antigenic stimulation relative to non-engineered T cells; d) maintained or increased expression of CD25 relative to non-engineered T cells; e) maintained or decreased expression of PD-1 relative to non-engineered T cells; and / or f) maintained or increased proliferation relative to non-engineered T cells.

[0066] In certain embodiments, the engineered immune cell further comprises reduced expression of wild-type TGFBR2.

[0067] In certain embodiments, the wild-type TGFBR2 expression is reduced by contacting the engineered immune cell with a genome editing system comprising: a gRNA containing a targeting domain complementary to a target sequence of the TGFBR2 gene; and an RNA-guided nuclease.

[0068] In certain embodiments, the disclosure relates to a ribonucleoprotein (RNP) complex comprising a gRNA and an RNA-guided nuclease, wherein the gRNA comprises a targeting domain complementary to a target sequence of a TGFBR2 gene.

[0069] In certain embodiments, the RNP of claim 117, wherein the RNA-guided nuclease is a Cas9 nuclease.

[0070] In certain embodiments, the RNP of claim 117, wherein the RNP enters the cell by electroporation.

[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs. Although those methods and materials similar or equivalent to the methods and materials described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In addition, materials, methods and embodiments are merely illustrative and are not intended to be limiting.

[0072] Headings, including numerical and letter headings and sub-headings, are for organizational and presentation purposes only and are not intended to be limiting.

[0073] Other features and advantages of the invention will be apparent from the detailed description, examples, drawings, and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0074] The accompanying drawings are intended to provide illustrative and schematic examples of certain aspects and embodiments of the present disclosure rather than comprehensive examples. The accompanying drawings are not intended to be limited or constrained to any particular theory or model and are not necessarily drawn to scale. Without limiting the foregoing, nucleic acids and polypeptides may be described as linear sequences or schematic two-dimensional or three-dimensional structures; these descriptions are intended to be illustrative and not to be limited or constrained to any particular model or theory regarding their structure.

[0075] Figure 1 Depicted is a list of exemplary gRNAs targeting exon 1A-5 of transforming growth factor beta receptor II (TGFBR2) and their associated % non-homologous end joining (NHEJ) activity.

[0076] Figure 2 The genome editing efficiencies of certain exemplary gRNA pairs are depicted.

[0077] Figure 3 Depicted are the % indel formation in the TGFBR2 gene as determined by miSeq. Seven gRNAs were tested at various RNP concentrations to generate dose response curves.

[0078] FIG. 4A to FIG. 4B Depicted are the % of cells edited with several test gRNAs targeting TGFBR2 and one control gRNA targeting the AAVS1 locus ( Figure 4A ) and insertion / deletion frequency%( Figure 4B ).

[0079] Figure 5 Depicted is a comparison of two gRNAs targeting TGFBR2 with respect to their ability to generate out-of-frame indel mutations.

[0080] Figure 6 Depicted are relative IFN-γ production in primary T cells transduced to express anti-BCMA CAR in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ. Single or paired gRNAs were compared.

[0081] Figure 7 Depicted are relative cell proliferation in primary T cells transduced to express anti-BCMA CAR in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ. Single or paired gRNAs were compared.

[0082] FIG. 8A to FIG. 8B Figure 3 shows the expression of CD25 in primary T cells transduced to express anti-BCMA CAR in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ. Fig. 8A ) and PD-1( Figure 8B ) expression. Single or paired gRNAs were compared. Cells were stimulated with RPMI 8226 cells for 48 hours.

[0083] Fig. 9 Depicted are Smad 2 / 3 phosphorylation in T cells transduced to express different CARs in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ.

[0084] Fig.10 Depicted are relative granzyme B expression in T cells transduced to express different CARs in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ.

[0085] Fig.11 Depicted is IFN-γ production in T cells transduced to express different CARs in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ.

[0086] Fig.12 Depicted are relative T cell proliferation in T cells transduced to express different CARs in the context of TGFBR2 gene editing in the presence (10 ng / ml) or absence of TGFβ.

[0087] FIG. 13A to FIG. 13B Figure 3 Granzyme B expression in primary T cells transduced to express anti-BCMA CAR in the TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ. Fig.13A ) and interferon gamma ( Fig. 13B )produce.

[0088] Fig.14 Depicted are the relative % lysis of RPMI 8226 cells by T cells expressing anti-BCMA CAR in a TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ.

[0089] FIG. 15A to FIG. 15F Depicted are T cells expressing anti-BCMA CAR in the context of TGFBR2 unedited, TGFBR2 gene-edited, or TGFBR2 DN under repeated TGFβ antigen stimulation. FIG. 15A to FIG. 15C Inferred cell numbers after stimulation with three different antigens are shown. FIG. 15D to FIG. 15F Shown is the change in the % of T cells expressing anti-BCMA CAR over time in the presence of repeated TGFβ antigen stimulation.

[0090] FIG. 16A to FIG. 16B Figure 3 INF-γ production in primary T cells transduced to express anti-BCMA CAR in the TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ. T cells were incubated with RPMI8226 cells ( Fig.16A ) or OPM2 cells ( Fig. 16B ) were incubated together.

[0091] FIG. 17A to FIG. 17B Depicted is the expression of CD25 in primary T cells transduced to express anti-BCMA CAR in the TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ. T cells were incubated with RPMI8226 cells ( Fig.17A ) or OPM2 cells ( Fig. 17B ) were incubated together.

[0092] FIG. 18A to FIG. 18B Depicted is PD-1 expression in primary T cells transduced to express anti-BCMA CAR in the TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ. T cells were incubated with RPMI8226 cells ( Fig.18A ) or OPM2 cells ( Fig.18B ) were incubated together.

[0093] FIG. 19A to FIG. 19B Figure 3 Relative cell proliferation of T cells expressing anti-BCMA CAR in the TGFBR2 gene-edited or TGFBR2 DN background in the presence (10 ng / ml) or absence of TGFβ ( Fig.19A ) and relative IFN-γ production ( Fig.19B). The cells were stimulated with RPMI 8226 cells in the same manner.

[0094] FIG. 20A to FIG. 20B Figure 3 shows the expression of several anti-BCMA CAR-expressing CD4+ ( Fig. 20A ) and CD8+( Fig. 20B ) % of PD-1+ cells in T cells. The cells were also stimulated with RPMI 8226 cells for 48 hours.

[0095] Fig.21 Expression levels of TGFβ signaling pathway genes PMEPA1, SKIL, SKI, and LDLRAD4 in T cells expressing anti-BCMA CAR in TGFBR2 gene-edited or TGFBR2 DN background are depicted. T cells were isolated from mouse spleens or from tumors derived from RPMI8226 cells.

[0096] Fig. 22 Depicted are Smad 2 / 3 phosphorylation levels, proliferation, and granzyme B expression in T cells expressing anti-CD19 CAR in the TGFBR2 DN background in the presence and absence of TGFβ.

[0097] Fig.23 Depicted is a schematic diagram for determining whether TGFBR2 gene editing in T cells confers a selective advantage over wild-type cells.

[0098] Fig.24 Depict anti-BCMA CAR, TGFBR2-KO cells and WT cells with different ratios (1, 0.75, 0.5, 0.25). Cells are co-cultured with RPMI8226 cells with a ratio of 1:1 effector to target ± 10ng / ml TGFβ. Cells are collected every 7 days for analysis of insertion and deletion by high-throughput sequencing. Fresh RPMI8226 is used to re-stimulate cells weekly and the effector to target ratio is readjusted to 1:1. DETAILED DESCRIPTION

[0099] Definitions and Abbreviations

[0100] Unless otherwise specified, each of the following terms has the meaning associated with this Section.

[0101] The indefinite articles "a" and "an" refer to at least one of the associated nouns and are used interchangeably with the terms "at least one" and "one or more." For example, "a module" means at least one module or one or more modules.

[0102] The conjunctions "or" and "and / or" are used interchangeably as non-exclusive disjuncts.

[0103] The phrase "consisting essentially of" means that the listed species is the major species, but other species may be present in trace amounts or in amounts that do not affect the structure, function, or behavior of the subject composition. For example, a composition consisting essentially of a particular species will typically contain 90%, 95%, 96%, or more of that species.

[0104] "Domain" is used to describe a segment of a protein or nucleic acid. Unless otherwise specified, a domain is not required to have any particular functional properties.

[0105] "Indels" are insertions and / or deletions in a nucleic acid sequence. Indels can be the product of repair of double-strand breaks of DNA (such as double-strand breaks formed by the genome editing system of the present disclosure). Indels are most often formed when breaks are repaired by "error-prone" repair pathways (such as the NHEJ pathway described below). Indels can produce insertions or deletions, thereby producing in-frame or out-of-frame mutations in the target sequence.

[0106] "Gene conversion" refers to the alteration of a DNA sequence by the incorporation of endogenous homologous sequences (e.g., homologous sequences within a gene array). "Gene correction" refers to the alteration of a DNA sequence by the incorporation of exogenous homologous sequences (e.g., exogenous single-stranded or double-stranded donor template DNA). Gene conversion and gene correction are products of repair of DNA double-strand breaks by HDR pathways (such as those described below).

[0107] Indels, gene conversions, gene corrections, and other genome editing results are typically assessed by sequencing (most commonly by "next generation" or "sequencing by synthesis" methods, but Sanger sequencing can still be used) and quantified by the relative frequency of numerical changes (e.g., ±1, ±2, or more bases) at the target site in all sequenced reads. DNA samples for sequencing can be prepared by a variety of methods known in the art, and can involve amplification of the target site by polymerase chain reaction (PCR), capture of DNA ends generated by double-strand breaks (such as in the GUIDEseq method described in Tsai et al. (Nat. Biotechnol. 34(5):483 (2016), incorporated herein by reference) or by other means well known in the art). Genome editing results can also be assessed by in situ hybridization methods (such as FiberComb commercialized by Genomic Vision (Pagneux, France)). TM system) and by any other suitable method known in the art.

[0108] "Alt-HDR", "alternative homology-directed repair" or "alternative HDR" refers to the process of repairing DNA damage using homologous nucleic acids (e.g., endogenous homologous sequences, such as sister chromatids; or exogenous nucleic acids, such as template nucleic acids). Alt-HDR differs from classical HDR in that the process utilizes a different pathway than classical HDR and can be inhibited by classical HDR mediators RAD51 and BRCA2. Alt-HDR also differs in that single-stranded or nicked homologous nucleic acid templates are involved, while classical HDR typically involves double-stranded homologous templates.

[0109] "Classical HDR", "classical homology-directed repair" or "cHDR" refers to the process of repairing DNA damage using homologous nucleic acids (e.g., endogenous homologous sequences, such as sister chromatids; or exogenous nucleic acids, such as template nucleic acids). Classical HDR usually works when there is significant resection at the double-strand break, forming at least one single-stranded portion of DNA. In normal cells, cHDR usually involves a series of steps, such as recognition of the break, stabilization of the break, resection, stabilization of single-stranded DNA, formation of DNA exchange intermediates, separation of exchange intermediates, and ligation. The process requires RAD51 and BRCA2, and the homologous nucleic acids are usually double-stranded.

[0110] Unless otherwise stated, the term "HDR" as used herein includes both classic HDR and alt-HDR.

[0111] "Non-homologous end joining" or "NHEJ" refers to ligation-mediated repair and / or non-template-mediated repair, including classical NHEJ (cNHEJ) and alternative NHEJ (altNHEJ), which in turn includes microhomology-mediated end joining (MMEJ), single-strand annealing (SSA), and synthesis-dependent microhomology-mediated end joining (SD-MMEJ).

[0112] When used in reference to modification of a molecule (eg, a nucleic acid or a protein), "replacing" or "substituted" does not require a process restriction but merely indicates the presence of a replacement entity.

[0113] "Subject" means a human or non-human animal. A human subject can be of any age (e.g., infant, child, young adult, or adult), and may suffer from a disease or may require a genetic change. Alternatively, a subject can be an animal, and the term includes, but is not limited to, mammals, birds, fish, reptiles, amphibians, and more particularly non-human primates, rodents (e.g., mice, rats, hamsters, etc.), rabbits, guinea pigs, dogs, cats, etc. In certain embodiments of the present disclosure, the subject is a domestic animal, such as a cow, horse, sheep, or goat. In certain embodiments, the subject is poultry.

[0114] "Treat," "treating," and "treatment" mean treating a disease in a subject (e.g., a human subject), including one or more of: inhibiting the disease, i.e., arresting or preventing its development or progression; relieving the disease, i.e., causing regression of the disease state; alleviating one or more symptoms of the disease; and curing the disease.

[0115] "Prevent," "preventing," and "prevention" refer to preventing a disease in a mammal (e.g., a human), including (a) avoiding or preventing the disease; (b) influencing susceptibility to the disease; or (c) preventing or delaying the onset of at least one symptom of the disease.

[0116] A "kit" refers to any collection of two or more components that together constitute a functional unit that can be used for a specific purpose. By way of example (but not limitation), a kit according to the present disclosure may include a guide RNA that is complexed with or capable of complexing with a nuclease guided by the RNA, and is accompanied by a pharmaceutically acceptable carrier (e.g., suspended in or suspendable in the pharmaceutically acceptable carrier). The kit can be used to introduce the complex into, for example, a cell or a subject, for the purpose of causing the desired genomic changes in such a cell or subject. The components of the kit can be packaged together, or they can be packaged separately. The kit according to the present disclosure may also optionally include a instruction manual (DFU) that describes the use of the kit, for example, according to the method of the present disclosure. The DFU can be physically packaged with the kit, or it can be provided to the user of the kit, for example, electronically.

[0117] The terms "polynucleotide", "nucleotide sequence", "nucleic acid", "nucleic acid molecule", "nucleic acid sequence" and "oligonucleotide" refer to a series of nucleotide bases (also called "nucleotides") in DNA and RNA, and mean any chain of two or more nucleotides. Polynucleotides, nucleotide sequences, nucleic acids, etc. can be single-stranded or double-stranded, chimeric mixtures or derivatives or modified forms thereof. They can be modified on the base moiety, sugar moiety or phosphate backbone, for example to improve the stability of the molecule, its hybridization parameters, etc. The nucleotide sequence generally carries genetic information, including but not limited to information used by the cellular machinery to make proteins and enzymes. These terms include double-stranded or single-stranded genomic DNA, RNA, any synthetic and genetically manipulated polynucleotides, and both sense and antisense polynucleotides. These terms also include nucleic acids containing modified bases.

[0118] Conventional IUPAC notation is used for the nucleotide sequences presented herein, as shown in Table 1 below (see also Cornish-Bowden A, Nucleic Acids Res. 1985 May 10; 13(9):3021-30, incorporated herein by reference). However, it should be noted that in those cases where the sequence may be encoded by DNA or RNA, such as in the gRNA targeting domain, "T" means "thymine or uracil".

[0119] Table 1: IUPAC nucleic acid notation

[0120] character Base A Adenine T Thymine or uracil G Guanine C Cytosine U Uracil K G or T / U M A or C R A or G Y C or T / U S C or G W A or T / U B C, G or T / U V A, C, or G H A, C or T / U D A, G or T / U N A, C, G or T / U

[0121] The terms "protein," "peptide," and "polypeptide" are used interchangeably to refer to a continuous chain of amino acids linked together via peptide bonds. The term includes individual proteins, groups or complexes of proteins associated together, and fragments or portions, variants, derivatives, and analogs of such proteins. Conventional notation is used herein to present peptide sequences starting from the amino or N-terminus on the left and proceeding to the carboxyl or C-terminus on the right. Standard one-letter or three-letter abbreviations may be used.

[0122] The term "variant" refers to an entity (such as a polypeptide, polynucleotide, or small molecule) that exhibits significant structural identity to a reference entity, but differs structurally from the reference entity in the presence of one or more chemical moieties or at the level of one or more chemical moieties as compared to the reference entity. In many embodiments, a variant is also functionally different from its reference entity. Typically, whether a particular entity is appropriately considered a "variant" of a reference entity is based on the degree of its structural identity to the reference entity.

[0123] Overview

[0124] The genome editing systems described herein generally comprise one or more gRNAs comprising a targeting domain complementary to one or more TGFBR2 target sequences, which in turn include or are adjacent to a protospacer adjacent motif (PAM) sequence recognized by one or more RNA-guided nucleases, to which the one or more gRNAs can bind (e.g., complex). Thus, the genome editing systems of the present disclosure target one or more TGFBR2 target sequences in a site-specific manner and operate to introduce changes within or proximal to those TGFBR2 target sequences.

[0125] Changes introduced into or near the TGFBR2 target site by the genome editing system of the present disclosure will most commonly include single-strand breaks (SSBs or "nicks") and / or double-strand breaks (DSBs) of DNA. The nicks and DSBs are in turn repaired by the cell in a manner that can result in the introduction of small indels or larger insertions or deletions at one or more TGFBR2 target sites, sequence deletions between two TGFBR2 target sites, and / or sequences (particularly exogenous sequences introduced into the cell via donor template oligonucleotides) inserted into the TGFBR2 site or between two TGFBR2 target sites in a manner that replaces endogenous cellular DNA sequences between those target sites. However, in some cases, the genome editing system introduces one or more of the following: point mutations (e.g., via cysteine ​​deamination), changes in DNA markers (e.g., DNA methylation, histone acetylation or deacetylation, or other chromatin modifications), and / or recruitment of trans-acting factors (such as transcription factors). Alternatively, the genome editing systems of the present disclosure can associate with one or more TGFBR2 target sequences in a persistent (e.g., over an interval of weeks, months, or longer) or transient (over an interval of seconds, minutes, hours, or days) manner, thereby preventing other factors (particularly RNA polymerases, but also DNA polymerases, transcription factors, and / or other cis- or trans-acting factors that affect gene expression) from associating with the TGFBR2 target sequence. These and other modes of action of the genome editing systems and their components are described in detail below under the headings "RNA-guided nucleases" and "Modification of RNA-guided nucleases."

[0126] The TGFBR2 target sequence and the corresponding gRNA targeting domain sequence are usually but not necessarily located in an exon, in which the introduction of small indels or larger insertions or deletions can result in one or more mutations (e.g., frameshift mutations, nonsense mutations, the introduction of codons for amino acids that disrupt the surrounding protein structure, and / or the removal of codons for amino acids required for protein activity), thereby reducing or eliminating the function of the TGFBR2 protein. Figure 1 A profile of the splicing activity of various S. pyogenes guide RNAs to the locations they target within the exonic structure of the TGFBR2 gene is shown. Throughout this specification, these mutations are referred to as "knockout" mutations, and their functional effect is to "knock out" TGFBR2 protein function.

[0127] Some TGFBR2 target sequences can be regarded as "hotspot" target sites of gRNA targeting domain sequences. As used herein, "hotspot" refers to a site that is preferentially targeted because it produces a high insertion and deletion frequency % or an effective knockdown or knockout of the TGFBR2 gene. The gRNA targeting one or more of these preferred sites can produce 30% or higher insertion and deletion frequency %. For example, the preferred target site in the TGFBR2 gene can have a complementary gRNA targeting domain, and the complementary gRNA targeting domain produces 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or higher insertion and deletion frequency %. The hotspot target sites in the TGFBR2 gene are described herein.

[0128] Preferred hotspot TGFBR2 regions are shown in Table x:

[0129] Table 2: Preferred TGFBR2 target sites

[0130]

[0131] Particularly preferred hotspot TGFBR2 regions are shown in Table 3:

[0132] TGFBR2 targets sequence SEQ ID NO:4 GTAGCTCTGATGAGTGCAAT SEQ ID NO:5 ATGAATCTCTTCACTCTAGG SEQ ID NO:6 ACAGGAGTACCTGACGCGGC SEQ ID NO:7 CTGTTAGCCAGGTCATCCAC SEQ ID NO:8 GGGTGTCCAGCTCAATGGGC SEQ ID NO:9 TCATAATGCACTTTGGAGAA SEQ ID NO:10 TGACTTTATTCTGGAAGATG

[0133] The TGFBR2 target sequence may be, for example, located in exon 3, 4, or 5 of the TGFBR2 gene. The gRNA targeting domain sequence corresponding to the TGFBR2 target sequence present in exon 3, 4, or 5 of the TGFBR2 gene may comprise a nucleotide sequence that is identical to or differs by no more than 1, 2, or 3 nucleotides from a nucleotide sequence selected from SEQ ID NOs: 5036 to 5096. For example, but not limitation, an exemplary targeting domain may comprise a nucleotide sequence that is identical to or differs by no more than 1, 2, or 3 nucleotides from a nucleotide sequence selected from:

[0134] (a) SEQ ID NO:5041;

[0135] (b) SEQ ID NO:5042;

[0136] (c) SEQ ID NO: 5047;

[0137] (d) SEQ ID NO:5050;

[0138] (e) SEQ ID NO:5052;

[0139] (f) SEQ ID NO:5092; and

[0140] g) SEQ ID NO:5093.

[0141] Table 4 - Targeting sequences

[0142] SEQ ID Targeting sequence PAM Exon 5041 ATTGCACTCATCAGAGCTAC AGG 4 5043 CCAATGAATCTCTTCACTCT AGG Intron-adjacent to 4 5047 GCCGCGTCAGGTACTCCTGT AGG 5 5050 GTGGATGACCTGGCTAACAG TGG 5 5052 GCCCATTGAGCTGGACACCC TGG 5 5092 TTCTCCAAAGTGCATTATGA AGG 4 5093 CATCTTCCAGAATAAAGTCA TGG 4

[0143] As an alternative to knocking out TGFBR2 expression, a transcriptional regulatory region (e.g., a promoter region (e.g., a promoter region that controls transcription of a TGFBR2 gene)) can be targeted to alter (e.g., knock out) gene expression. As described herein, targeted knockout methods can be mediated by a CRISPR / Cas system comprising an enzymatically inactive Cas9 (eiCas9) molecule or an eiCas9 fusion protein (e.g., an eiCas9 fused to a transcription repressor domain or a chromatin modification protein). For example, one or more gRNA molecules comprising a targeting domain can be configured to target the eiCas9 molecule or eiCas9 fusion protein to be sufficiently close to a transcriptional regulatory region, such as a promoter region (e.g., a promoter region that controls transcription of a TGFBR2 gene), thereby reducing and / or eliminating transcription of a TGFBR2 gene. In certain embodiments, eiCas9 or eiCas9 fusion proteins can be used to knock down TGFBR2 expression in T cells (e.g., human T cells).

[0144] TGFBR2 knockout and / or knockdown can be assessed by any suitable means, including but not limited to examining the sequence of the TGFBR2 gene, assessing TGFBR2 protein expression on the cell surface (e.g., by immunostaining and cell sorting, particularly by fluorescence activated cell sorting or FACS (including indirect intracellular staining flow cytometry)), detecting cellular or molecular changes mediated by TGFBR2, assessing the effects of TGF-β on cell proliferation or survival, or detecting TGFBR2 protein levels by Western blot. In particular, for T cells, TGFBR2 knockout can be confirmed by (a) sequencing the TGFBR2 locus or T7E1 primer extension assay and / or (b) intracellular FACS assessment of SMAD2 / 3 phosphorylation. Sequencing and T7E1 are described in more detail below, while intracellular SMAD2 / 3 phosphorylation assays are described in, for example, Chen, et al., J. Experimental Med. Vol. 198, No. 12, Dec. 15, 2003, 1875-1886 (which reference is incorporated by reference in its entirety and for all purposes herein), particularly the “Materials and Methods” section on page 1877 and Supplementary Figure S2.

[0145] Knockout and / or knockdown of TGFBR2 may correspond to a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95% or 100% decrease in TGFBR2 expression relative to baseline measurements or wild-type cells.

[0146] In some aspects, provided compositions and methods include those wherein: at least or greater than about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the cells in the composition of cells (in which an agent for knockout or gene disruption of a TGFBR2 gene is introduced (e.g., gRNA / Cas9)) contain gene disruption; do not express endogenous TGFBR2 polypeptides; do not contain continuous TGFBR2 genes, TGFBR2 genes, and / or functional TGFBR2 genes. In some embodiments, methods, compositions, and cells according to the present disclosure include those wherein at least or greater than about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the cells in the composition of cells (in which an agent for knockout or gene disruption of a TGFBR2 gene is introduced (e.g., gRNA / Cas9)) do not express TGFBR2 polypeptides (e.g., on the cell surface). In some embodiments, at least or greater than about 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of the cells in the composition of cells into which an agent for knockout or gene disruption of the TGFBR2 gene (e.g., gRNA / Cas9) is introduced have both alleles knocked out, i.e., such percentage of cells contain a biallelic deletion.

[0147] The genome editing system targeting TGFBR2 can be implemented in a variety of ways, and its implementation can be customized for the environment of editing cells. Some embodiments of the present disclosure relate to, for example, using an electroporator and a test tube that can be obtained from a commercial supplier such as MaxCyte (Gaithersburg, Maryland) or Lonza (Basel, Switzerland) to deliver RNA-guided nucleases and targeting TGFBR2 guide RNAs to ex vivo cells in the form of ribonucleoprotein (RNP) complexes by means of electroporation. However, other embodiments can implement nucleic acid vectors (such as viral vectors or lipid nanoparticles) in vivo or in vitro editing. The details of these implementations are described in more detail below under the title "Implementation of a Genome Editing System".

[0148] Knockout and / or knockdown of TGFBR2 can be used in a variety of environments (including but not limited to the context of adaptive T cell therapy). According to certain embodiments of the present disclosure, TGFBR2 is knocked out in immune cells (such as T cells) to be used in therapy. As an example, T cells can express engineered receptors, such as chimeric antigen receptors (CAR) or heterologous T cell receptors (TCR), and the receptors can be configured to identify antigens on cells or tissues involved in pathology (such as tumors). Whether they express engineered receptors, knockout T cells according to the TGFBR2 of the present disclosure can be used for targeted tissues or organs, in which TGF-β is present in an amount sufficient to reduce the proliferation or activity of T cells expressing TGFBR2.

[0149] TGFBR2 knockout and / or knockdown cells can be used in "autologous" cell therapy, where cells are harvested from a subject, altered to knock out or knock down TGFBR2 expression, and then returned to the same subject; alternatively, these cells can be given to a different subject in an "allogeneic" cell therapy. In either approach, between harvesting and administering the TGFBR2 cells of the present disclosure, manipulation can be performed in a variety of ways (such as amplification, stimulation, purification or sorting, transduction with a transgene, freezing and / or thawing).

[0150] Knocking out or knocking down the presence of the TGFBR2 gene as described herein can: (1) improve T cell proliferation; (2) improve T cell survival; and / or (3) improve T cell function. Knocking down the expression of the TGFBR2 gene as described herein can similarly: (1) improve T cell proliferation; (2) improve T cell survival; and / or (3) improve T cell function.

[0151] Genome Editing System

[0152] The term "genome editing system" refers to any system with RNA-guided DNA editing activity. The genome editing system of the present disclosure includes at least two components adapted from a naturally occurring CRISPR system: a guide RNA (gRNA) and an RNA-guided nuclease. These two components form a complex that can associate with a specific nucleic acid sequence and, for example, edit the DNA in or around the nucleic acid sequence by making one or more of a single-strand break (SSB or nick), a double-strand break (DSB) and / or a point mutation. In certain embodiments, double-strand or single-strand breaks are within about 500bp, about 450bp, about 400bp, about 350bp, about 300bp, about 250bp, about 200bp, about 150bp, about 100bp, about 50bp, about 25bp, or about 10bp of a TGFBR2 target position, thereby inducing changes in TGFBR2 gene expression.

[0153] Naturally occurring CRISPR systems are evolutionarily divided into two classes and five types (Makarova et al. Nat Rev Microbiol. 2011 Jun; 9(6):467-477 (Makarova), incorporated herein by reference), and although the genome editing systems of the present disclosure can adapt components of any type or class of naturally occurring CRISPR systems, the embodiments presented herein are generally adapted from Class 2 and Type II or V CRISPR systems. Class 2 systems, covering Types II and V, are characterized by relatively large multidomain RNA-guided nuclease proteins (e.g., Cas9 or Cpf1) and one or more guide RNAs (e.g., crRNA and optionally tracrRNA) that form ribonucleoprotein (RNP) complexes that associate (i.e., target) and cleave specific loci that are complementary to the targeting (or spacer) sequence of the crRNA. The genome editing systems according to the present disclosure similarly target and edit cellular DNA sequences, but differ significantly from naturally occurring CRISPR systems. For example, the single-molecule guide RNAs described herein do not occur in nature, and both the guide RNAs and RNA-guided nucleases according to the present disclosure can incorporate any number of non-naturally occurring modifications.

[0154] Genome editing systems can be implemented in a variety of ways (e.g., administered or delivered to cells or subjects), and different implementations can be suitable for different applications. For example, in certain embodiments, the genome editing system is implemented as a protein / RNA complex (ribonucleoprotein or RNP) that can be included in a pharmaceutical composition, which optionally includes a pharmaceutically acceptable carrier and / or encapsulant (such as lipid or polymer microparticles or nanoparticles, micelles, liposomes, etc.). In certain embodiments, the genome editing system is implemented as one or more nucleic acids encoding the above-mentioned RNA-guided nuclease and guide RNA components (optionally with one or more additional components); in certain embodiments, the genome editing system is implemented as one or more vectors comprising such nucleic acids, such as viral vectors, such as adeno-associated viruses; and in certain embodiments, the genome editing system is implemented as a combination of any of the foregoing. Additional or modified implementations that operate according to the principles set forth herein will be clear to skilled technicians and are within the scope of the present disclosure.

[0155] It should be noted that the genome editing system of the present disclosure can target a single specific nucleotide sequence, or can target and edit two or more specific nucleotide sequences in parallel by using two or more guide RNAs. Throughout the present disclosure, the use of multiple gRNAs is referred to as "multiplexing", and can be used to target multiple unrelated target sequences of interest or to form multiple SSBs or DSBs within a single target domain, and in some cases to generate specific edits within such target domains. For example, International Patent Publication No. WO2015 / 138510 of Maeder et al. (Maeder), incorporated herein by reference, describes a genome editing system for correcting point mutations (C.2991+1655A to G) in the human CEP290 gene, which results in the generation of hidden splicing sites, which in turn reduces or eliminates the function of the gene. Maeder's genome editing system utilizes two guide RNAs targeting sequences on both sides (i.e., flanks) of the point mutation, and forms DSBs flanking the mutation. This in turn promotes deletion (including mutation) of the intervening sequences, thereby eliminating the cryptic splice site and restoring normal gene function.

[0156] As another example, WO 2016 / 073990 by Cotta-Ramusino et al. ("Cotta-Ramusino"), incorporated herein by reference, describes a genome editing system that utilizes a combination of two gRNAs and a Cas9 nickase (Cas9 that makes single-stranded nicks, such as Streptococcus pyogenes D10A), components of a "double nickase system". Cotta-Ramusino's double nickase system is configured to make two nicks on opposite strands of a target sequence that are offset by one or more nucleotides, and the nicks combine to form a double-strand break with an overhang (5' in the case of Cotta-Ramusino, but it may also be a 3' overhang). In some cases, the overhangs can in turn promote homology-directed repair events. And as another example, WO 2015 / 070083 by Palestrant et al. ("Palestrant", incorporated herein by reference) describes a gRNA targeting a nucleotide sequence encoding Cas9 (referred to as a "regulatory RNA") that can be included in a genome editing system containing one or more additional gRNAs to allow transient expression of Cas9 that might otherwise be constitutively expressed in, for example, some virally transduced cells. These multiplexing applications are intended to be exemplary and not limiting, and the skilled artisan will appreciate that other applications of multiplexing are generally compatible with the genome editing systems described herein.

[0157] In some cases, the genome editing system can form double-strand breaks, which are repaired by cellular DNA double-strand break mechanisms (such as NHEJ or HDR). These mechanisms are described throughout the following documents: for example, Davis and Maizels, PNAS, 111 (10): E924-932, March 11, 2014 (Davis) (describing Alt-HDR); Frit et al. DNA Repair 17 (2014) 81-97 (Frit) (describing Alt-NHEJ); and Iyama and Wilson III, DNA Repair (Amst.) August 2013; 12 (8): 620-636 (Iyama) (generally describing classical HDR and NHEJ pathways).

[0158] In the case where the genome editing system operates by forming DSBs, such systems optionally include one or more components that promote or facilitate a particular double-strand break repair mode or a particular repair outcome. For example, Cotta-Ramusino also describes a genome editing system in which a single-stranded oligonucleotide "donor template" is added; the donor template is incorporated into a target region of cellular DNA that is cut by the genome editing system and can result in a change in the target sequence.

[0159] In certain embodiments, the genome editing system modifies the target sequence or modifies the expression of the gene in or near the target sequence without causing single-strand or double-strand breaks.For example, the genome editing system may include a nuclease guided by RNA, and the nuclease guided by RNA is fused with a functional domain acting on DNA to modify the target sequence or its expression. As an example, the nuclease guided by RNA can be connected (e.g., fused) to a cytidine deaminase functional domain, and can be operated by generating a targeted C to A substitution. Exemplary nuclease / deaminase fusions are described in Komor et al. Nature 533, 420-424 (May 19, 2016) ("Komor"), which is incorporated by reference. Alternatively, the genome editing system can utilize a nuclease (such as dead Cas9 (dCas9)) that is inactivated by cutting (i.e., "dead"), and can be operated in the following manner: a stable complex is formed on one or more targeted regions of cell DNA, thereby hindering the function of one or more targeted regions, including but not limited to mRNA transcription, chromatin remodeling, etc.

[0160] Guide RNA (gRNA) molecules

[0161] The terms "guide RNA" and "gRNA" refer to any nucleic acid that promotes the specific association (or "targeting") of an RNA-guided nuclease (such as Cas9 or Cpf1) with a target sequence (such as a genomic sequence or a free sequence) in a cell. The gRNA can be unimolecular (comprising a single RNA molecule, and also alternatively referred to as a chimera), or modular (comprising more than one, usually two separate RNA molecules (such as crRNA and tracrRNA), which are usually associated with each other, such as by duplexing). gRNA and its components are described throughout the following literature, such as Briner et al. (Molecular Cell 56 (2), 333-339, October 23, 2014 (Briner), which is incorporated by reference) and Cotta-Ramusino.

[0162] In bacteria and archaea, type II CRISPR systems typically include RNA-guided nuclease proteins (such as Cas9), CRISPR RNA (crRNA) comprising a 5' region complementary to an external sequence, and a trans-activating crRNA (tracrRNA) comprising a 5' region complementary to the 3' region of crRNA and forming a duplex therewith. Although not wishing to be bound by any theory, it is believed that this duplex promotes the formation of the Cas9 / gRNA complex and is essential for its activity. Since type II CRISPR systems are suitable for gene editing, it is found that crRNA and tracrRNA can be connected to a single single molecule or chimeric guide RNA, and in a non-limiting example, the connection is by means of four nucleotides (e.g., GAAA) "tetraloops" or "joints" sequences bridging the complementary regions of crRNA (at its 3' end) and tracrRNA (at its 5' end). (Mali et al. Science. 2013 Feb 15;339(6121):823-826 (“Mali”); Jiang et al. Nat Biotechnol. 2013 Mar;31(3):233-239 (“Jiang”); and Jinek et al., 2012 Science Aug. 17;337(6096):816-821 (“Jinek”), all incorporated herein by reference)

[0163] Whether it is a single molecule or a module, the guide RNA includes a "targeting domain" that is fully or partially complementary to the target domain in the target sequence (such as the DNA sequence in the cell genome that needs to be edited). The targeting domain is mentioned in the literature with a variety of names, including but not limited to "guide sequence" (Hsu et al., Nat Biotechnol. September 2013; 31 (9): 827-832, ("Hsu"), which is incorporated herein by reference), "complementary region" (Cotta-Ramusino), "spacer" (Briner) and collectively "crRNA" (Jiang). Regardless of the name given, the length of the targeting domain is generally 10-30 nucleotides, and in certain embodiments the length is 16-24 nucleotides (e.g., 16, 17, 18, 19, 20, 21, 22, 23 or 24 nucleotides), and in the case of Cas9 gRNA, the targeting domain is located at or near the 5' end, and in the case of Cpf1 gRNA, it is located at or near the 3' end.

[0164] In addition to the targeting domain, gRNA generally (but not necessarily, as described below) comprises multiple domains that can affect the formation or activity of gRNA / Cas9 complexes. For example, as described above, the duplex structure (also referred to as a repeat sequence: anti-repeat sequence duplex) formed by the first and second complementary domains of gRNA interacts with the recognition (REC) blade of Cas9, and can mediate the formation of Cas9 / gRNA complexes. (Nishimasu et al., Cell 156, 935-949, February 27, 2014 (Nishimasu 2014) and Nishimasu et al., Cell 162, 1113-1126, August 27, 2015 (Nishimasu 2015), these two documents are incorporated herein by reference). It should be noted that the first and / or second complementary domains can contain one or more poly-A segments that can be recognized as termination signals by RNA polymerase. Therefore, the sequence of the first and second complementary domains is optionally modified (e.g., by using AG exchange or AU exchange as described in Bnerer) to eliminate these segments and promote complete in vitro transcription of gRNA. These and other similar modifications to the first and second complementary domains are within the scope of the present disclosure.

[0165] Along with the first and second complementary domains, Cas9 gRNAs typically contain two or more additional duplex regions that participate in nuclease activity in vivo, but not necessarily in vitro. (Nishimasu 2015). The first stem-loop near the 3' portion of the second complementary domain is variously referred to as the "proximal domain" (Cotta-Ramusino), "stem-loop 1" (Nishimasu 2014and 2015), and "junction" (Briner). One or more additional stem-loop structures are typically present near the 3' end of the gRNA, and their number varies by species: S. pyogenes gRNAs typically contain two 3' stem-loops (a total of four stem-loop structures, including the repeat: anti-repeat duplex), while S. aureus and other species have only one (a total of three stem-loop structures). A description of conserved stem-loop structures (and gRNA structures more generally) organized by species is provided in Briner.

[0166] Although the foregoing description has focused on the gRNA used with Cas9, it should be understood that other RNA-guided nucleases have been (or may be) discovered or invented, and the RNA-guided nucleases utilize gRNAs that are different in some respects from those described in this regard. For example, Cpf1 ("CRISPR from Prevotella and Francisella 1") is a recently discovered RNA-guided nuclease that does not require tracrRNA to work. (Zetsche et al., 2015, Cell 163, 759-771 October 22, 2015 (Zetsche I), incorporated by reference). The gRNA used in the Cpf1 genome editing system generally includes a targeting domain and a complementary domain (alternatively referred to as a "handle"). It should also be noted that in the gRNA used with Cpf1, the targeting domain is generally present at or near the 3' end, rather than the 5' end described above for Cas9 gRNA (the handle is located at or near the 5' end of the Cpf1 gRNA).

[0167] Those skilled in the art will appreciate that, although there may be structural differences between gRNAs from different prokaryotic species or between Cpf1 and Cas9 gRNAs, the principles of gRNA operation are generally consistent. Due to this consistency of operation, gRNAs can be broadly defined by their targeting domain sequences, and skilled artisans will appreciate that a given targeting domain sequence can be incorporated into any suitable gRNA, including a single molecule or chimeric gRNA or a gRNA comprising one or more chemical modifications and / or modifications of the sequence (substitution, additional nucleotides, truncation, etc.). Therefore, for ease of presentation in the present disclosure, gRNAs can be described only with respect to their targeting domain sequences.

[0168] More generally, the skilled artisan will appreciate that some aspects of the present disclosure relate to systems, methods, and compositions that can be implemented using a variety of RNA-guided nucleases. Therefore, unless otherwise indicated, the term gRNA should be understood to encompass any suitable gRNA that can be used with any RNA-guided nuclease, not limited to those gRNAs that are compatible with Cas9 or Cpf1 of a particular species. For example, in certain embodiments, the term gRNA can include a gRNA used with any RNA-guided nuclease present in a Class 2 CRISPR system (such as a Type II or Type V CRISPR system) or an RNA-guided nuclease derived from or adapted from the Class 2 CRISPR system.

[0169] Table 2 below provides exemplary gRNAs targeting TGFBR2 together with S. pyogenes Cas9.

[0170] Table 5.

[0171]

[0172]

[0173] gRNA design

[0174] Selection and verification methods for target sequences and off-target analysis have been previously described in, for example, the following documents: Mali; Hsu; Fu et al., 2014 Nat Biotechnol 32(3):279-84, Heigwer et al., 2014 Nat methods 11(2):122-3; Bae et al. (2014) Bioinformatics 30(10):1473-5; and Xiao A et al. (2014) Bioinformatics 30(8):1180-1182. Each of these references is incorporated herein by reference. As a non-limiting example, gRNA design can involve the use of software tools to optimize the selection of potential target sequences corresponding to the user's target sequence, for example to minimize off-target activity across the genome. Although off-target activity is not limited to cutting, the cutting efficiency at each off-target sequence can be predicted, for example, using a weighted scheme derived from an experiment. These and other guide selection methods are described in detail in Maeder and Cotta-Ramusino.

[0175] gRNA Modification

[0176] The activity, stability or other characteristics of gRNA can be changed by incorporating certain modifications. As an example, the nucleic acid transiently expressed or delivered may be easily degraded by, for example, cellular nucleases. Therefore, the gRNA described herein may contain one or more modified nucleosides or nucleotides introduced to the stability of nucleases. Although it is not desired to be bound by theory, it is also believed that when the gRNA of certain modifications described herein is introduced into cells, a reduced innate immune response can be exhibited. Those skilled in the art will recognize that certain cellular responses to exogenous nucleic acids, particularly those of viral or bacterial origin, are commonly observed in cells (e.g., mammalian cells). Such reactions can be reduced or completely eliminated by the modifications presented herein, which may include cytokine expression and release and the induction of cell death.

[0177] Certain exemplary modifications described in this section may be included at any position within the gRNA sequence, including but not limited to at or near the 5' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of the 5' end) and / or at or near the 3' end (e.g., within 1-10, 1-5, or 1-2 nucleotides of the 3' end). In some cases, the modification is located within a functional motif (e.g., a repeat-anti-repeat duplex of a Cas9 gRNA, a stem-loop structure of a Cas9 or Cpf1 gRNA, and / or a targeting domain of a gRNA).

[0178] As an example, the 5' end of the gRNA can include a eukaryotic mRNA cap structure or cap analog (e.g., a G(5')ppp(5')G cap analog, a m7G(5')ppp(5')G cap analog, or a 3'-O-Me-m7G(5')ppp(5')G anti-reverse cap analog (ARCA)), as shown below:

[0179]

[0180] A cap or cap analog can be included during chemical synthesis or in vitro transcription of the gRNA.

[0181] Similarly, the 5' end of the gRNA can lack a 5' triphosphate group. For example, the in vitro transcribed gRNA can be treated with a phosphatase (e.g., using calf intestinal alkaline phosphatase) to remove the 5' triphosphate group.

[0182] Another common modification involves the addition of multiple (e.g., 1-10, 10-20, or 25-200) adenine (A) residues, referred to as poly A tracts, at the 3' end of the gRNA. Poly A tracts can be added to the gRNA during chemical synthesis following in vitro transcription using a polyadenosine polymerase (e.g., E. coli poly (A) polymerase) or in vivo with the aid of a polyadenylation sequence, as described in Maeder et al.

[0183] It should be noted that the modifications described herein can be combined in any suitable manner, for example, a gRNA (whether transcribed from a DNA vector in vivo or a gRNA transcribed in vitro) can include one or both of a 5' cap structure or cap analog and a 3' poly A stretch.

[0184] The guide RNA can be modified at the 3' terminal U ribose. For example, the two terminal hydroxyl groups of the U ribose can be oxidized to aldehyde groups with the opening of the ribose ring to provide a modified nucleoside as shown below:

[0185]

[0186] Wherein "U" can be unmodified or modified uridine.

[0187] The 3' terminal U ribose can be modified with a 2'3' cyclic phosphate as follows:

[0188]

[0189] Wherein "U" can be unmodified or modified uridine.

[0190] The guide RNA may contain a 3' nucleotide that is stable for degradation, for example, by incorporating one or more modified nucleotides described herein. In certain embodiments, uridine may be replaced with a modified uridine (e.g., 5-(2-amino)propyluridine and 5-bromouridine) or any modified uridine described herein; adenosine and guanosine may be replaced with a modified adenosine and guanosine (e.g., with a modification at the 8 position, e.g., 8-bromoguanosine) or with any modified adenosine or guanosine described herein.

[0191] In certain embodiments, sugar-modified ribonucleotides can be incorporated into the gRNA, for example, where the 2'OH-group is replaced by a group selected from: H, -OR, -R (wherein R can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), halogen, -SH, -SR (wherein R can be, for example, alkyl, cycloalkyl, aryl, aralkyl, heteroaryl, or sugar), amino (wherein the amino group can be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino, diheteroarylamino, or amino acid); or cyano (-CN). In certain embodiments, the phosphate backbone can be modified, for example, with a phosphorothioate (PhTx) group as described herein. In certain embodiments, one or more nucleotides of the gRNA may each independently be a modified or unmodified nucleotide, including but not limited to 2'-sugar modified (such as 2'-O-methyl, 2'-O-methoxyethyl) or 2'-fluoro modified (including, for example, 2'-F or 2'-O-methyladenosine (A), 2'-F or 2'-O-methylcytidine (C), 2'-F or 2'-O-methyluridine (U), 2'-F or 2'-O-methylthymidine (T), 2'-F or 2'-O-methylguanine (G), 2'-O-methoxyethyl-5-methyluridine (Teo), 2'-O-methoxyethyladenosine (Aeo), 2'-O-methoxyethyl-5-methylcytidine (m5Ceo) and any combination thereof).

[0192] The guide RNA may also include a "locked" nucleic acid (LNA), in which the 2'OH-group may be linked to the 4' carbon of the same ribose, for example, via a C1-6 alkylene or C1-6 heteroalkylene bridge. Such a bridge may be provided using any suitable moiety, including but not limited to methylene, propylene, ether or amino bridges; O-amino (wherein the amino group may be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino) and aminoalkoxy or O(CH2) n -amino (wherein the amino group can be, for example, NH2; alkylamino, dialkylamino, heterocyclyl, arylamino, diarylamino, heteroarylamino or diheteroarylamino, ethylenediamine or polyamino).

[0193] In certain embodiments, the gRNA can comprise modified nucleotides of multiple rings (e.g., tricyclics; and "unlocked" forms such as glycol nucleic acids (GNAs) (e.g., R-GNA or S-GNA, in which the ribose is replaced by an ethylene glycol unit attached to a phosphodiester bond) or threose nucleic acids (TNA, in which the ribose is replaced by α-L-threofuranosyl-(3'→2'))).

[0194] Typically, gRNA includes glycosyl ribose, which is an oxygen-containing 5-membered ring. Exemplary modified gRNAs may include, but are not limited to, substitution of oxygen in ribose (e.g., by sulfur (S), selenium (Se) or alkylene (e.g., methylene or ethylene)); addition of double bonds (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ribose ring contraction (e.g., to form a 4-membered ring of cyclobutane or oxetane); ribose ring expansion (e.g., to form a 6-membered or 7-membered ring with additional carbon atoms or heteroatoms, such as anhydrohexitol, altritol, mannitol, cyclohexyl, cyclohexenyl and morpholino also having an aminophosphoroester skeleton). Although most sugar analogs are located at the 2' position, other sites (including the 4' position) may also be modified. In certain embodiments, gRNA includes 4'-S, 4'-Se or 4'-C-aminomethyl-2'-O-Me modifications.

[0195] In certain embodiments, deaza nucleotides (e.g., 7-deazaadenosine) can be incorporated into the gRNA. In certain embodiments, O- and N-alkylated nucleotides (e.g., N6-methyladenosine) can be incorporated into the gRNA. In certain embodiments, one or more or all nucleotides in the gRNA are deoxynucleotides.

[0196] RNA-guided nuclease

[0197] RNA-guided nucleases according to the present disclosure include, but are not limited to, naturally occurring Class 2 CRISPR nucleases (such as Cas9 and Cpf1) and other nucleases derived or obtained therefrom. In terms of function, RNA-guided nucleases are defined as those nucleases that: (a) interact (e.g., complex) with gRNA; and (b) associate with gRNA and optionally cleave or modify a target region of DNA, the target region comprising (i) a sequence complementary to the targeting domain of the gRNA, and optionally (ii) an additional sequence called a "protospacer adjacent motif" or "PAM", which will be described in more detail below. As shown in the following examples, RNA-guided nucleases can be broadly defined by their PAM specificity and cleavage activity, even though there may be variations between separate RNA-guided nucleases that share the same PAM specificity or cleavage activity. The skilled artisan will appreciate that some aspects of the present disclosure relate to systems, methods, and compositions that can be implemented using any suitable RNA-guided nuclease with a specific PAM specificity and / or cleavage activity. Thus, unless otherwise indicated, the term "RNA-guided nuclease" should be understood as a general term and is not limited to any particular type (e.g., Cas9 vs. Cpf1), species (e.g., S. pyogenes vs. S. aureus), or variant (e.g., full-length vs. truncated or segmented; naturally occurring PAM specificity vs. engineered PAM specificity, etc.) of RNA-guided nuclease.

[0198] The name of the PAM sequence is derived from the sequence relationship to a "protospacer" sequence that is complementary to the gRNA targeting domain (or "spacer"). The PAM sequence and the protospacer sequence together define the target region or target sequence for a specific RNA-guided nuclease / gRNA combination.

[0199] A variety of RNA-guided nucleases may require different sequence relationships between the PAM and the protospacer.

[0200] In addition to recognizing the specific sequence orientation of PAM and protospacer, RNA-guided nucleases can also recognize specific PAM sequences. For example, Staphylococcus aureus Cas9 recognizes the PAM sequence of NNGRRT or NNGRRV, where the N residue is immediately 3' of the region recognized by the gRNA targeting domain. Streptococcus pyogenes Cas9 recognizes the NGG PAM sequence. And Francisella novicida (F.novicida) Cpf1 recognizes the TTN PAM sequence. PAM sequences for a variety of RNA-guided nucleases have been identified, and Shmakov et al., 2015, Molecular Cell 60, 385-397, November 5, 2015 have described strategies for identifying novel PAM sequences. It should also be noted that the engineered RNA-guided nuclease can have a PAM specificity different from the PAM specificity of the reference molecule (for example, in the case of an engineered RNA-guided nuclease, the reference molecule can be a naturally occurring variant from which the RNA-guided nuclease is derived, or a naturally occurring variant with the greatest amino acid sequence homology to the engineered RNA-guided nuclease).

[0201] In addition to their PAM specificity, RNA-guided nucleases can also be characterized by their DNA cleavage activity: naturally occurring RNA-guided nucleases typically form DSBs in target nucleic acids, but engineered variants have been generated that only generate SSBs (as described above) (Ran & Hsu, et al., Cell 154(6), 1380-1389, Sept. 12, 2013 (Ran), incorporated herein by reference) or do not cleave at all.

[0202] Cas9

[0203] The crystal structures of Streptococcus pyogenes Cas9 (Jinek 2014) and Staphylococcus aureus Cas9 in complex with single-molecule guide RNA and target DNA (Nishimasu 2014; Anders 2014; and Nishimasu 2015) have been determined.

[0204] The naturally occurring Cas9 protein comprises two blades: a recognition (REC) blade and a nuclease (NUC) blade; each comprising a specific domain and / or functional domain. The REC blade comprises an arginine-rich bridge helix (BH) domain and at least one REC domain (e.g., a REC1 domain and an optional REC2 domain). The REC blade has no structural similarity to other known proteins, indicating that it is a unique functional domain. Although not wishing to be bound by any theory, mutation analysis has shown specific functional roles for the BH and REC domains: the BH domain appears to play a role in gRNA: DNA recognition, while the REC domain is thought to interact with the gRNA's repeat sequence: anti-repeat sequence duplex and mediate the formation of the Cas9 / gRNA complex.

[0205] The NUC blade contains a RuvC domain, an HNH domain, and a PAM interaction (PI) domain. The RuvC domain has structural similarities to members of the retroviral integrase superfamily and cuts the non-complementary (i.e., bottom) strand of the target nucleic acid. It may be formed by two or more segmented RuvC motifs (such as RuvC I, RuvCII, and RuvCIII in Streptococcus pyogenes and Staphylococcus aureus). At the same time, the HNH domain is structurally similar to the HNN endonuclease motif and cuts the complementary (i.e., top) strand of the target nucleic acid. As the name implies, the PI domain contributes to PAM specificity.

[0206] While some functions of Cas9 are associated with (but not necessarily entirely determined by) specific domains described above, these and other functions may be mediated or influenced by other Cas9 domains or multiple domains on either blade. For example, in S. pyogenes Cas9, as described in Nishimasu 2014, the gRNA repeat:antirepeat duplex falls into a groove between the REC and NUC blades, and nucleotides in the duplex interact with amino acids in the BH, PI, and REC domains. Some nucleotides in the first stem-loop structure also interact with amino acids in multiple domains (PI, BH, and REC1), as do some nucleotides in the second and third stem-loops (RuvC and PI domains).

[0207] Cpf1

[0208] The crystal structure of Acidaminococcus sp. Cpf1 in a complex with crRNA and a double-stranded (ds) DNA target containing a TTTN PAM sequence has been solved by Yamano et al. (Cell. 2016 May 5; 165(4):949-962 (Yamano), incorporated herein by reference). Like Cas9, Cpf1 also has two blades: the REC (recognition) blade and the NUC (nuclease) blade. The REC blade contains REC1 and REC2 domains that lack similarity to any known protein structure. At the same time, the NUC blade contains three RuvC domains (RuvC-I, -II and -III) and a BH domain. However, compared to Cas9, the Cpf1 REC blade lacks the HNH domain and includes other domains that also lack similarity to known protein structures: a structurally unique PI domain, three Wedge (WED) domains (WED-I, -II, and -III), and a nuclease (Nuc) domain.

[0209] Although Cas9 and Cpf1 share structural and functional similarities, it is understood that certain Cpf1 activities are mediated by domains that are not similar to any Cas9 domain. For example, cleavage of the complementary strand of the target DNA appears to be mediated by the Nuc domain, which is sequence- and spatially distinct from the HNH domain of Cas9. In addition, the non-targeting portion (handle) of the Cpf1 gRNA adopts a pseudoknot structure rather than a stem-loop structure formed by the repeat: anti-repeat duplex in the Cas9 gRNA.

[0210] Modification by RNA-guided nucleases

[0211] The RNA-guided nucleases described above have activities and properties that are useful for a variety of applications, but the skilled artisan will appreciate that RNA-guided nucleases may also be modified in certain circumstances to alter cleavage activity, PAM specificity, or other structural or functional characteristics.

[0212] First is the modification that changes the cleavage activity, and mutations that reduce or eliminate the activity of the domain within the NUC blade have been described above. Exemplary mutations that can be made in the RuvC domain, in the Cas9 HNH domain, or in the Cpf1 Nuc domain are described in Ran and Yamano and Cotta-Ramusino. Typically, mutations that reduce or eliminate the activity of one of the two nuclease domains result in RNA-guided nucleases with nickase activity, but it should be noted that the type of nickase activity varies depending on the inactivated domain. As an example, inactivation of the RuvC domain of Cas9 will result in a nickase that cuts the complementary strand or the top strand. On the other hand, inactivation of the Cas9 HNH domain results in a nickase that cuts the bottom or non-complementary strand.

[0213] Kleinstiver et al. have described PAM-specific modifications relative to naturally occurring Cas9 reference molecules for both Streptococcus pyogenes (Kleinstiver et al., Nature. July 23, 2015; 523(7561): 481-5 (Kleinstiver I)) and Staphylococcus aureus (Kleinstiver et al., Nat Biotechnol. December 2015; 33(12): 1293-1298 (Klienstiver II)). Kleinstiver et al. have also described modifications that improve the targeting fidelity of Cas9 (Nature, January 28, 2016; 529, 490-495 (Kleinstiver III)). Each of these references is incorporated herein by reference.

[0214] RNA-guided nucleases have been split into two or more parts as described by Zetsche et al. (Nat Biotechnol. 2015 Feb;33(2):139-42 (Zetsche II), incorporated by reference) and by Fine et al. (Sci Rep. 2015 Jul 1;5:10777 (Fine), incorporated by reference).

[0215] In certain embodiments, the RNA-guided nuclease can be size-optimized or truncated (e.g., via one or more deletions that reduce nuclease size while still retaining gRNA association, target and PAM recognition, and cleavage activity). In certain embodiments, the RNA-guided nuclease is covalently or non-covalently bound to another polypeptide, nucleotide, or other structure, optionally with the aid of a linker. Exemplary bound nucleases and linkers are described by Guilinger et al., Nature Biotechnology 32, 577-582 (2014), which is incorporated herein by reference for all purposes.

[0216] The RNA-guided nuclease also optionally comprises a tag, such as, but not limited to, a nuclear localization signal to facilitate the movement of the RNA-guided nuclease protein into the nucleus. In certain embodiments, the RNA-guided nuclease may incorporate a C- and / or N-terminal nuclear localization signal. Nuclear localization sequences are known in the art and are described in Maeder and elsewhere.

[0217] The foregoing list of modifications is intended to be exemplary in nature, and in light of the present disclosure, the skilled artisan will appreciate that other modifications are possible or desirable in certain applications. Thus, for the sake of brevity, the exemplary systems, methods, and compositions of the present disclosure are presented with reference to specific RNA-guided nucleases, but it should be understood that the RNA-guided nucleases used can be modified in a manner that does not change their operating principles. Such modifications are within the scope of the present disclosure.

[0218] Nucleic acid encoding an RNA-guided nuclease

[0219] Provided herein are nucleic acids encoding RNA-guided nucleases (e.g., Cas9, Cpf1, or functional fragments thereof). Exemplary nucleic acids encoding RNA-guided nucleases have been previously described (see, e.g., Cong 2013; Wang 2013; Mali 2013; Jinek 2012).

[0220] In some cases, the nucleic acid encoding the RNA-guided nuclease can be a synthetic nucleic acid sequence. For example, the synthetic nucleic acid molecule can be chemically modified. In certain embodiments, the mRNA encoding the RNA-guided nuclease will have one or more (e.g., all) of the following properties: it can be capped; polyadenylated; and substituted with 5-methylcytidine and / or pseudouridine.

[0221] Synthetic nucleic acid sequences can also be codon optimized, e.g., at least one uncommon codon or less common codon has been replaced by a common codon. For example, the synthetic nucleic acid can direct the synthesis of an optimized (e.g., optimized for expression in a mammalian expression system) messenger mRNA, such as described herein. Examples of codon-optimized Cas9 coding sequences are presented in Cotta-Ramusino.

[0222] Additionally or alternatively, the nucleic acid encoding the RNA-guided nuclease can comprise a nuclear localization sequence (NLS). Nuclear localization sequences are known in the art.

[0223] Functional analysis of candidate molecules

[0224] Candidate RNA-guided nucleases, gRNAs, and complexes thereof can be evaluated by standard methods known in the art. See, e.g., Cotta-Ramusino. The stability of the RNP complex can be evaluated by differential scanning fluorimetry, as described below.

[0225] Differential Scanning Fluorescence (DSF)

[0226] The thermal stability of ribonucleoprotein (RNP) complexes containing gRNA and RNA-guided nucleases can be measured via DSF. The DSF technique measures the thermal stability of proteins, which can be increased under favorable conditions such as the addition of binding RNA molecules, such as gRNA.

[0227] The DSF assay can be performed according to any suitable protocol and can be used in any suitable environment, including but not limited to (a) testing different conditions (e.g., different gRNA: RNA-guided nuclease protein stoichiometric ratios, different buffers, etc.) to identify optimal conditions for RNP formation; and (b) testing RNA-guided nucleases and / or gRNA modifications (e.g., chemical modifications, sequence changes, etc.) to identify those modifications that improve RNP formation or stability. One readout of the DSF assay is a change in the melting temperature of the RNP complex; a relatively high change indicates that the RNP complex is more stable (and therefore may have greater activity or more favorable formation kinetics, degradation kinetics, or another functional feature) relative to a reference RNP complex characterized by a lower change. When the DSF assay is used as a screening tool, a threshold melting temperature change can be specified so that the output is one or more RNPs with a melting temperature change equal to or greater than the threshold. For example, the threshold can be 5°C-10°C (e.g., 5°, 6°, 7°, 8°, 9°, 10°) or higher, and the output can be one or more RNPs characterized by a melting temperature change greater than or equal to the threshold.

[0228] Two non-limiting examples of DSF assay conditions are as follows:

[0229] To determine the optimal solution for forming RNP complexes, 10x SYPRO A fixed concentration (e.g., 2 μM) of Cas9 in a 384-well plate (LifeTechnologies cat# S-6650) was dispensed into a 384-well plate. Equimolar amounts of gRNA diluted in solutions with different pH and salt were then added. After incubation at room temperature for 10' and brief centrifugation to remove any bubbles, the plates were analyzed using the Bio-Rad CFX384 with Bio-Rad CFX Manager software. TM Real-time system C1000Touch TMThe thermal cycler ran a gradient from 20°C to 90°C with a temperature increase of 1°C every 10 seconds.

[0230] The second assay consists of mixing various concentrations of gRNA with a fixed concentration (e.g., 2 μM) of Cas9 in the optimal buffer from assay 1 above, and incubating in a 384-well plate (e.g., at room temperature for 10'). Add an equal volume of optimal buffer + 10x SYPRO (Life Technologies cat# S-6650) and used After brief centrifugation to remove any bubbles, the plates were sealed using the Bio-Rad CFX384 TM Real-time system C1000 Touch TM The thermal cycler ran a gradient from 20°C to 90°C with a temperature increase of 1°C every 10 seconds.

[0231] Genome editing strategies

[0232] In various embodiments of the present disclosure, the genome editing systems described above are used to edit (i.e., change) a targeted region of DNA (e.g., TGFBR2 DNA) in or obtained from a cell. Various strategies for generating specific edits are described herein, and these strategies are generally described with respect to the desired repair outcome, the number and location of each edit (e.g., SSB or DSB), and the target location of such edits.

[0233] Genome editing strategies involving SSB or DSB formation are characterized by repair outcomes including: (a) deletion of all or part of the targeted region; (b) insertion or substitution of all or part of the targeted region; or (c) interruption of all or part of the targeted region. This grouping is not intended to limit or constrain any particular theory or model, but is provided only for ease of presentation. A skilled artisan will understand that the listed outcomes are not mutually exclusive, and that some repairs may lead to other outcomes. Unless otherwise stated, descriptions of specific editing strategies or methods should not be understood as requiring specific repair outcomes.

[0234] The replacement of the targeted region generally involves the replacement of all or part of the existing sequence in the targeted region by a homologous sequence, such as by gene correction or gene conversion (which is two repair results mediated by the HDR approach). HDR is promoted by using a donor template, which can be single-stranded or double-stranded, as described in more detail below. Single-stranded or double-stranded templates can be exogenous, in which case they will promote gene correction, or they can be endogenous (for example, homologous sequences in the cell genome) to promote gene conversion. The exogenous template can have an asymmetric overhang (i.e., the portion complementary to the site of the DSB in the template can be offset in the 3' or 5' direction, rather than in the center of the donor template), such as by Richardson et al. (Nature Biotechnology 34, 339-344 (2016), (Richardson), incorporated by reference). In the case where the template is single-stranded, it can correspond to the complementary (top) or non-complementary (bottom) chain of the targeted region.

[0235] As described in Ran and Cotta-Ramusino, in some cases, gene conversion and gene correction are facilitated by forming one or more nicks in or around the targeted region. In some cases, a double nickase strategy is used to form two offset SSBs, which in turn form a single DSB with an overhang (e.g., a 5' overhang).

[0236] Disruption and / or deletion of all or part of the targeted sequence can be achieved by a variety of repair outcomes. As an example, a sequence can be deleted by simultaneously creating two or more DSBs flanking the targeted region, which is then excised when the DSBs are repaired, as described by Maeer for the LCA10 mutation. As another example, a sequence can be interrupted by forming a deletion generated by a double-strand break with a single-stranded overhang, followed by exonucleolytic treatment of the overhang and then repair.

[0237] A specific subset of target sequence disruptions is mediated by the formation of indels within the targeted sequence, where the repair outcome is typically mediated by the NHEJ pathway (including Alt-NHEJ). NHEJ is known as an "error-prone" repair pathway because of its association with indel mutations. However, in some cases, DSBs are repaired by NHEJ without altering the sequence around them (so-called "perfect" or "scarless" repair); this typically requires perfect ligation of both ends of the DSB. At the same time, indels are believed to be generated by enzymatic treatment of free DNA ends before they are ligated, which adds and / or removes nucleotides from either or both strands of either or both free ends.

[0238] Since enzymatic processing of free DSB ends can be stochastic in nature, indel mutations tend to be variable, occur along a distribution, and can be influenced by a variety of factors, including the specific target site, the cell type used, the genome editing strategy used, etc. Even so, limited generalizations can be made about the formation of indels: deletions formed by repairing a single DSB are most often in the range of 1-50 bp, but can reach greater than 100-200 bp. Insertions formed by repairing a single DSB tend to be shorter and often include short repeats of the sequence immediately surrounding the break site. However, it is possible to obtain large insertions, and in these cases, the inserted sequence has often been traced to other regions of the genome or plasmid DNA present in the cell.

[0239] Insertion-deletion mutations and genome editing systems configured to produce insertions and deletions can be used, for example, to interrupt the target sequence when a specific final sequence does not need to be generated and / or when frameshift mutations are allowed. They can also be used in environments where specific sequences are preferred, as long as certain desired sequences tend to preferentially be generated from repairing SSBs or DSBs at a given site. Insertion-deletion mutations are also useful tools for evaluating or screening the activity of specific genome editing systems and components thereof. In these and other environments, insertions and deletions can be characterized by their relative and absolute frequencies in the cell genome contacted with the genome editing system (a), and (b) distribution of numerical differences (e.g., ±1, ±2, ±3, etc.) relative to unedited sequences. As an example, in a lead discovery environment, multiple gRNAs can be screened according to insertion-deletion readouts under controlled conditions to identify those gRNAs that most effectively drive shearing at the target site. Instructions for producing insertions and deletions equal to or below a threshold frequency or producing specific insertion-deletion distributions can be selected for further research and development. Indel frequency and distribution can also be used as a readout for evaluating different genome editing system implementations or formulations and delivery methods, for example by keeping the gRNA constant and varying certain other reaction conditions or delivery methods.

[0240] Multiplexing strategy

[0241] Although the exemplary strategies described above focus on repair outcomes mediated by a single DSB, the genome editing system according to the present disclosure can also be used to generate two or more DSBs in the same locus or in different loci. For example, editing strategies involving the formation of multiple DSBs or SSBs are described in Cotta-Ramusino.

[0242] Donor template design

[0243] Donor template design is described in detail in the literature, for example, in Cotta-Ramusino. DNA oligomer donor templates (oligodeoxynucleotides or ODNs) that can be single-stranded (ssODN) or double-stranded (dsODN) can be used to promote HDR-based DSB repair, and are particularly useful for introducing changes into a target DNA sequence, inserting a new sequence into a target sequence, or completely replacing a target sequence.

[0244] Whether single-stranded or double-stranded, the donor template generally contains regions homologous to regions of DNA within or near (e.g., flanking or adjacent) the target sequence to be cleaved. These regions of homology are referred to herein as "homology arms" and are schematically illustrated below:

[0245] [5' homology arm]-[alternative sequence]-[3' homology arm].

[0246] Homologous arms can have any suitable length (if only one homology arm is used, 0 nucleotides are included), and 3' and 5' homology arms can have the same length or can be different in length. The selection of suitable homology arm length may be affected by a variety of factors, such as the homology or microhomology with certain sequences (such as Alu repetitive sequences) or other very common elements that are desired to be avoided. For example, 5' homology arms can be shortened to avoid sequence repeat elements. In other embodiments, 3' homology arms can be shortened to avoid sequence repeat elements. In some embodiments, both 5' and 3' homology arms can be shortened to avoid including certain sequence repeat elements. In addition, some homology arm designs can improve editing efficiency or increase the frequency of desired repair results. For example, Richardson et al. Nature Biotechnology 34, 339-344 (2016) (Richardson) incorporated by reference found that the relative asymmetry of 3' and 5' homology arms of single-stranded donor templates affects repair rate and / or results.

[0247] Replacement sequences in donor templates have been described elsewhere, including by Cotta-Ramusino et al. Replacement sequences can be of any suitable length (including zero nucleotides, where the desired repair outcome is a deletion), and typically comprise one, two, three or more sequence modifications relative to the sequence naturally occurring in the cell that requires editing. One common sequence modification involves altering the naturally occurring sequence to repair a mutation associated with the disease or condition that requires treatment. Another common sequence modification involves altering one or more sequences complementary to or encoding the PAM sequence of an RNA-guided nuclease or the targeting domain of one or more gRNAs used to generate SSBs or DSBs to reduce or eliminate repeated cleavage of the target site after the replacement sequence is incorporated into the target site.

[0248] In the case of using a linear ssODN, it can be configured to (i) anneal to the nicked strand of the target nucleic acid, (ii) anneal to the intact strand of the target nucleic acid, (iii) anneal to the plus strand of the target nucleic acid and / or (iv) anneal to the minus strand of the target nucleic acid. The ssODN can have any suitable length, such as about, at least or no more than 150-200 nucleotides (e.g., 150, 160, 170, 180, 190 or 200 nucleotides).

[0249] It should be noted that template nucleic acid can also be a nucleic acid vector, such as a viral genome or a circular double-stranded DNA (e.g., plasmid). The nucleic acid vector comprising a donor template can include other coding or non-coding elements. For example, template nucleic acid can be delivered as a part of a viral genome (e.g., in an AAV or lentiviral genome), the viral genome comprising certain genomic backbone elements (e.g., in the case of an AAV genome, reverse terminal repeats), and optionally comprising other sequences of nucleases encoding gRNA and / or RNA guidance. In certain embodiments, the donor template can be adjacent to or flanked by a target site identified by one or more gRNAs to promote the formation of free DSBs at one or both ends of the donor template, and the donor template can participate in the repair of the corresponding SSB or DSB formed in the cell DNA using the same gRNA. Exemplary nucleic acid vectors suitable for use as donor templates are described in Cotta-Ramusino.

[0250] No matter which form is used, the template nucleic acid can be designed to avoid unwanted sequences. In certain embodiments, one or both homology arms can be shortened to avoid overlapping with certain sequence repeat elements (e.g., Alu repeats, LINE elements, etc.).

[0251] Target cells

[0252] The genome editing system according to the present disclosure can be used to manipulate or change cells, for example to edit or change a target nucleic acid. In various embodiments, the manipulation can occur in vivo or ex vivo.

[0253] According to the embodiments of the present disclosure, various cell types can be manipulated or changed, and in some cases (such as in vivo applications), various cell types are, for example, changed or manipulated by delivering the genome editing system according to the present disclosure to various cell types. However, in other cases, manipulation or change may need to be limited to one or more specific cell types. For example, in some cases, it may be necessary to edit cells with limited differentiation potential or terminally differentiated cells, such as photoreceptor cells in the case of Maeder, where the modification of the desired genotype leads to changes in cell phenotypes. However, in other cases, it may be necessary to edit stem cells or progenitor cells with a lower degree of differentiation, multipotency or multipotency. For example, cells can be embryonic stem cells, induced pluripotent stem cells (iPSC), hematopoietic stem / progenitor cells (HSPC) or other stem cells or progenitor cell types that are differentiated into cell types related to a given application or indication. In certain embodiments, the cell is a T cell.

[0254] As a corollary, the cells that are altered or manipulated are variously dividing cells or non-dividing cells, depending on the cell type or cells targeted and / or the desired editing outcome.

[0255] When cells are manipulated or altered ex vivo, the cells can be used immediately (e.g., administered to a subject), or they can be maintained or stored for later use. Those skilled in the art will appreciate that cells can be maintained in culture or stored (e.g., frozen in liquid nitrogen) using any suitable method known in the art.

[0256] Implementation of genome editing systems: delivery, formulation, and administration routes

[0257] As described above, the genome editing system of the present disclosure can be implemented in any suitable manner, which means that the components of such systems (including but not limited to RNA-guided nucleases, gRNAs, and optional donor template nucleic acids) can be delivered, formulated, or administered in any suitable form or combination of forms that result in transduction, expression, or introduction of the genome editing system and / or cause the desired repair results in cells, tissues, or subjects. Tables 3 and 4 list several non-limiting examples of genome editing implementations. However, those skilled in the art will appreciate that these lists are not comprehensive and other implementations are also possible. With particular reference to Table 3, the table lists several exemplary implementations of genome editing systems comprising a single gRNA and an optional donor template. However, the genome editing system according to the present disclosure can incorporate multiple gRNAs, multiple RNA-guided nucleases, and other components (such as proteins), and skilled technicians will understand multiple implementations based on the principles shown in the table. In the table, [N / A] indicates that the genome editing system does not include the indicated components.

[0258] Table 6

[0259]

[0260] Table 7 summarizes various delivery methods for components of the genome editing system as described herein. Again, the list is intended to be exemplary rather than limiting.

[0261] Table 7

[0262]

[0263] Nucleic acid-based delivery of genome editing systems

[0264] Nucleic acids encoding various elements of the genome editing system according to the present disclosure can be administered to a subject or delivered to a cell by methods known in the art or as described herein. For example, DNA encoding RNA-guided nucleases and / or gRNAs and donor template nucleic acids can be delivered by, for example, vectors (e.g., viral or non-viral vectors), non-vector-based methods (e.g., using naked DNA or DNA complexes), or a combination thereof.

[0265] The nucleic acid encoding the elements of the genome editing system may include sequences encoding one, two, three, four or more gRNAs. For example, the nucleic acid may encode both the first and second gRNA molecules, for example, wherein the second gRNA has a second targeting domain complementary to the second target sequence of the TGFBR2 gene. The nucleic acid disclosed herein may further include a nucleotide sequence encoding a third gRNA molecule, the third gRNA molecule having a third targeting domain complementary to the third target sequence of the TGFBR2 gene. The nucleic acid composition disclosed herein may further include a nucleotide sequence encoding a fourth gRNA molecule as described herein, the fourth gRNA molecule having a fourth targeting domain complementary to the fourth target sequence of the TGFBR2 gene. In certain embodiments, the second, third and / or fourth gRNA molecule comprises a targeting domain containing a nucleotide sequence selected from SEQ ID NO:5036 to 5096.

[0266] Nucleic acids encoding genome editing systems or components thereof can be delivered directly to cells as naked DNA or RNA, for example, by transfection or electroporation, or can be conjugated to molecules (e.g., N-acetylgalactosamine) that promote uptake by target cells (e.g., erythrocytes, HSCs). Nucleic acid vectors, such as those summarized in Table 4, can also be used.

[0267] The nucleic acid vector may include one or more sequences encoding genome editing system components (such as RNA-guided nucleases, gRNAs, and / or donor templates). The vector may also include a sequence encoding a signal peptide (e.g., for nuclear localization, nucleolar localization, or mitochondrial localization) that is associated with (e.g., inserted into or fused to) a sequence encoding a protein. As an example, a nucleic acid vector may include a Cas9 coding sequence that includes one or more nuclear localization sequences (e.g., a nuclear localization sequence from SV40).

[0268] The nucleic acid vector may also contain any suitable number of regulatory / control elements, such as promoters, enhancers, introns, polyadenylation signals, Kozak consensus sequences, or internal ribosome entry sites (IRES). These elements are well known in the art and are described in Cotta-Ramusino.

[0269] Nucleic acid vectors according to the present disclosure include recombinant viral vectors. Exemplary viral vectors are listed in Table 7, and other suitable viral vectors and their uses and production are described in Cotta-Ramusino. In certain embodiments, the vector is a viral vector, such as an adeno-associated virus (AAV) vector or a lentivirus (LV) vector. Other viral vectors known in the art can also be used. In addition, viral particles can be used to deliver genome editing system components in the form of nucleic acids and / or peptides. For example, "empty" viral particles can be assembled to accommodate any suitable load. Viral vectors and viral particles can also be engineered to incorporate targeting ligands to change target tissue specificity.

[0270] In addition to viral vectors, non-viral vectors can also be used to deliver nucleic acids encoding genome editing systems according to the present disclosure. An important class of non-viral nucleic acid vectors are nanoparticles, which can be organic or inorganic. Nanoparticles are well known in the art and are summarized in Cotta-Ramusino. Any suitable nanoparticle design can be used to deliver genome editing system components or nucleic acids encoding such components. For example, organic (e.g., lipid and / or polymer) nanoparticles can be suitable for use as delivery vehicles in certain embodiments of the present disclosure. Table 8 shows exemplary lipids for nanoparticle formulations and / or gene transfer, and Table 9 lists exemplary polymers for gene transfer and / or nanoparticle formulations.

[0271] Table 8: Lipids used for gene transfer

[0272]

[0273] Table 9: Polymers used for gene transfer

[0274] polymer abbreviation Polyethylene glycol PEG Polyethyleneimine PEI Bis(succinimidyl propionate) dithioate DSP 3,3'-Dithiodipropylimidate dimethyl ester DTBP Poly(ethyleneimine) diurethane PEIC Poly(L-lysine) PLL His-modified PLL Poly(N-vinylpyrrolidone) PVP Poly(propyleneimide) PPI Poly(amidoamine) PAMAM Poly(aminoethyleneimine) SS-PAEI Triethylenetetramine TETA Poly(β-amino ester) Poly(4-hydroxy-L-proline ester) PHP Poly(allylamine) Poly(α-[4-aminobutyl]-L-glycolic acid) PAGA Poly (D,L-lactic-co-glycolic acid) PLGA Poly(N-ethyl-4-vinylpyridinium bromide) Poly(phosphazene) PPZ Poly(phosphate) PPE Poly(phosphoramidate) PPA Poly(N-2-hydroxypropylmethacrylamide) pHPMA Poly(2-(dimethylamino)ethyl methacrylate) pDMAEMA Poly(2-aminoethyl propylene phosphate) PPE-EA Chitosan Galactosylated chitosan N-dodecyl chitosan Histone Collagen Dextran-spermine D-SPM

[0275] Non-viral vectors optionally include targeted modifications to improve uptake and / or selective targeting of specific cell types. These targeted modifications can include, for example, cell-specific antigens, monoclonal antibodies, single-chain antibodies, aptamers, polymers, sugars (e.g., N-acetylgalactosamine (GalNAc)) and cell-penetrating peptides. Such carriers also optionally use peptides / polymers that promote fusion and endosomal instability, undergo acid-triggered conformational changes (e.g., to accelerate the endosomal escape of the load), and / or incorporate stimulation that can be cut polymers, for example, to release in a cell compartment. For example, cationic polymers based on disulfide cut in a reducing cell environment can be used.

[0276] In certain embodiments, one or more nucleic acid molecules (e.g., DNA molecules) other than the components of the genome editing system (e.g., the nuclease components and / or gRNA components guided by RNA as described herein) are delivered. In certain embodiments, nucleic acid molecules are delivered simultaneously with one or more components of the genome editing system. In certain embodiments, nucleic acid molecules are delivered before or after (e.g., less than about 30 minutes, 1 hour, 2 hours, 3 hours, 6 hours, 9 hours, 12 hours, 1 day, 2 days, 3 days, 1 week, 2 weeks, or 4 weeks) one or more components of the genome editing system are delivered. In certain embodiments, nucleic acid molecules are delivered in a different manner from the delivery of one or more components of the genome editing system (e.g., the nuclease components and / or gRNA components guided by RNA). Nucleic acid molecules can be delivered by any delivery method described herein. For example, nucleic acid molecules can be delivered by viral vectors (e.g., integration defective lentiviruses), and RNA-guided nuclease molecule components and / or gRNA components can be delivered by electroporation, such as to reduce the toxicity caused by nucleic acids (e.g., DNA). In certain embodiments, nucleic acid molecules encode therapeutic proteins, such as proteins described herein. In certain embodiments, nucleic acid molecules encode RNA molecules, such as RNA molecules described herein.

[0277] Delivery of RNPs and / or RNA encoding components of genome editing systems

[0278] RNPs (complexes of gRNA and RNA-guided nucleases, i.e., ribonucleoprotein complexes) and / or RNA encoding RNA-guided nucleases and / or gRNAs can be delivered to cells or administered to subjects by methods known in the art, some of which are described in Cotta-Ramusino. In vitro, RNA encoding RNA-guided nucleases and / or gRNAs can be delivered, for example, by microinjection, electroporation, transient cell compression or extrusion (see, e.g., Lee 2012). Lipid-mediated transfection, peptide-mediated delivery, GalNAc or other conjugate-mediated delivery, and combinations thereof can also be used for in vitro and in vivo delivery.

[0279] In vitro, delivery via electroporation includes mixing cells with RNA encoding RNA-guided nucleases and / or gRNAs with or without donor template nucleic acid molecules in a box, chamber, or test tube, and applying one or more electric pulses of defined duration and amplitude. Systems and protocols for electroporation are known in the art, and any suitable electroporation tools and / or protocols can be used in conjunction with various embodiments of the present disclosure.

[0280] In certain embodiments, the RNP complexes of the present disclosure (including, for example, RNP pharmaceutical compositions) can be used to: (1) improve T cell proliferation; (2) improve T cell survival; and / or (3) improve T cell function. For example, but not limiting, two or more RNP complexes comprising different gRNAs can be used simultaneously or sequentially to change TGFBR2 gene expression in cells (e.g., T cells). Such RNP complexes can include different gRNAs targeting different TGFBR2 gene sequences. In some cases, the RNP complex can induce a cleavage event, such as a double-strand or single-strand break. For example, the RNP complex can include an enzymatically active Cas9 (eaCas9) molecule that forms a double-strand break in a target nucleic acid or an eaCas9 molecule (e.g., a nickase molecule) that forms a single-strand break in a target nucleic acid. In certain embodiments, a double nickase RNP strategy can be used to form two offset single-strand breaks, which in turn form a single double-strand break with an overhang (e.g., a 5' overhang).

[0281] Ways to Give

[0282] Genome editing systems or cells altered or manipulated using such systems can be administered to subjects by any suitable mode or approach (whether local or systemic). Systemic administration modes include oral and parenteral routes. Parenteral routes include, for example, intravenous, intramedullary, intraarterial, intramuscular, intradermal, subcutaneous, intranasal and intraperitoneal routes. Systemic components can be modified or formulated to target, for example, HSC, hematopoietic stem cells / progenitor cells or erythroid progenitor cells or precursor cells.

[0283] The local administration mode includes, for example, intramedullary injection into the trabecular bone or intramedullary injection into the femur in the medullary cavity and infusion into the portal vein. In certain embodiments, compared with systemic (e.g., intravenous) administration, when local (e.g., directly into the bone marrow) administration, significantly less amount of components (compared with systemic methods) can play a role. The local administration mode can reduce or eliminate the occurrence of potential toxic and side effects that may occur when systemic administration of the component of the therapeutically effective amount.

[0284] Administration may be provided as periodic boluses (eg intravenously) or as continuous infusion from an internal reservoir or from an external reservoir (eg from an IV bag or an implantable pump).The components may be administered topically, for example by continuous release from a sustained release drug delivery device.

[0285] In addition, component can be formulated to allow to release in a long time. Release system can comprise biodegradable material or the matrix of the material of the component that releases is incorporated by diffusion. Component can be evenly or unevenly distributed in release system. Can use multiple release system, but the selection of suitable system will depend on the release rate required for specific application. Can use non-degradable and degradable release system both. Suitable release system comprises polymer and polymer matrix, non-polymer matrix or inorganic and organic excipient and diluent, such as but not limited to calcium carbonate and sugar (such as trehalose). Release system can be natural or synthetic. However, synthetic release system is preferred, because usually they are more reliable, more reproducible and generate more definite release curve. Can select release system material, make component with different molecular weight release by diffusion of material or by the degradation of material.

[0286] Representative synthetic biodegradable polymers include, for example: polyamides, such as poly(amino acids) and poly(peptides); polyesters, such as poly(lactic acid), poly(glycolic acid), poly(lactic-co-glycolic acid) and poly(caprolactone); poly(anhydrides); polyorthoesters; polycarbonates; and chemical derivatives thereof (substitution, addition of chemical groups (e.g., alkyl, alkylene), hydroxylation, oxidation, and other modifications routinely performed by those skilled in the art), copolymers, and mixtures thereof. Representative synthetic non-degradable polymers include, for example: polyethers, such as poly(ethylene oxide), poly(ethylene glycol), and poly(tetramethylene oxide); vinyl polymers - polyacrylates and polymethacrylates (such as methyl methacrylate, ethyl methacrylate, other alkyl methacrylates, hydroxyethyl methacrylate, acrylic acid and methacrylic acid), as well as others (such as poly(vinyl alcohol), poly(vinyl pyrrolidone), and poly(vinyl acetate)); poly(urethane); cellulose and its derivatives, such as alkyl cellulose, hydroxyalkyl cellulose, cellulose ethers, cellulose esters, nitrocellulose, and various cellulose acetates; polysiloxanes; and any chemical derivatives thereof (substitution, addition of chemical groups (e.g., alkyl, alkylene), hydroxylation, oxidation, and other modifications routinely performed by those skilled in the art), copolymers, and mixtures thereof.

[0287] Poly(lactide-co-glycolide) microspheres can also be used. Typically, microspheres are composed of polymers of lactic acid and glycolic acid, and their structure forms hollow spheres. The diameter of the spheres can be about 15-30 microns and can be loaded with the components described herein.

[0288] Multimodal or differential delivery of components

[0289] In view of the present disclosure, the skilled artisan will appreciate that the different components of the genome editing systems disclosed herein can be delivered together or individually and simultaneously or non-simultaneously. It may be particularly desirable to deliver the components of the genome editing system individually and / or asynchronously to provide temporal or spatial control over the function of the genome editing system and to limit certain effects caused by its activity.

[0290] Different or differential modes used herein refer to delivery modes that confer different pharmacodynamic or pharmacokinetic properties to component molecules of the present invention (e.g., RNA-guided nuclease molecules, gRNA, template nucleic acids, or payloads). For example, the delivery mode can result in different tissue distributions, different half-lives, or different time distributions, for example, in selected chambers, tissues, or organs.

[0291] Some modes of delivery (e.g., delivery by a nucleic acid vector that persists in a cell or cell progeny, such as by autonomous replication or insertion into cellular nucleic acid) result in more persistent expression and presence of the component. Examples include viral (e.g., AAV or lentiviral) delivery.

[0292] For example, the components of the genome editing system (e.g., RNA-guided nucleases and gRNAs) can be delivered by different modes in terms of the resulting half-life or persistence of the delivered components in the body or a specific compartment, tissue, or organ. In certain embodiments, the gRNA can be delivered by such a mode. The RNA-guided nuclease molecule components can be delivered in a mode that results in less persistence or less exposure to the body or a specific compartment, tissue, or organ.

[0293] More generally, in certain embodiments, a first mode of delivery is used to deliver a first component, and a second mode of delivery is used to deliver a second component. The first mode of delivery imparts a first pharmacodynamic or pharmacokinetic property. The first pharmacodynamic property can be, for example, the distribution, persistence, or exposure of a component or a nucleic acid encoding a component in the body, compartment, tissue, or organ. The second mode of delivery imparts a second pharmacodynamic or pharmacokinetic property. The second pharmacodynamic property can be, for example, the distribution, persistence, or exposure of a component or a nucleic acid encoding a component in the body, compartment, tissue, or organ.

[0294] In certain embodiments, a first pharmacodynamic or pharmacokinetic property (eg, distribution, persistence, or exposure) is more restricted than a second pharmacodynamic or pharmacokinetic property.

[0295] In certain embodiments, the first mode of delivery is selected to optimize (eg, minimize) a pharmacodynamic or pharmacokinetic property, such as distribution, persistence, or exposure.

[0296] In certain embodiments, the second mode of delivery is selected to optimize (eg, maximize) a pharmacodynamic or pharmacokinetic property, such as distribution, persistence, or exposure.

[0297] In certain embodiments, the first mode of delivery includes the use of relatively durable elements (e.g., nucleic acids, such as plasmids or viral vectors (e.g., AAV or lentivirus). Because such vectors are relatively durable, the products transcribed from them will be relatively durable.

[0298] In certain embodiments, the second mode of delivery includes a relatively transient element, such as RNA or a protein.

[0299] In certain embodiments, the first component comprises gRNA, and the delivery mode is relatively durable, for example, gRNA is transcribed from a plasmid or viral vector (e.g., AAV or lentivirus). The transcription of these genes has almost no physiological significance, because these genes do not encode protein products, and gRNA cannot function alone. The nuclease molecule guided by the second component RNA is delivered in a transient manner (e.g., in the form of mRNA or protein), thereby ensuring that the complete RNA-guided nuclease molecule / gRNA complex exists and is active only in a short time.

[0300] Furthermore, the components may be delivered in different molecular forms or using different delivery vehicles that complement each other to enhance safety and tissue specificity.

[0301] Using differential delivery modes can enhance performance, safety and / or efficacy, for example, the possibility of eventual off-target modification can be reduced. Delivery of immunogenic components (e.g., Cas9 molecules) in a less persistent mode can reduce immunogenicity because MHC molecules display peptides from bacterial-derived Cas enzymes on the cell surface. Two-part delivery systems can mitigate these disadvantages.

[0302] Differential delivery mode can be used to deliver components to different but overlapping target areas. The formation of active complex is minimized outside the overlap of target area. Therefore, in certain embodiments, the first component (e.g., gRNA) is delivered by the first delivery mode that causes the first space (e.g., tissue) distribution. The second component (e.g., RNA-guided nuclease molecule) is delivered by the second delivery mode that causes the second space (e.g., tissue) distribution. In certain embodiments, the first mode includes a first element selected from liposomes, nanoparticles (e.g., polymer nanoparticles) and nucleic acids (e.g., viral vectors). The second mode includes a second element selected from the group. In certain embodiments, the first delivery mode includes a first targeting element (e.g., cell-specific receptor or antibody), and the second delivery mode does not include the element. In certain embodiments, the second delivery mode includes a second targeting element, such as a second cell-specific receptor or a second antibody.

[0303] When RNA-guided nuclease molecules are delivered in viral delivery vectors, liposomes, or polymer nanoparticles, there is the potential for delivery to multiple tissues and therapeutic activity therein, where targeting of only a single tissue may be desired. A two-part delivery system can address this challenge and enhance tissue specificity. If the gRNA and RNA-guided nuclease molecules are packaged in separate delivery vehicles with different but overlapping tissue tropisms, a fully functional complex is formed only in tissues targeted by both vectors.

[0304] Genetically engineered cells and methods for producing cells expressing recombinant receptors

[0305] Provided herein are cells for adoptive cell therapy (e.g., adoptive immunotherapy), and methods for producing or generating cells. Cells include immune cells, such as T cells. Typically, cells are engineered by introducing one or more genetically engineered nucleic acids or their products. Such products include genetically engineered antigen receptors, including engineered T cell receptors (TCR) and functional non-TCR antigen receptors (such as chimeric antigen receptors (CAR), including activated, stimulated and costimulatory CARs), and combinations thereof. In some embodiments, nucleic acids encoding genetically engineered antigen receptors are also introduced into cells simultaneously or sequentially with agents (e.g., Cas9 / gRNA RNP) that can destroy genes encoding TGFBR2.

[0306] In some embodiments, cells (e.g., T cells) may be incubated or cultivated before, during, and / or after the introduction of nucleic acid molecules encoding recombinant receptors and / or agents (e.g., Cas9 / gRNA RNP). In some embodiments, cells (e.g., T cells) may be incubated or cultivated before, during, or after the introduction of nucleic acid molecules encoding recombinant receptors, such as before, during, or after transduction of cells with viral vectors (e.g., lentiviral vectors) encoding recombinant receptors. In some embodiments, cells (e.g., T cells) may be incubated or cultivated before, during, or after the introduction of agents (e.g., Cas9 / gRNA RNP), such as before, during, or after contacting cells with agents, or before, during, or after delivering agents to (e.g., via electroporation) cells. In some embodiments, the incubation may be performed in the context of introducing nucleic acid molecules encoding recombinant receptors and introducing agents (e.g., Cas9 / gRNARNP). In some embodiments, the incubation can be carried out in the presence of cytokines (such as IL-2, IL-7 or IL-15), or in the presence of stimulators or activators that induce proliferation or activation of cells (such as anti-CD3 / anti-CD28 antibodies).

[0307] In some embodiments, the method includes activating or stimulating cells with a stimulant or activator (e.g., anti-CD3 / anti-CD28 antibody) before introducing nucleic acid molecules and agents (e.g., Cas9 / gRNA RNP) encoding recombinant receptors. In some embodiments, the incubation can also be carried out in the presence of cytokines such as IL-2 (e.g., 1U / mL to 500U / mL, such as 10U / mL to 200U / mL, such as at least or about 50U / mL or 100U / mL), IL-7 (e.g., 0.5ng / mL to 50ng / mL, such as 1ng / mL to 20ng / mL, such as at least or about 5ng / mL or 10ng / mL) or IL-15 (e.g., 0.1ng / mL to 50ng / mL, such as 0.5ng / mL to 25ng / mL, such as at least or about 1ng / mL or 5ng / mL). In some embodiments, the cells are incubated for 6 hours to 96 hours, such as 24-48 hours or 24-36 hours, prior to introduction of a nucleic acid molecule encoding a recombinant receptor (eg, via transduction).

[0308] Cells and cell preparation for genetic engineering

[0309] Recombinant receptors bound to specific antigens and agents (e.g., Cas9 / gRNARNP) for gene editing of TGFBR2 genes encoding TGFBR2 polypeptides can be introduced into a variety of cells. In some embodiments, the recombinant receptors are engineered and / or the TGFBR2 target gene is manipulated in vitro, and the resulting genetically engineered cells are administered to the subject. The source of the target cells for in vitro manipulation can include, for example, the blood of the subject, the umbilical cord blood of the subject, or the bone marrow of the subject. The source of the target cells for in vitro manipulation can also include, for example, heterologous donor blood, umbilical cord blood, or bone marrow.

[0310] In some embodiments, the cell (e.g., engineered cell) is a eukaryotic cell (e.g., a mammalian cell, e.g., a human cell). In some embodiments, the cell is derived from blood, bone marrow, lymph or lymphoid organs, and is a cell of the immune system, such as a cell of innate immunity or adaptive immunity, such as bone marrow or lymphoid cells (including lymphocytes, typically T cells and / or NK cells). Other exemplary cells include stem cells, such as pluripotent stem cells and multipotent stem cells, including induced pluripotent stem cells (iPSC). In some aspects, the cell is a human cell. With respect to a subject to be treated, the cell can be allogeneic and / or autologous. The cell is typically a primary cell, such as those directly separated from a subject and / or separated and frozen from a subject.

[0311] In some embodiments, the target cell is a T cell, such as a CD8+T cell (e.g., a CD8+ naive T cell, a central memory T cell, or an effector memory T cell), a CD4+T cell, a natural killer T cell (NKT cell), a regulatory T cell (Treg), a stem cell memory T cell, a lymphocyte progenitor cell, a hematopoietic stem cell, a natural killer cell (NK cell), or a dendritic cell. In some embodiments, the cell is a monocyte or a granulocyte, such as a bone marrow cell, a macrophage, a neutrophil, a dendritic cell, a mast cell, an eosinophil, and / or a basophil. In one embodiment, the target cell is an induced pluripotent stem (iPS) cell or a cell derived from an iPS cell, such as an iPS cell that is generated from a subject, manipulated to change (e.g., induce mutations in one or more target genes) or manipulate the expression of one or more target genes, and differentiated into, for example, a T cell (e.g., a CD8+ T cell (e.g., a CD8+ naive T cell, a central memory T cell, or an effector memory T cell), a CD4+ T cell, a stem cell memory T cell), a lymphoid progenitor cell, or a hematopoietic stem cell.

[0312] In some embodiments, the cells include one or more subsets of T cells or other cell types, such as the entire T cell population, CD4+ cells, CD8+ cells, and subsets thereof, such as those defined by function, activation state, maturity, differentiation potential, expansion, recirculation, localization and / or persistence capacity, antigen specificity, antigen receptor type, presence in a specific organ or compartment, marker or cytokine secretion characteristics, and / or degree of differentiation.

[0313] Subtypes and subpopulations of T cells and / or CD4+ and / or CD8+ T cells include naive T (TN) cells, effector T cells (TEFF), memory T cells and their subtypes (such as stem cell memory T (TSCM), central memory T (TCM), effector memory T (TEM) or terminally differentiated effector memory T cells), tumor infiltrating lymphocytes (TIL), immature T cells, mature T cells, helper T cells, cytotoxic T cells, mucosa-associated invariant T (MAIT) cells, naturally occurring and adaptive regulatory T (Treg) cells, helper T cells (such as TH1 cells, TH2 cells, TH3 cells, TH17 cells, TH9 cells, TH22 cells, follicular helper cell T cells), α / β T cells and δ / γ T cells.

[0314] In some embodiments, the method includes separating cells from a subject, preparing, processing, culturing and / or engineering them. In some embodiments, the preparation of the engineered cells includes one or more culture and / or preparation steps. As described herein, the cells for engineering can be separated from a sample (such as a biological sample, for example, a biological sample obtained from or derived from a subject). In some embodiments, the subject separating the cells is a subject suffering from a disease or illness or needs a cell therapy or will be given a cell therapy. In some embodiments, the subject is a person who needs a specific therapeutic intervention (such as the adoptive cell therapy used for the separated, processed and / or engineered cells).

[0315] Therefore, in some embodiments, the cell is a primary cell, such as a primary human cell. Samples include tissues, fluids and other samples taken directly from a subject, as well as samples from one or more processing steps (such as separation, centrifugation, genetic engineering (e.g., transduction with a viral vector), washing and / or incubation). Biological samples can be samples obtained directly from a biological source or processed samples. Biological samples include, but are not limited to, body fluids (such as blood, plasma, serum, cerebrospinal fluid, synovial fluid, urine and sweat), tissue and organ samples, including processed samples obtained therefrom.

[0316] In some aspects, the sample from which the cell originates or is separated is a sample derived from blood or blood, or is or is derived from apheresis or leukocyte apheresis product. Exemplary samples include whole blood, peripheral blood mononuclear cells (PBMC), leukocytes, bone marrow, thymus, tissue biopsy, tumor, leukemia, lymphoma, lymph node, gut-associated lymphoid tissue, mucosa-associated lymphoid tissue, spleen, other lymphoid tissues, liver, lung, stomach, intestine, colon, kidney, pancreas, breast, bone, prostate, cervix, testis, ovary, tonsil or other organs and / or cells derived therefrom. In the context of cell therapy (e.g., adoptive cell therapy), samples include samples from autologous and allogeneic sources.

[0317] In some embodiments, the cell is derived from a cell line, such as a T cell line. In some embodiments, the cell is obtained from a xenogeneic source, such as from a mouse, rat, non-human primate, or pig.

[0318] In some embodiments, the separation of cells includes one or more preparation steps and / or non-affinity-based cell separation steps. In some examples, cells are washed, centrifuged and / or incubated in the presence of one or more reagents, for example to remove unwanted components, enrich, crack or remove cells sensitive to specific reagents for desired components. In some examples, cells are separated based on one or more characteristics (such as density, adhesion properties, size, sensitivity and / or resistance to specific components).

[0319] In some examples, cells from the circulating blood of a subject are obtained, for example, by apheresis or leukapheresis. In some aspects, the sample contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells and / or platelets, and in some aspects contains cells other than red blood cells and platelets.

[0320] In some embodiments, the blood cells collected from the subject are washed to, for example, remove the plasma fraction, and the cells are placed in an appropriate buffer or medium for subsequent processing steps. In some embodiments, cells are washed with phosphate buffered saline (PBS). In some embodiments, the washing solution lacks calcium and / or magnesium and / or many or all divalent cations. In some respects, according to the manufacturer's instructions, washing steps are completed by a semi-automatic "flow-through" centrifuge (e.g., Cobe 2991 cell processor, Baxter). In some respects, washing steps are completed by tangential flow filtration (TFF) according to the manufacturer's instructions. In some embodiments, after washing, the cells are resuspended in a variety of biocompatible buffers (e.g., PBS without Ca++ / Mg++). In certain embodiments, the components of the blood cell sample are removed and the cells are directly resuspended in culture medium.

[0321] In some embodiments, the methods include density-based cell separation methods, such as preparing white blood cells from peripheral blood by lysing red blood cells and centrifuging through a Percoll or Ficoll gradient.

[0322] In some embodiments, separation methods include separating different cell types based on the expression or presence of one or more specific molecules, such as surface markers (e.g., surface proteins), intracellular markers, or nucleic acids in cells. In some embodiments, any known separation method based on such markers can be used. In some embodiments, separation is based on affinity or based on immunoaffinity separation. For example, in some aspects, separation includes separating cells and cell populations based on the expression or expression level of one or more markers (typically cell surface markers) in cells, for example, by incubating with antibodies or binding partners that specifically bind to such markers, followed by washing steps and separating cells that have bound the antibodies or binding partners from those that have not yet bound to the antibodies or binding partners.

[0323] Such separation steps can be based on positive selection (wherein cells that have bound the agent are retained for further use) and / or negative selection (wherein cells that have not bound the antibody or binding partner are retained). In some examples, both fractions are retained for further use. In some aspects, negative selection can be particularly useful in cases where antibodies that specifically identify cell types in a heterogeneous population are not available, making it best to perform separation based on markers expressed by cells other than the desired population.

[0324] Separation need not result in 100% enrichment or removal of a particular cell population or cells expressing a particular marker. For example, positive selection or enrichment for a particular type of cell (such as those expressing a marker) refers to increasing the number or percentage of such cells, but need not result in the complete absence of cells that do not express the marker. Similarly, negative selection, removal or depletion of a particular type of cell (such as those expressing a marker) refers to reducing the number or percentage of such cells, but need not result in the complete removal of all such cells.

[0325] In some examples, multiple rounds of separation steps are performed, wherein the fractions from the positive or negative selection of one step are subjected to another separation step, such as a subsequent positive or negative selection. In some examples, a single separation step can simultaneously deplete cells expressing multiple markers, such as by incubating the cells with multiple antibodies or binding partners, each of which is specific for the marker targeted for negative selection. Similarly, multiple cell types can be positively selected simultaneously by incubating the cells with multiple antibodies or binding partners expressed on various cell types.

[0326] In some embodiments, one or more T cell populations are enriched or depleted for cells that are positive for one or more specific markers (e.g., surface markers) (marker+) or express high levels of one or more specific markers (e.g., surface markers) (markerhigh), or negative for one or more markers (markerhigh). -) or cells expressing relatively low levels of one or more markers (marker low). For example, in some aspects, a specific subset of T cells, such as cells that are positive or express high levels of one or more surface markers (e.g., CD28+, CD62L+, CCR7+, CD27+, CD127+, CD4+, CD8+, CD45RA+, and / or CD45RO+ T cells) are separated by positive or negative selection techniques. In some cases, such markers are those that are absent or expressed at relatively low levels on certain T cell populations (e.g., non-memory cells), but present or expressed at relatively high levels on certain other T cell populations (e.g., memory cells). In one embodiment, cells (such as CD8+ cells or T cells, such as CD3+ cells) are enriched (i.e., positively selected) for cells that are positive for CD45RO, CCR7, CD28, CD27, CD44, CD127, and / or CD62L or express high surface levels of CD45RO, CCR7, CD28, CD27, CD44, CD127, and / or CD62L, and / or cells that are positive for CD45RA or express high levels of CD45RA are depleted (e.g., negatively selected). In some embodiments, cells are enriched or depleted for cells that are positive for CD122, CD95, CD25, CD27, and / or IL7-Rα (CD127) or express high surface levels of CD122, CD95, CD25, CD27, and / or IL7-Rα (CD127). In some examples, CD8+ T cells are enriched for cells that are positive for CD45RO (or negative for CD45RA) and positive for CD62L.

[0327] For example, CD3+, CD28+ T cells can be detected using CD3 / CD28 conjugated magnetic beads (e.g., M-450 CD3 / CD28 T cell expander) for positive selection.

[0328] In some embodiments, T cells are separated from peripheral blood mononuclear cells (PBMC) samples by negative selection for markers (such as CD14) expressed on non-T cells (such as B cells, monocytes or other leukocytes). In some aspects, CD4+ or CD8+ selection steps are used to separate CD4+ helper cells and CD8+ cytotoxic T cells. Such CD4+ and CD8+ populations can be further classified into subgroups by positive or negative selection of markers expressed or expressed at a relatively high degree on one or more naive, memory and / or effector T cell subsets.

[0329] In some embodiments, CD8+ cells are further enriched or depleted for naive, central memory, effector memory and / or central memory stem cells, such as by positive or negative selection based on surface antigens associated with the corresponding subpopulations. In some embodiments, central memory T (TCM) cells are enriched to increase efficacy, such as to improve long-term survival, expansion and / or transplantation after administration, which is particularly robust in such subpopulations in some aspects. (See Terakura et al. (2012) Blood. 1: 72-82; Wang et al. (2012) J Immunother. 35 (9): 689-701.) In some embodiments, CD8+T cells rich in TCM are combined with CD4+T cells to further enhance efficacy.

[0330] In an embodiment, memory T cells are present in both CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes.PBMCs can be enriched or depleted for CD62L-CD8+ and / or CD62L+CD8+ fractions, for example, using anti-CD8 and anti-CD62L antibodies.

[0331] In some embodiments, CD4+T cell colonies and CD8+T cell subpopulations, such as subpopulations enriched in central memory (TCM) cells. In some embodiments, the enrichment of central memory T (TCM) cells is based on the positive or high surface expression of CD45RO, CD62L, CCR7, CD28, CD3 and / or CD 127; In some aspects, it is based on the negative selection of cells expressing or highly expressing CD45RA and / or granzyme B. In some aspects, the separation of CD8+ populations enriched in TCM cells is carried out by the depletion of cells expressing CD4, CD14, CD45RA and the positive selection or enrichment of cells expressing CD62L. In one aspect, the enrichment of central memory T (TCM) cells is carried out from the negative cell fraction selected based on CD4 expression, and the negative cell fraction is negatively selected based on the expression of CD14 and CD45RA and positively selected based on CD62L. In some aspects, such selections are carried out simultaneously, and in other aspects, they are carried out sequentially in any order. In some aspects, the same selection step based on CD4 expression used to prepare a CD8+ cell population or subpopulation is also used to generate a CD4+ cell population or subpopulation, such that positive and negative fractions from the CD4-based separation are retained and used in subsequent steps of the method, optionally after one or more additional positive or negative selection steps.

[0332] In a specific example, a PBMC sample or other leukocyte sample is subjected to selection of CD4+ cells, wherein both negative and positive fractions are retained. The negative fraction is then subjected to negative selection based on expression of CD14 and CD45RA or CD19, and positive selection based on markers specific to central memory T cells (such as CD62L or CCR7), wherein positive and negative selection are performed in either order.

[0333] CD4+T helper cells are classified into naive, central memory and effector cells by identifying cell populations with cell surface antigens. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, naive CD4+T lymphocytes are CD45RO-, CD45RA+, CD62L+, CD4+T cells. In some embodiments, central memory CD4+ cells are CD62L+ and CD45RO+. In some embodiments, effector CD4+ cells are CD62L- and CD45RO.

[0334] In one example, to enrich CD4+ cells by negative selection, the monoclonal antibody cocktail typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In some embodiments, the antibody or binding partner is bound to a solid support or matrix (such as magnetic beads or paramagnetic beads) to allow separation of cells for positive and / or negative selection. For example, in some embodiments, immunomagnetic (or affinity magnetic) separation techniques are used to separate or isolate cells and cell populations (reviewed in Methods in Molecular Medicine, Vol. 58: Metastasis Research Protocols, Vol. 2: Cell Behavior In Vitro and In Vivo, pp. 17-25, SA Brooks and U. Schumacher, ed. Humana Press Inc., Totowa, NJ).

[0335] In some embodiments, cells are hatched and / or cultured before or in combination with genetic engineering. The incubation step may include culturing, nurturing, stimulating, activating and / or breeding. In some embodiments, the composition or cells are incubated in the presence of stimulating conditions or stimulants. Such conditions include those designed for: inducing proliferation, amplification, activation and / or survival of cells in the population, simulating antigen exposure, and / or initiating cells for genetic engineering (e.g., for introducing recombinant antigen receptors).

[0336] The conditions may include one or more of: a specific culture medium, temperature, oxygen content, carbon dioxide content, time, agents (e.g., nutrients, amino acids, antibiotics, ions and / or stimulatory factors such as cytokines, chemokines, antigens, binding partners, fusion proteins, recombinant soluble receptors and any other agents intended to activate cells)).

[0337] In some embodiments, the stimulation condition or stimulant includes one or more agents (e.g., ligands) capable of activating the intracellular signaling domain of the TCR complex. In some aspects, the agent turns on or starts the TCR / CD3 intracellular signaling cascade in T cells. Such agents may include, for example, antibodies bound to a solid support (e.g., beads), such as antibodies specific to TCR components and / or co-stimulatory receptors (e.g., anti-CD3, anti-CD28); and / or one or more cytokines. Optionally, the amplification method may also include the step of adding anti-CD3 and / or anti-CD28 antibodies to the culture medium (e.g., at a concentration of at least about 0.5 ng / ml). In some embodiments, the stimulant includes IL-2 and / or IL-15, for example, an IL-2 concentration of at least about 10 units / mL.

[0338] In some aspects, incubation is performed according to a variety of techniques, such as those described in U.S. Pat. No. 6,040,177 to Riddell et al., Klebanoff et al. (2012) J Immunother. 35(9):651-660, Terakura et al. (2012) Blood. 1:72-82, and / or Wang et al. (2012) J Immunother. 35(9):689-701.

[0339] In some embodiments, T cells are expanded in the following manner: feeder cells (such as non-dividing PBMC) are added to the culture starting composition (for example, so that for each T lymphocyte in the initial population to be expanded, the resulting cell population contains at least about 5, 10, 20 or 40 or more PBMC feeder cells) and incubation of the culture (for example, for a time sufficient to expand the number of T cells). In some aspects, non-dividing feeder cells can include γ-irradiated PBMC feeder cells. In some embodiments, PBMCs are irradiated with gamma rays in the range of about 3000 to 3600 rads to prevent cell division. In some aspects, feeder cells are added to the culture medium before adding the T cell population.

[0340] In some embodiments, the stimulating conditions include a temperature suitable for the growth of human T lymphocytes, such as at least about 25 degrees Celsius, typically at least about 30 degrees Celsius, and typically at or at about 37 degrees Celsius. Optionally, incubation may also include the addition of non-dividing EBV-transformed lymphoblastoid cells (LCL) as feeder cells. LCL can be irradiated with gamma rays in the range of about 6000 to 10,000 rads. In some aspects, LCL feeder cells are provided with any suitable amount (such as the ratio of LCL feeder cells to initial T lymphocytes is at least about 10:1).

[0341] In some embodiments, the preparation method includes a step of freezing (e.g., cryopreservation) the cell before or after separation, incubation and / or engineering. In some embodiments, the freezing and subsequent thawing steps remove granulocytes in the cell population, and remove monocytes to a certain extent. In some embodiments, for example, after the washing step removes plasma and platelets, the cells are suspended in a freezing solution. Any of a variety of known freezing solutions and parameters can be used in some aspects. An example involves the use of PBS containing 20% ​​DMSO and 8% human serum albumin (HSA), or other suitable cell freezing medium. Then it is diluted 1: 1 with culture medium so that the final concentrations of DMSO and HSA are 10% and 4%, respectively. The cells are then usually frozen to -80 ° C at a rate of 1 ° / minute and stored in the gas phase of a liquid nitrogen storage tank.

[0342] In some embodiments, the method comprises reintroducing the engineered cells into the same patient either before or after cryopreservation.

[0343] Recombinant receptor

[0344] In some embodiments, the cell comprises one or more nucleic acids encoding recombinant receptors introduced via genetic engineering and genetically engineered products of such nucleic acids. In some embodiments, the cell can be produced or generated by introducing nucleic acid molecules encoding recombinant receptors into the cell (e.g., via transduction of a viral vector (e.g., a retrovirus or a lentiviral vector). In some embodiments, the nucleic acid is heterologous, i.e., not usually present in a cell or a sample obtained from a cell, such as a nucleic acid obtained from another organism or cell, for example, the nucleic acid is not usually found in an engineered cell and / or an organism derived from such a cell. In some embodiments, the nucleic acid is not naturally occurring, such as a nucleic acid not found in nature, including nucleic acids comprising a chimeric combination of nucleic acids encoding various domains from a variety of different cell types.

[0345] In some embodiments, the target cell has been altered to bind to one or more target antigens (e.g., one or more tumor antigens). In some embodiments, the target antigen is selected from ROR1, B cell maturation antigen (BCMA), carbonic anhydrase 9 (CAIX), tEGFR, Her2 / neu (receptor tyrosine kinase erbB2), L1-CAM, CD19, CD20, CD22, mesothelin, CEA and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, epithelial glycoprotein 2 (EPG-2), epithelial glycoprotein 40 (EPG-40), EPHa2, erb-B2, erb-B3, erb-B4, erbB dimer, EGFRvIII, folate binding FBP, FCRL5, FCRH5, fetal acetylcholine receptor, GD2, GD3, HMW-MAA, IL-22R-α, IL-13R-α2, kinase insert domain receptor (kdr), kappa light chain, Lewis Y, L1 cell adhesion molecule (L1-CAM), melanoma associated antigen (MAGE)-A1, MAGE-A3, MAGE-A6, preferentially expressed antigen in melanoma (PRAME), survivin, TAG72, B7-H6, IL-13 receptor α2 (IL-13Ra2), CA9, GD3, HMW-MAA, CD171, G250 / CAIX, HLA-AI MAGEAl, HLA-A2NY-ESO-1, PSCA, folate receptor-a, CD44v6, CD44v7 / 8, avb6 integrin, 8H9, NCAM, VEGF receptor, 5T4, fetal AchR, NKG2D ligand, CD44v6, dual antigen, cancer-testis antigen, mesothelin, mouse CMV, mucin 1 (MUC1), MUC16, PSCA, NKG2D, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, c-Met, GD-2, O-acetylated GD2 (OGD2), CE7, Wilms tumor 1 (WT-1), cyclins, cyclin A2, CCL-1, CD138, pathogen-specific antigens, and antigens associated with universal tags. In some embodiments, the target cell has been altered (e.g., by TCR or CAR) to bind to one or more of the following tumor antigens.Tumor antigens may include, but are not limited to, AD034, AKT1, BRAP, CAGE, CDX2, CLP, CT-7, CT8 / HOM-TES-85, cTAGE-1, Peroneal protein-1, HAGE, HCA587 / MAGE-C2, hCAP-G, HCE661, HER2 / neu, HLA-Cw, HOM-HD-21 / Galectin 9, HOM-MEEL-40 / SSX2, HOM-RCC-3.1.3 / CAXII, HOXA7, HOXB6, Hu, HUB1, KM-HN-3, KM-KN-1, KOC1, KOC2, KOC3, KOC3, LAGE-1, MAGE-1, MAGE-4a, MPP11, MSLN, NN P-1, NY-BR-1, NY-BR-62, NY-BR-85, NY-CO-37, NY-CO-38, NY-ESO-1, NY-ESO-5, NY-LU-12, NY-REN-10, NY-REN-19 / LKB / STK11, NY-REN-21, NY-REN-26 / BCR, NY-REN- 3 / NY-CO-38, NY-REN-33 / SNC6, NY-REN-43, NY-REN-65, NY-REN-9, NY-SAR-35, OGFr, PLU-1, Rab38, RBPJκ, RHAMM, SCP1, SCP-1, SSX3, SSX4, SSX5, TOP2A, TOP2B or tyrosinase.

[0346] Antigen receptors:

[0347] Chimeric Antigen Receptor (CAR)

[0348] The cells typically express recombinant receptors, such as antigen receptors (including functional non-TCR antigen receptors, such as chimeric antigen receptors (CARs)) and other antigen binding receptors (such as transgenic T cell receptors (TCRs)). Receptors also include other chimeric receptors.

[0349] Exemplary antigen receptors (including CARs) and methods of engineering and introducing such receptors into cells include, for example, those described in International Patent Application Publication Nos. WO 200014257, WO 2013126726, WO 2012 / 129514, WO 2014031687, WO 2013 / 166321, WO 2013 / 071154, WO 2013 / 123061, U.S. Patent Application Publication Nos. US 2002131960, US 2013287748, US 20130149337, U.S. Patent Nos. 6,451,995, 7,446,190, 8,252,592, , 8,339,645, 8,398,282, 7,446,179, 6,410,319, 7,070,995, 7,265,209, 7,354,762, 7,446,191, 8,324,353, and 8,479,118, and European Patent Application No. EP 2537416, and / or those described in Sadelain et al., Cancer Discov. 2013 Apr;3(4):388-398; Davila et al. (2013) PLoS ONE 8(4):e61338; Turtle et al., Curr. Opin. Immunol., October 2012; 24(5):633-39; Wu et al., Cancer, March 2012 18(2):160-75. In some aspects, the antigen receptor includes a CAR as described in U.S. Pat. No. 7,446,190 and those described in International Patent Application Publication No. WO / 2014055668A1. Examples of CARs include CARs as disclosed in any of the above-mentioned publications, such as WO 2014031687, US8,339,645, US 7,446,179, US 2013 / 0149337, U.S. Pat. No. 7,446,190, U.S. Pat. No. 8,389,282; Kochenderfer et al., 2013, Nature Reviews Clinical Oncology, 10, 267-276 (2013); Wang et al. (2012) J. Immunother. 35(9): 689-701; and Brentjens et al., Sci Transl Med. 20135(177). See also WO 2014031687, US 8,339,645, US 7,446,179, US 2013 / 0149337, US Patent No. 7,446,190, and US Patent No. 8,389,282.Chimeric receptors (such as CARs) typically include an extracellular antigen binding domain, such as a portion of an antibody molecule, typically a variable heavy (VH) chain region and / or a variable light (VL) chain region of said antibody, such as a scFv antibody fragment.

[0350] In some embodiments, the antigen targeted by the receptor is a polypeptide. In some embodiments, it is a carbohydrate or other molecule. In some embodiments, the antigen is selectively expressed or overexpressed on cells (e.g., tumors or pathogenic cells) of a disease or disorder compared to normal or non-targeted cells or tissues. In other embodiments, the antigen is expressed on normal cells and / or expressed on engineered cells.

[0351] Antigens targeted by the receptor include, but are not limited to, αvβ6 integrin (avb6 integrin), B cell maturation antigen (BCMA), B7-H6, carbonic anhydrase 9 (CA9, also known as CAIX or G250), cancer-testis antigen, cancer / testis antigen 1B (CTAG, also known as NY-ESO-1 and LAGE-2), carcinoembryonic antigen (CEA), cyclins, cyclin A2, CC motif chemokine ligand 1 (CCL-1), CD19, CD20, CD22, CD23, CD24, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD123, CD138, CD171, epidermal growth factor protein (EGFR), truncated epidermal growth factor protein (tEGFR), epidermal growth factor receptor type III mutant (EGFR vIII), epithelial glycoprotein 2 (EPG-2), epithelial glycoprotein 40 (EPG-40), ephrin B2, ephrin receptor A2 (EPHa2), estrogen receptor, Fc receptor-like 5 (FCRL5;also known as Fc receptor homolog 5 or FCRH5), fetal acetylcholine receptor (fetal AchR), folate binding protein (FBP), folate receptor alpha, fetal acetylcholine receptor, ganglioside GD2, O-acetylated GD2 (OGD2), ganglioside GD3, glycoprotein 100 (gp100), Her2 / neu (receptor tyrosine kinase erbB2), Her3 (erb-B3), Her4 (erb-B4), erbB dimer, Human high molecular weight melanoma associated antigen (HMW-MAA), hepatitis B surface antigen, human leukocyte antigen A1 (HLA-AI), human leukocyte antigen A2 (HLA-A2), IL-22 receptor alpha (IL-22Ra), IL-13 receptor alpha 2 (IL-13Ra2), kinase insert domain receptor (kdr), kappa light chain, L1 cell adhesion molecule (L1CAM), CE7 epitope of L1-CAM, 8 families containing leucine-rich repeat sequences family member A (LRRC8A), Lewis Y, melanoma-associated antigen (MAGE)-A1, MAGE-A3, MAGE-A6, mesothelin, c-Met, murine cytomegalovirus (CMV), mucin 1 (MUC1), MUC16, natural killer cell family 2 member D (NKG2D) ligand, melanin A (MART-1), neural cell adhesion molecule (NCAM), carcinoembryonic antigen, preferentially expressed antigen in melanoma (PRAME), progesterone receptor, prostate-specific antigen, prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), survivin, trophoblast glycoprotein (TPBG, also known as 5T4), tumor-associated glycoprotein 72 (TAG72), vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor receptor 2 (VEGFR2), Wilms tumor 1 (WT-1), and pathogen-specific antigen. ;

[0352] In some embodiments, the antigens targeted by the receptor include orphan tyrosine kinase receptor ROR1, tEGFR, Her2, Ll-CAM, CD19, CD20, CD22, mesothelin, CEA and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, OEPHa2, ErbB2, 3 or 4, FBP, fetal acetylcholine e receptor, GD2, GD3, HMW-MAA, IL-22R- α, IL-13R-α2, kdr, kappa light chain, Lewis Y, L1-cell adhesion molecule, MAGE-A1, mesothelin, MUC1, MUC16, PSCA, NKG2D ligand, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, c-Met, GD-2 and MAGE A3, CE7, Wilms tumor 1 (WT-1), cell cycle proteins such as cyclin A1 (CCNA1) and / or biotinylated molecules and / or molecules expressed by HIV, HCV, HBV or other pathogens.

[0353] In some embodiments, the CAR has binding specificity for a tumor-associated antigen, such as CD19, CD20, carbonic anhydrase IX (CAIX), CD171, CEA, ERBB2, GD2, α-folate receptor, Lewis Y antigen, prostate-specific membrane antigen (PSMA), or tumor-associated glycoprotein 72 (TAG72).

[0354] In some embodiments, CAR binds to pathogen-specific antigens. In some embodiments, CAR is specific to viral antigens (such as HIV, HCV, HBV, etc.), bacterial antigens and / or parasite antigens.

[0355] Chimeric receptors include chimeric antigen receptors (CARs). Chimeric receptors (such as CARs) typically include an extracellular antigen binding domain, such as a portion of an antibody molecule, typically a variable weight (V) portion of the antibody. H ) chain region and / or variable lightness (V L ) chain region, such as a scFv antibody fragment.

[0356] In some embodiments, the antibody portion of the recombinant receptor (eg, CAR) further includes at least a portion of an immunoglobulin constant region, such as a hinge region (eg, IgG4 hinge region) and / or CH1 / CL and / or Fc region. In some embodiments, the constant region or portion is human IgG (eg, IgG4 or IgG1). In some aspects, the portion of the constant region is used as a spacer region between an antigen recognition component (eg, scFv) and a transmembrane domain. Compared to the absence of a spacer, the length of the spacer can provide increased cellular reactivity after antigen binding. Exemplary spacers (eg, hinge regions) include those described in International Patent Application Publication No. WO 2014031687. In some examples, the length of the spacer is or is about 12 amino acids or is no more than 12 amino acids in length. Exemplary spacers include those having at least about 10 to 229 amino acids, about 10 to 200 amino acids, about 10 to 175 amino acids, about 10 to 150 amino acids, about 10 to 125 amino acids, about 10 to 100 amino acids, about 10 to 75 amino acids, about 10 to 50 amino acids, about 10 to 40 amino acids, about 10 to 30 amino acids, about 10 to 20 amino acids, or about 10 to 15 amino acids (and including any integer between the endpoints of any listed ranges). In some embodiments, the spacer region has about 12 or fewer amino acids, about 119 or fewer amino acids, or about 229 or fewer amino acids. Exemplary spacers include an IgG4 hinge alone, an IgG4 hinge connected to a CH2 and CH3 domain, or an IgG4 hinge connected to a CH3 domain.

[0357] Exemplary spacers include, but are not limited to, those described in Hudecek et al. (2013) Clin. Cancer Res., 19:3153 or International Patent Application Publication No. WO 2014031687.

[0358] The antigen recognition domain is typically connected to one or more intracellular signaling components (such as a signaling component that simulates activation by an antigen receptor complex (such as a TCR complex) (in the case of a CAR) and / or conducts signals via another cell surface receptor). Therefore, in some embodiments, the antigen binding component (e.g., an antibody) is connected to one or more transmembrane domains and an intracellular signaling domain. In some embodiments, the transmembrane domain is fused to the extracellular domain. In one embodiment, a transmembrane domain that naturally associates with a domain in a receptor (e.g., CAR) is used. In some cases, the transmembrane domain is selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex.

[0359] In some embodiments, the membrane-spanning domain is derived from a natural source or from a synthetic source. In the case where the source is natural, the domain is derived from any membrane-bound protein or a membrane-spanning protein in some aspects. The membrane-spanning region includes those derived from the following (i.e., comprising at least one or more membrane-spanning regions): α, β or ζ chains of T cell receptors, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD 16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154. Alternatively, in some embodiments, the membrane-spanning domain is synthetic. In some aspects, the synthetic membrane-spanning domain mainly comprises hydrophobic residues, such as leucine and valine. In some aspects, a triplet of phenylalanine, tryptophan and valine will be found at each end of the synthetic membrane-spanning domain. In some embodiments, connection is achieved by a joint, a spacer and / or one or more membrane-spanning domains.

[0360] The intracellular signaling domain includes those that simulate or approach signals through natural antigen receptors, simulate or approach signals through a combination of such receptors and costimulatory receptors, and / or simulate or approach signals only through costimulatory receptors. In some embodiments, there is a short oligopeptide or polypeptide linker, such as a linker having a length between 2 and 10 amino acids (such as a linker containing glycine and serine, such as a glycine-serine doublet), and a connection is formed between the transmembrane domain of the CAR and the cytoplasmic signaling domain.

[0361] Receptors (e.g., CAR) typically include at least one or more intracellular signaling components. In some embodiments, the receptor includes intracellular components of the TCR complex, such as TCR CD3 chains that mediate T cell activation and cytotoxicity, such as CD3 ζ chains. Therefore, in some aspects, the antigen binding portion is connected to one or more cell signaling modules. In some embodiments, the cell signaling module includes a CD3 transmembrane domain, a CD3 intracellular signaling domain, and / or other CD transmembrane domains. In some embodiments, the receptor (e.g., CAR) also includes a portion of one or more additional molecules (such as Fc receptor γ, CD8, CD4, CD25, or CD16). For example, in some aspects, CAR or other chimeric receptors include a chimeric molecule between CD3-ζ (CD3-ζ) or Fc receptor γ and CD8, CD4, CD25, or CD16.

[0362] In some embodiments, after connecting CAR or other chimeric receptors, the cytoplasmic domain or intracellular signaling domain of the receptor activates at least one of the normal effector functions or responses of immune cells (e.g., engineered to express T cells of the CAR). For example, in some situations, CAR induces the function of T cells, such as cytolytic activity or T helper activity, such as the secretion of cytokines or other factors. In some embodiments, a truncated portion of the intracellular signaling domain of an antigen receptor component or a co-stimulatory molecule is used to replace a complete immunostimulatory chain, for example, under the condition that the truncated portion transduces an effector function signal. In some embodiments, one or more intracellular signaling domains include a cytoplasmic sequence of a T cell receptor (TCR), and in some aspects also include a co-receptor (which works in concert with this receptor in a natural context to initiate signal transduction after antigen receptor engagement) and / or any derivative or variant of such molecules, and / or any synthetic sequence with the same functional capabilities.

[0363] In the context of natural TCR, full activation generally requires not only signal transduction by TCR, but also co-stimulatory signals. Therefore, in some embodiments, in order to promote full activation, components for generating secondary or co-stimulatory signals are also included in CAR. In other embodiments, CAR does not include components for generating co-stimulatory signals. In some aspects, other CARs are expressed in the same cell, and components for generating secondary or co-stimulatory signals are provided.

[0364] In some aspects, T cell activation is described as being mediated by two categories of cytoplasmic signaling sequences: those sequences (primary cytoplasmic signaling sequences) that initiate antigen-dependent primary activation by TCR and those sequences (secondary cytoplasmic signaling sequences) that act in an antigen-independent manner to provide secondary or costimulatory signals. In some aspects, CAR includes one or both of such signaling components.

[0365] In some aspects, CAR includes a primary cytoplasmic signaling sequence for the primary activation of the TCR complex. The primary cytoplasmic signaling sequence that works in a stimulatory manner can contain a signaling motif (which is referred to as an activation motif or ITAM based on immunoreceptor tyrosine). Examples of primary cytoplasmic signaling sequences containing ITAM include those derived from CD3γ chains, FcRγ, CD3γ, CD3δ, and CD3ε. In some embodiments, one or more cytoplasmic signaling molecules in CAR contain a cytoplasmic signaling domain, a portion thereof, or a sequence derived from CD3ζ.

[0366] In some embodiments, CAR includes signaling domains and / or transmembrane portions of costimulatory receptors such as CD28, 4-1BB, OX40, DAP10, and ICOS. In some aspects, the same CAR includes both activation components and costimulatory components.

[0367] In some embodiments, the activation domain is included in a CAR, and the costimulatory component is provided by another CAR that recognizes another antigen. In some embodiments, CAR includes activation or stimulation CAR, costimulatory CAR, and they are all expressed on the same cell (see WO 2014 / 055668). In some aspects, cells include one or more stimulation or activation CAR and / or costimulatory CAR. In some embodiments, cells also include inhibitory CAR (iCAR, see Fedorov et al., Sci. Transl. Medicine, 5 (215) (December 2013), such as identifying CARs other than antigens related to and / or specific to the disease or illness, wherein the activation signal delivered by the CAR of the targeted disease is reduced or suppressed due to the combination of inhibitory CAR and its ligand, for example, to reduce off-target effects.

[0368] In certain embodiments, the intracellular signaling domain comprises a CD28 transmembrane and signaling domain connected to a CD3 (e.g., CD3-ζ) intracellular domain. In some embodiments, the intracellular signaling domain comprises a chimeric CD28 and CD137 (4-1BB, TNFRSF9) co-stimulatory domain connected to a CD3 ζ intracellular domain.

[0369] In some embodiments, CAR encompasses one or more (e.g., two or more) co-stimulatory domains and activation domains (e.g., primary activation domains) in the cytoplasmic portion. Exemplary CARs include intracellular components of CD3-ζ, CD28, and 4-1BB.

[0370] In some embodiments, CAR or other antigen receptors further include a marker, such as a cell surface marker, which can be used to confirm that the cell is transduced or engineered to express the receptor, such as a truncated form of a cell surface receptor, such as a truncated EGFR (tEGFR). In some aspects, the marker includes all or part (e.g., a truncated form) of CD34, NGFR, or epidermal growth factor receptor (e.g., tEGFR). In some embodiments, the nucleic acid encoding the marker is operably connected to a polynucleotide encoding a joint sequence (e.g., a cleavable joint sequence, e.g., T2A). See WO 2014031687. In some embodiments, the constructs encoding CAR and EGFRt separated by a T2A ribosomal switch can express two proteins from the same construct, so that EGFRt can be used as a marker for detecting cells expressing such a construct. In some embodiments, the marker and the optional joint sequence can be any one disclosed in the disclosed application number WO 2014 / 031687. For example, the tag can be a truncated EGFR (tEGFR), optionally linked to a linker sequence, such as a T2A cleavable linker sequence.

[0371] In some embodiments, a marker is a molecule (eg, a cell surface protein) or a portion thereof that is not naturally found on a T cell or that is not naturally found on the surface of a T cell.

[0372] In some embodiments, the molecule is a non-self molecule, such as a non-self protein, ie, a molecule that is not recognized as "self" by the immune system of the host into which the cell is to be adoptively transferred.

[0373] In some embodiments, the marker does not have any therapeutic effect and / or does not produce an effect other than being used as a marker for genetic engineering (e.g., for selecting successfully engineered cells). In other embodiments, the marker can be a therapeutic molecule or a molecule that otherwise exerts some desired effect, such as a ligand of a cell to be encountered in vivo, such as a co-stimulatory or immune checkpoint molecule, to enhance and / or weaken the response of the cell when adoptively transferred and encountering a ligand.

[0374] In some cases, CAR is referred to as first generation, second generation and / or third generation CAR. In some aspects, first generation CAR is a CAR that only provides a signal induced by CD3 chain when antigen binds; in some aspects, second generation CAR is a CAR that provides such a signal and a costimulatory signal, such as a signal including an intracellular signaling domain from a costimulatory receptor (such as CD28 or CD137); in some aspects, third generation CAR is a CAR including multiple costimulatory domains of different costimulatory receptors.

[0375] In some embodiments, the chimeric antigen receptor includes an extracellular portion containing an antibody or antibody fragment. In some aspects, the chimeric antigen receptor includes an extracellular portion containing an antibody or fragment and an intracellular signaling domain. In some embodiments, the antibody or fragment includes an scFv, and the intracellular domain contains ITAM. In some aspects, the intracellular signaling domain includes the signaling domain of the ζ chain of the CD3-zeta (CD3ζ) chain. In some embodiments, the chimeric antigen receptor includes a transmembrane domain connecting the extracellular domain to the intracellular signaling domain. In some aspects, the transmembrane domain contains the transmembrane portion of CD28. The extracellular domain and the transmembrane can be directly or indirectly connected. In some embodiments, the extracellular domain and the transmembrane are connected by a spacer (such as any spacer described herein). In some embodiments, the chimeric antigen receptor contains the intracellular domain of a T cell costimulatory molecule, such as between the transmembrane domain and the intracellular signaling domain. In some aspects, the T cell costimulatory molecule is CD28 or 41BB.

[0376] In some embodiments, CAR contains an antibody (e.g., an antibody fragment), a transmembrane domain (which is or contains a transmembrane portion of CD28 or a functional variant thereof), and an intracellular signaling domain containing a signaling portion of CD28 or a functional variant thereof and a signaling portion of CD3ζ or a functional variant thereof. In some embodiments, CAR contains an antibody (e.g., an antibody fragment), a transmembrane domain (which is or contains a transmembrane portion of CD28 or a functional variant thereof), and an intracellular signaling domain containing a signaling portion of 4-1BB or a functional variant thereof and a signaling portion of CD3ζ or a functional variant thereof. In some such embodiments, the receptor also includes a spacer containing a portion of an Ig molecule (e.g., a human Ig molecule) (e.g., an Ig hinge, e.g., an IgG4 hinge), such as only a hinge spacer.

[0377] In some embodiments, the transmembrane domain of the receptor (eg, CAR) is the transmembrane domain of human CD28 or a variant thereof, such as the 27 amino acid transmembrane domain of human CD28 (Accession No.: P10747.1).

[0378] In some embodiments, the chimeric antigen receptor contains the intracellular domain of a T cell co-stimulatory molecule. In some aspects, the T cell co-stimulatory molecule is CD28 or 41BB.

[0379] In some embodiments, the intracellular signaling domain comprises an intracellular co-stimulatory signaling domain of human CD28 or a functional variant or portion thereof, such as a 41 amino acid domain thereof, and / or such a domain having a LL to GG substitution at position 186-187 of a native CD28 protein. In some embodiments, the intracellular domain comprises an intracellular co-stimulatory signaling domain of 41BB or a functional variant or portion thereof, such as a 42 amino acid cytoplasmic domain of human 4-1BB (Accession No. Q07011.1) or a functional variant or portion thereof.

[0380] In some embodiments, the intracellular signaling domain comprises a human CD3 zeta stimulatory signaling domain or a functional variant thereof, such as a 112 AA cytoplasmic domain of isoform 3 of human CD3 zeta (Accession No.: P20963.2) or a CD3 zeta signaling domain as described in U.S. Pat. No. 7,446,190 or U.S. Pat. No. 8,911,993.

[0381] In some aspects, the spacer contains only the hinge region of IgG, such as only the hinge of IgG4 or IgG1. In other embodiments, the spacer is an Ig hinge connected to the CH2 and / or CH3 domains, such as an IgG4 hinge. In some embodiments, the spacer is an Ig hinge connected to the CH2 and CH3 domains, such as an IgG4 hinge. In some embodiments, the spacer is an Ig hinge connected to the CH3 domain only, such as an IgG4 hinge. In some embodiments, the spacer is or comprises a glycine-serine-rich sequence or other flexible linker, such as a known flexible linker.

[0382] For example, in some embodiments, CAR includes an antibody or fragment that specifically binds to an antigen, a spacer (such as any spacer containing an Ig hinge), a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 ζ signaling domain. In some embodiments, CAR includes an antibody or fragment that specifically binds to an antigen, a spacer (such as any spacer containing an Ig hinge), a CD28 transmembrane domain, a CD28 intracellular signaling domain, and a CD3 ζ signaling domain. In some embodiments, such CAR constructs also include, for example, a T2A ribosomal skipping element and / or a tEGFR sequence downstream of the CAR.

[0383] The terms "polypeptide" and "protein" are used interchangeably and refer to polymers of amino acid residues and are not limited to a minimum length. Polypeptides (including provided receptors and other polypeptides, such as linkers or peptides) may include amino acid residues, including natural and / or non-natural amino acid residues. The term also includes post-expression modifications of the polypeptide, such as glycosylation, sialylation, acetylation and phosphorylation. In some aspects, the polypeptide may contain modifications about the native or native sequence, as long as the protein retains the desired activity. These modifications may be intentional (such as by site-directed mutagenesis), or may be accidental (such as by mutations in the host producing the protein or errors caused by PCR amplification).

[0384] T cell receptor

[0385] In some embodiments, the genetically engineered antigen receptor includes a recombinant T cell receptor (TCR) and / or TCR cloned from a naturally occurring T cell. Therefore, in some embodiments, the target cell has been changed to contain a specific T cell receptor (TCR) gene (e.g., TRAC and TRBC gene). TCR or its antigen binding portion includes peptide epitopes or T cell epitopes that recognize target polypeptides (e.g., tumor antigens, viruses, or autoimmune proteins). In some embodiments, TCR has binding specificity to tumor-associated antigens, such as carcinoembryonic antigen (CEA), GP100, melanoma antigen 1 (MART1) recognized by T cells, melanoma antigen A3 (MAGEA3), NYESO1, or p53.

[0386] In some embodiments, a "T cell receptor" or "TCR" is a molecule or antigen binding portion thereof containing variable α and β chains (also referred to as TCRα and TCRβ, respectively) or variable γ and δ chains (also referred to as TCRγ and TCRδ, respectively), and the molecule or antigen binding portion thereof is capable of specifically binding to a peptide bound to an MHC molecule. In some embodiments, the TCR is in the form of αβ. Typically, TCRs in the form of αβ and γδ are generally similar in structure, but the T cells expressing them may have different anatomical locations or functions. Typically, the TCR is on the surface of a T cell (or T lymphocyte) or may be expressed on the surface of a T cell (or T lymphocyte), where it is typically responsible for recognizing an antigen bound to a major histocompatibility complex (MHC) molecule.

[0387] In some embodiments, TCR is a complete TCR or its antigen binding portion or antigen binding fragment. In some embodiments, TCR is a complete or full-length TCR, including a TCR in the form of αβ or γδ. In some embodiments, TCR is such an antigen binding portion that is less than the full-length TCR but binds to a specific peptide bound in an MHC molecule, such as binding to an MHC-peptide complex. In some cases, the antigen binding portion or fragment of TCR may contain only a portion of the structural domain of the full-length or complete TCR, but is still able to bind to a peptide epitope (such as an MHC-peptide complex) bound to the complete TCR. In some cases, the antigen binding portion contains the variable domains of TCR (such as the variable α chain and variable β chain of TCR), which are sufficient to form a binding site for binding to a specific MHC-peptide complex. Typically, the variable chain of TCR contains a complementary determining region (CDR) that participates in the recognition of the peptide, MHC and / or MHC-peptide complex.

[0388] In some embodiments, the variable domain of TCR contains hypervariable loop or CDR, which is usually the main contributor of antigen recognition and binding ability and specificity. In some embodiments, the CDR of TCR or its combination forms all or substantially all antigen binding sites of a given TCR molecule. Each CDR in the variable region of TCR chain is usually separated by a framework region (FR), and compared with CDR, the framework region usually displays lower variability between TCR molecules (see, for example, Jores et al., Proc. Nat'l Acad. Sci. USA 87: 9138, 1990; Chothia et al., EMBO J. 7: 3745, 1988; See also Lefranc et al., Dev. Comp. Immunol. 27: 55, 2003). In some embodiments, CDR3 is the main CDR responsible for antigen binding or specificity, or in three CDRs on a given TCR variable region for antigen recognition and / or for the interaction of the processed peptide part with a peptide-MHC complex is most important. In some cases, the CDR1 of the α chain can interact with the N-terminal portion of some antigenic peptides. In some cases, the CDR1 of the β chain can interact with the C-terminal portion of the peptide. In some cases, the CDR2 has the strongest effect or is the main responsible CDR for the interaction or recognition with the MHC portion of the MHC-peptide complex. In some embodiments, the variable region of the β chain can contain other hypervariable regions (CDR4 or HVR4), which are usually involved in superantigen binding rather than antigen recognition (Kotb (1995) Clinical Microbiology Reviews, 8: 411-426).

[0389] In some embodiments, the TCR contains a variable alpha domain (V α) and / or variable β domain (V β ) or its antigen binding fragment. In some embodiments, the α-chain and / or β-chain of TCR can also contain constant domains, transmembrane domains and / or short cytoplasmic tails (see, for example, Janeway et al., Immunobiology: The Immune System in Health and Disease, 3rd edition, Current Biology Publications, page 4: 33, 1997). In some embodiments, the α chain constant domain is encoded by the TRAC gene (IMGT nomenclature) or is a variant thereof. In some embodiments, the β chain constant region is encoded by the TRBC1 or TRBC2 gene (IMGT nomenclature) or is a variant thereof. In some embodiments, the constant domain is adjacent to the cell membrane. For example, in some cases, the extracellular portion of the TCR formed by the two chains contains two membrane proximal constant domains and two membrane distal variable domains, each of which contains CDRs.

[0390] Determine or identify that various domains or regions of TCR are within the level of skilled artisans.In some respects, the residue of TCR is known, or can be identified according to the International Immunogenetics Information System (IMGT) numbering system (see, for example, www.imgt.org; See also Lefranc et al. (2003) Developmental and Comparative Immunology, 2&;55-77; With The T Cell Factsbook the 2nd edition, Lefranc and LeFranc Academic Press 2001). Using this system, the CDR1 sequence in TCR V α chain and / or V β chain corresponds to the amino acid present between residue numbering 27-38 (including end values), the CDR2 sequence in TCR V α chain and / or V β chain corresponds to the amino acid present between residue numbering 56-65 (including end values), and the CDR3 sequence in TCR V α chain and / or V β chain corresponds to the amino acid present between residue numbering 105-117 (including end values).

[0391] In some embodiments, TCR can be a heterodimer of two chains α and β (or optionally γ and δ) connected by one or more disulfide bonds. In some embodiments, the constant domain of TCR can contain a short connection sequence, in which cysteine ​​residues form a disulfide bond, thereby connecting the two chains of the TCR. In some embodiments, TCR can have additional cysteine ​​residues in each of the α chain and the β chain, so that TCR contains two disulfide bonds in the constant domain. In some embodiments, each of the constant and variable domains contains a disulfide bond formed by cysteine ​​residues.

[0392] In some embodiments, the TCR for cell engineering is produced from one or more known TCR sequences (such as sequences of Vα and Vβ chains), and the substantially full-length coding sequences of the one or more known TCR sequences are easily available TCRs. The method for obtaining full-length TCR sequences (including V chain sequences) from cell sources is well known. In some embodiments, nucleic acids encoding TCRs can be obtained from a variety of sources, such as polymerase chain reaction (PCR) amplification of nucleic acids encoding TCRs separated from one or more given cells or from the one or more given cells, or obtained by synthesis of publicly available TCR DNA sequences. In some embodiments, TCRs are obtained from biological sources, such as from cells (such as from T cells (e.g., cytotoxic T cells)), T cell hybridomas, or other publicly available sources. In some embodiments, T cells can be obtained from cells isolated in vivo. In some embodiments, T cells can be cultured T cell hybridomas or clones. In some embodiments, TCRs or their antigen binding portions can be produced synthetically from the knowledge of TCR sequences.

[0393] In some embodiments, a high-affinity T cell clone of a target antigen (e.g., a cancer antigen) is identified and separated from a patient and introduced into a cell. In some embodiments, a TCR clone for a target antigen has been produced in a transgenic mouse engineered with a human immune system gene (e.g., a human leukocyte antigen system or HLA). See, for example, tumor antigens (see, for example, Parkhurst et al. (2009) Clin Cancer Res. 15: 169-180 and Cohen et al. (2005) J Immunol. 175: 5799-5808. In some embodiments, phage display is used to separate TCRs for a target antigen (see, for example, Varela-Rohena et al. (2008) Nat Med. 14: 1390-1395 and Li (2005) Nat Biotechnol. 23: 349-354.

[0394] In some embodiments, TCR or its antigen binding portion is a modified or engineered TCR or its antigen binding portion. In some embodiments, directed evolution methods are used to generate TCRs with altered properties (such as having higher affinity for specific MHC-peptide complexes). In some embodiments, directed evolution is achieved by display methods, including but not limited to yeast display (Holler et al. (2003) Nat Immunol, 4, 55-62; Holler et al. (2000) Proc Natl Acad Sci USA, 97, 5387-92), phage display (Li et al. (2005) Nat Biotechnol, 23, 349-54) or T cell display (Chervin et al. (2008) J Immunol Methods, 339, 175-84). In some embodiments, the display method involves engineering or modifying a known parent or reference TCR. For example, in some cases, a wild-type TCR can be used as a template for generating a mutagenized TCR in which one or more residues of a CDR are mutated, and mutants are selected that have the desired altered property (e.g., higher affinity for a desired target antigen).

[0395] In some embodiments as described, TCR may contain one or more disulfide bonds introduced. In some embodiments, there is no natural disulfide bond. In some embodiments, one or more natural cysteines (e.g., in the constant domains of α chains and β chains) forming natural interchain disulfide bonds are replaced by another residue (e.g., serine or alanine). In some embodiments, the disulfide bonds introduced can be formed by mutating non-cysteine ​​residues on α chains and β chains (e.g., in the constant domains of α chains and β chains) to cysteine. The exemplary non-natural disulfide bonds of TCR are described in disclosed international PCT Nos. WO2006 / 000830 and WO 2006 / 037960. In some embodiments, cysteine ​​can be introduced at residue Thr48 of the alpha chain and residue Ser57 of the beta chain, at residue Thr45 of the alpha chain and residue Ser77 of the beta chain, at residue Tyr10 of the alpha chain and residue Ser17 of the beta chain, at residue Thr45 of the alpha chain and residue Asp59 of the beta chain, and / or at residue Ser15 of the alpha chain and residue Glu15 of the beta chain. In some embodiments, the presence of non-natural cysteine ​​residues in the recombinant TCR (e.g., generating one or more non-natural disulfide bonds) can facilitate the production of the desired recombinant TCR in the cell into which it is introduced, rather than expressing mismatched TCR pairs containing natural TCR chains.

[0396] In some embodiments, TCR chains contain transmembrane domains. In some embodiments, transmembrane domains are positively charged. In some cases, TCR chains contain cytoplasmic tails. In some aspects, each chain (such as α or β) of TCR can have an N-terminal immunoglobulin variable domain, an immunoglobulin constant domain, a transmembrane region and a short cytoplasmic tail at the C-terminus. In some embodiments, TCR (such as via cytoplasmic tail) is associated with the constant protein of the CD3 complex involved in mediating signal transduction. In some cases, the structure allows TCR to associate with other molecules (like CD3) and their subunits. For example, TCR containing constant domains and transmembrane regions can anchor proteins in cell membranes and associate with the constant subunits of CD3 signal transduction devices or complexes. The intracellular tail of CD3 signal transduction subunits (for example, CD3γ, CD3δ, CD3ε and CD3ζ chains) contains one or more activation motifs or ITAMs based on immunoreceptor tyrosine involved in the signal transduction ability of TCR complexes.

[0397] In some embodiments, TCR is a full-length TCR. In some embodiments, TCR is an antigen binding portion. In some embodiments, TCR is a dimeric TCR (dTCR). In some embodiments, TCR is a single-chain TCR (sc-TCR). TCR can be cell-bound or in soluble form. In some embodiments, for the purpose of the provided method, TCR is in a cell-bound form expressed on the cell surface.

[0398] In some embodiments, dTCR contains a first polypeptide (wherein the sequence corresponding to the TCR α chain variable region sequence is fused to the N-terminal of the sequence corresponding to the TCR α chain constant region extracellular sequence) and a second polypeptide (wherein the sequence corresponding to the TCR β chain variable region sequence is fused to the N-terminal of the sequence corresponding to the TCR β chain constant region extracellular sequence), and the first and second polypeptides are connected by a disulfide bond. In some embodiments, the bond may correspond to the natural interchain disulfide bond present in the natural dimer α β TCR. In some embodiments, the interchain disulfide bond is not present in the natural TCR. For example, in some embodiments, one or more cysteines can be incorporated into the constant region extracellular sequence of the dTCR polypeptide pair. In some cases, both natural and non-natural disulfide bonds may be required. In some embodiments, TCR contains a transmembrane sequence to anchor to the membrane.

[0399] In some embodiments, the dTCR contains a TCR α chain, which contains a variable α domain, a constant α domain, and a first dimerization motif attached to the C-terminus of the constant α domain; and a TCR β chain, which contains a variable β domain, a constant β domain, and a first dimerization motif attached to the C-terminus of the constant β domain, wherein the first and second dimerization motifs are susceptible to interacting to form a covalent bond between the amino acids of the first dimerization motif and the amino acids of the second dimerization motif, thereby connecting the TCR α chain and the TCR β chain together.

[0400] In some embodiments, TCR is scTCR, which is a single amino acid chain containing α chain and β chain capable of binding to MHC-peptide complex. Generally, scTCR can be produced using methods known to those skilled in the art, see, for example, internationally disclosed PCT Nos. WO 1996 / 13593, WO 1996 / 18105, WO 1999 / 18129, WO 2004 / 033685, WO 2006 / 037960, WO 2011 / 044186; U.S. Patent No. 7,569,664; and Schlueter, CJ et al. J.Mol.Biol.256,859 (1996).

[0401] In some embodiments, the scTCR contains a first segment (which is composed of an amino acid sequence corresponding to the variable region of the TCR α chain), a second segment (which is composed of an amino acid sequence corresponding to the variable region sequence of the TCR β chain fused to the N-terminus of an amino acid sequence corresponding to the extracellular sequence of the TCR β chain constant domain), and a linker sequence (which connects the C-terminus of the first segment to the N-terminus of the second segment).

[0402] In some embodiments, the scTCR contains a first segment composed of an amino acid sequence corresponding to the variable region of the TCR β chain, a second segment composed of an amino acid sequence corresponding to the variable region sequence of the TCR α chain fused to the N-terminus of an amino acid sequence corresponding to the extracellular sequence of the constant domain of the TCR α chain, and a linker sequence connecting the C-terminus of the first segment to the N-terminus of the second segment.

[0403] In some embodiments, the scTCR contains a first segment consisting of an α chain variable region sequence fused to the N-terminus of the α chain extracellular constant domain sequence and a second segment consisting of a β chain variable region sequence fused to the N-terminus of the β chain extracellular constant and transmembrane sequences and optionally a linker sequence connecting the C-terminus of the first segment to the N-terminus of the second segment.

[0404] In some embodiments, the scTCR contains a first segment (which is composed of the TCR β chain variable region sequence fused to the N-terminus of the β chain extracellular constant domain sequence) and a second segment (which is composed of the α chain variable region sequence fused to the N-terminus of the α chain extracellular constant and transmembrane sequence) and optionally a linker sequence (which connects the C-terminus of the first segment to the N-terminus of the second segment).

[0405] In some embodiments, for a scTCR to bind to an MHC-peptide complex, the α and β chains must be paired so that their variable region sequences are oriented for such binding. Various methods for promoting α and β pairing in scTCRs are well known in the art. In some embodiments, a linker sequence is included that connects the α and β chains to form a single polypeptide chain. In some embodiments, the linker should be of sufficient length to span the distance between the C-terminus of the α chain and the N-terminus of the β chain, or vice versa, while also ensuring that the linker length is not so long that it blocks or reduces the binding of the scTCR to the target peptide-MHC complex.

[0406] In some embodiments, the joint connecting the first and second TCR segments of the scTCR can be any joint capable of forming a single polypeptide chain while maintaining TCR binding specificity. In some embodiments, the joint sequence can, for example, have the formula -P-AA-P-, wherein P is proline, and AA represents an amino acid sequence, wherein the amino acid is glycine and serine. In some embodiments, the first and second segments are paired so that their variable region sequences are directed for this combination. Therefore, in some cases, the joint has a sufficient length to span the distance between the C-terminus of the first segment and the N-terminus of the second segment, or vice versa, but it cannot be too long to block or reduce the binding of the scTCR to the target ligand. In some embodiments, the joint can contain from or from about 10 to 45 amino acids, such as 10 to 30 amino acids or 26 to 41 amino acid residues, such as 29, 30, 31 or 32 amino acids. In some embodiments, the linker has the formula -PGGG-(SGGGG)5-P- or -PGGG-(SGGGG)6-P-, wherein P is proline, G is glycine, and S is serine. In some embodiments, the linker has the sequence GSADDAKKDAAKKDGKS).

[0407] In some embodiments, scTCR contains a disulfide bond between the residues of the single amino acid chain, which can promote the stability of the pairing between the α and β regions of the single-chain molecule in some cases (see, e.g., U.S. Patent No. 7,569,664). In some embodiments, scTCR contains a covalent disulfide bond, which connects the residues of the immunoglobulin region of the α chain constant domain of the single-chain molecule to the residues of the immunoglobulin region of the β chain constant domain. In some embodiments, the disulfide bond corresponds to the natural disulfide bond present in the natural dTCR. In some embodiments, there is no disulfide bond in the natural TCR. In some embodiments, the disulfide bond is an introduced non-natural disulfide bond, for example, by incorporating one or more cysteines into the constant region extracellular sequence of the first and second chain regions of the scTCR polypeptide. Exemplary cysteine ​​mutations include any mutations as described above. In some cases, natural and non-natural disulfide bonds may be present.

[0408] In some embodiments, the scTCR is a non-disulfide-linked truncated TCR in which a heterologous leucine zipper fused to its C-terminus promotes chain association (see, e.g., International Publication No. WO1999 / 60120). In some embodiments, the scTCR contains a TCRα variable domain covalently linked to a TCRβ variable domain via a peptide linker (see, e.g., International Publication No. WO 1999 / 18129).

[0409] In some embodiments, any TCR (including dTCR or scTCR) can be connected to a signaling domain to generate an active TCR on the surface of a T cell. In some embodiments, the TCR is expressed on the cell surface. In some embodiments, the TCR does contain a sequence corresponding to a transmembrane sequence. In some embodiments, the transmembrane domain can be a Cα or Cβ transmembrane domain. In some embodiments, the transmembrane domain can be from a non-TCR source, such as a transmembrane region from CD3z, CD28 or B7.1. In some embodiments, the TCR does contain a sequence corresponding to a cytoplasmic sequence. In some embodiments, the TCR contains a CD3z signaling domain. In some embodiments, the TCR is capable of forming a TCR complex with CD3.

[0410] In some embodiments, the TCR or antigen-binding fragment thereof exhibits affinity for the target antigen with an equilibrium binding constant at or about 10 -5 with 10 -12 All individual values ​​and ranges between and within M. In some embodiments, the target antigen is an MHC-peptide complex or ligand.

[0411] In some embodiments, TCR or its antigen binding portion can be a recombinantly produced natural protein or a mutant form thereof, wherein one or more properties (such as binding characteristics) have changed. In some embodiments, TCR can be derived from one of multiple animal species, such as humans, mice, rats or other mammals. In some embodiments, in order to produce a vector encoding TCR, the α and β chains can be PCR amplified from total cDNA (which is separated from a T cell clone expressing the target TCR) and cloned into an expression vector. In some embodiments, α and β chains can be produced synthetically.

[0412] In some embodiments, TCR α and β chains are separated and cloned into gene expression vectors. In some embodiments, the transcription unit can be engineered to contain a bicistronic unit containing IRES (internal ribosome entry site), which allows co-expression of gene products (e.g., encoding α and β chains) by information from a single promoter. Alternatively, in some cases, a single promoter can guide the expression of RNA, which contains multiple genes (e.g., encoding α and β chains) separated from each other by sequences encoding self-cleavage peptides (e.g., T2A) or protease recognition sites (e.g., furin) in a single open reading frame (ORF). Therefore, the ORF encodes a single polyprotein, which is cut into single proteins during translation (in the case of T2A) or after translation. In some cases, peptides (such as T2A) can cause ribosomes to skip the synthesis (ribosome jump) of peptide bonds at the C-terminal end of 2A elements, resulting in separation between the end of the 2A sequence and the next peptide downstream. Examples of 2A cleavage peptides (including those that can induce ribosome skipping) are T2A, P2A, E2A, and F2A. In some embodiments, the α and β chains are cloned into different vectors. In some embodiments, the generated α and β chains are incorporated into retroviral (e.g., lentiviral) vectors.

[0413] In some embodiments, TCR α and β genes are connected by picornavirus 2A ribosomal jumping peptides so that two chains are co-expressed. In some embodiments, the genetic transfer of TCR is completed by retrovirus or slow virus vector or by transposon (see, for example, Baum et al. (2006) Molecular Therapy: The Journal of the American Society of Gene Therapy. 13: 1050-1063; Frecha et al. (2010) Molecular Therapy: The Journal of the American Society of Gene Therapy. 18: 1748-1757; and Hackett et al. (2010) Molecular Therapy: The Journal of the American Society of Gene Therapy. 18: 674-683.

[0414] Engineered vectors and methods

[0415] The methods provided include expressing recombinant receptors (including CAR or TCR) for producing genetically engineered cells expressing such binding molecules.Genetic engineering generally involves introducing nucleic acids encoding recombinant or engineered components into cells, such as by retroviral transduction, transfection or transformation.

[0416] In some embodiments, gene transfer is accomplished by first stimulating the cells, such as by combining them with a stimulus that induces a response (such as proliferation, survival and / or activation), e.g., as measured by expression of cytokines or activation markers, and then transducing the activated cells and expanding them in culture to numbers sufficient for clinical use.

[0417] Various methods for introducing genetically engineered components (e.g., antigen receptors, such as CAR) are well known and can be used together with the provided methods and compositions. Exemplary methods include those for transferring nucleic acids encoding receptors, including by viruses (such as retroviruses or slow viruses), transduction, transposons, and electroporation.

[0418] In some embodiments, the nucleic acid encoding the recombinant receptor can be cloned into one or more suitable expression vectors. The expression vector can be any suitable recombinant expression vector and can be used to transform or transfect any suitable host. Suitable vectors include those designed for propagation and amplification or for expression or for both, such as plasmids and viruses.

[0419] In some embodiments, the vector can be a vector of the following series: pUC series (Fermentas LifeSciences), pBluescript series (Stratagene, La Jolla, California), pET series (Novagen, Madison, Wisconsin), pGEX series (Pharmacia Biotech, Uppsala, Sweden) or pEX series (Clontech, Palo Alto, California). In some cases, phage vectors such as λG10, λGT11, λZapII (Stratagene), λEMBL4 and λNM1149 can also be used. In some embodiments, plant expression vectors can be used, and include pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). In some embodiments, animal expression vectors include pEUK-Cl, pMAM and pMAMneo (Clontech). In some embodiments, viral vectors are used, such as retroviral vectors.

[0420] In some embodiments, the recombinant expression vector can be prepared using standard recombinant DNA techniques. In some embodiments, the vector may contain regulatory sequences (such as transcription and translation initiation and termination codons) that are specific to the type of host (e.g., bacteria, fungi, plants or animals) into which the vector is introduced, and it is appropriate and considered that the vector is based on DNA or RNA. In some embodiments, the vector may contain a non-natural promoter operably connected to a nucleotide sequence encoding a recombinant receptor. In some embodiments, the promoter may be a non-viral promoter or a viral promoter, such as a cytomegalovirus (CMV) promoter, a SV40 promoter, a RSV promoter, and a promoter found in the long terminal repeat sequence of a mouse stem cell virus. Other promoters known to skilled artisans are also contemplated.

[0421] In some embodiments, the recombinant nucleic acid is transferred into cells using recombinant infectious viral particles, such as, for example, vectors derived from simian virus 40 (SV40), adenovirus, adeno-associated virus (AAV). In some embodiments, the recombinant nucleic acid is transferred into T cells using recombinant lentiviral vectors or retroviral vectors, such as gamma-retroviral vectors (see, e.g., Koste et al. (2014) Gene Therapy 2014 Apr 3. doi: 10.1038 / gt.2014.25; Carlens et al. (2000) Exp Hematol 28(10): 1137-46; Alonso-Camino et al. (2013) Mol Ther Nucl Acids 2, e93; Park et al., Trends Biotechnol. 2011 Nov 29(11): 550-557.

[0422] In some embodiments, the retroviral vector has a long terminal repeat sequence (LTR), for example, a retroviral vector derived from Moloney murine leukemia virus (MoMLV), myeloproliferative sarcoma virus (MPSV), mouse embryonic stem cell virus (MESV), mouse stem cell virus (MSCV), spleen focus forming virus (SFFV) or adeno-associated virus (AAV). Most retroviral vectors are derived from mouse retroviruses. In some embodiments, retroviruses include those derived from any avian or mammalian cell source. Retroviruses are usually amphotropic, which means that they can infect host cells of several species including humans. In one embodiment, the gene to be expressed replaces the retroviral gag, pol and / or env sequences. Many illustrative retroviral systems have been described (e.g., U.S. Pat. Nos. 5,219,740; 6,207,453; 5,219,740; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, AD (1990) Human Gene Therapy 1:5-14; Scarpa et al. (1991) Virology 180:849-852; Burns et al. (1993) Proc. Natl. Acad. Sci. USA 90:8033-8037; and Boris-Lawrie and Temin (1993) Cur. Opin. Genet. Develop. 3:102-109).

[0423] Methods of lentiviral transduction are known in the art. Exemplary methods are described in, for example, Wang et al. (2012) J. Immunother. 35(9): 689-701; Cooper et al. (2003) Blood. 101: 1637-1644; Verhoeyen et al. (2009) Methods Mol Biol. 506: 97-114; and Cavalieri et al. (2003) Blood. 102(2): 497-505.

[0424] In some embodiments, the recombinant nucleic acid is transferred into T cells by electroporation (see, e.g., Chicaybam et al., (2013) PLoS ONE 8(3):e60298 and Van Tedeloo et al. (2000) Gene Therapy 7(16):1431-1437). In some embodiments, the recombinant nucleic acid is transferred into T cells by transposition (see, e.g., Manuri et al. (2010) Hum Gene Ther 21(4):427-437; Sharma et al. (2013) Molec Ther Nucl Acids 2, e74; and Huang et al. (2009) Methods Mol Biol 506:115-126). Other methods for introducing and expressing genetic material in immune cells include calcium phosphate transfection (e.g., as described in Current Protocols in Molecular Biology, John Wiley & Sons, New York. NY), protoplast fusion, cationic liposome-mediated transfection; tungsten particle-promoted microprojectile bombardment (Johnston, Nature, 346:776-777 (1990)); and strontium phosphate DNA coprecipitation (Brash et al., Mol. Cell Biol., 7:2031-2034 (1987)).

[0425] Other methods and vectors for transferring nucleic acids encoding recombinant products are, for example, those described in International Patent Application Publication No. WO 2014 / 055668 and U.S. Patent No. 7,446,190.

[0426] In some situations, the overexpression of stimulatory factors (e.g., lymphokines or cytokines) may be toxic to the subject. Therefore, in some situations, the engineered cells include gene segments that cause cells to be susceptible to negative selection in vivo (such as when given in adoptive immunotherapy). For example, in some aspects, the cells are engineered so that they can be eliminated due to changes in the in vivo conditions of the patient given them. The negative selective phenotype can be produced by the insertion of genes that confer sensitivity to the administered agent (e.g., compound). Negative selective genes include herpes simplex virus type I thymidine kinase (HSV-I TK) gene (Wigler et al., Cell II: 223, 1977), which confers ganciclovir sensitivity; cell hypoxanthine phosphoribosyl transferase (HPRT) gene; cell adenine phosphoribosyl transferase (APRT) gene; bacterial cytosine deaminase (Mullen et al., Proc. Natl. Acad. Sci. USA. 89: 33 (1992)).

[0427] In some aspects, the cells are further engineered to promote expression of cytokines or other factors.

[0428] Additional nucleic acids (e.g., genes for introduction) include: those for improving therapeutic efficacy, such as by promoting the viability and / or function of the transferred cells; genes for providing genetic markers for selecting and / or evaluating cells (e.g., for assessing survival or location in vivo); genes for improving safety, such as by sensitizing cells to negative selection in vivo, as described in Lupton SD et al., Mol. and Cell Biol., 11: 6 (1991); and Riddell et al., Human Gene Therapy 3: 319-338 (1992); see also the disclosures of PCT / US91 / 08442 and PCT / US94 / 05601 of Lupton et al., which describe the use of bifunctional selective fusion genes derived by fusing dominant positive selective markers to negative selective markers. See, e.g., Riddell et al., U.S. Patent No. 6,040,177, columns 14-17.

[0429] Compositions and formulations

[0430] Also provided are colonies of such cells, compositions containing such cells and / or enriched in such cells, such as in the compositions expressing recombinant receptors, at least 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of the total cells or cells of a certain type (such as T cells or CD8+ or CD4+ cells) in the compositions. Compositions include pharmaceutical compositions and formulations for administration (such as for adoptive cell therapy). Also provided are methods of administering the cells and compositions to a subject (e.g., a patient).

[0431] Compositions comprising cells for administration are also provided, including pharmaceutical compositions and formulations, such as unit dosage compositions comprising a number of cells for administration at a given dose or a portion thereof. Pharmaceutical compositions and formulations typically include one or more optional pharmaceutically acceptable carriers or excipients. In some embodiments, the composition comprises at least one additional therapeutic agent.

[0432] The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of the active ingredient contained therein to be effective, and which does not contain any additional components which would be unacceptably toxic to a subject to which the formulation would be administered.

[0433] "Pharmaceutically acceptable carrier" refers to ingredients in a pharmaceutical formulation that are non-toxic to a subject other than the active ingredient. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers or preservatives.

[0434] In some aspects, the selection of carriers depends in part on specific cells and / or methods of administration. Therefore, there are a variety of suitable formulations. For example, the pharmaceutical composition can contain a preservative. Suitable preservatives can include, for example, methylparaben, propylparaben, sodium benzoate, and benzalkonium chloride. In some aspects, a mixture of two or more preservatives is used. Preservatives or mixtures thereof are typically present in an amount of about 0.0001% to about 2% by weight of the total composition. Carriers are described in, for example, Remington's Pharmaceutical Sciences 16th edition, Osol, A. editor (1980). Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers, such as polyvinylpyrrolidone; amino acids, such as glycine, glutamine, asparagine, histidine, arginine or lysine; monosaccharides, disaccharides and other carbohydrates, including glucose, mannose or dextrins; chelating agents, such as EDTA; sugars, such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions, such as sodium; metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants, such as polyethylene glycol (PEG).

[0435] In some aspects, a buffer is included in the composition. Suitable buffers include, for example, citric acid, sodium citrate, phosphoric acid, potassium phosphate, and various other acids and salts. In some aspects, a mixture of two or more buffers is used. The buffer or a mixture thereof is generally present in an amount of about 0.001% to about 4% by weight of the total composition. Methods for preparing a pharmaceutical composition that can be administered are known. Exemplary methods are described in more detail, for example, in Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins; 21st ed. (May 1, 2005).

[0436] The preparation may include an aqueous solution. The preparation or composition may also contain more than one active ingredient that can be used for a specific indication, disease or condition treated with cells, preferably those ingredients with an activity complementary to the cells, wherein the respective activities do not adversely affect each other. Such active ingredients are suitably combined in an amount effective for a given purpose. Therefore, in some embodiments, the pharmaceutical composition also includes other pharmaceutically active agents or drugs, such as chemotherapeutic agents, for example, asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine and / or vincristine.

[0437] In some embodiments, the pharmaceutical composition comprises cells in an amount (e.g., a therapeutically effective amount or a prophylactically effective amount) effective to treat or prevent a disease or condition. In some embodiments, the therapeutic or prophylactic efficacy is monitored by regularly assessing the treated subject. The desired dose can be delivered by a single bolus of cells, by multiple boluses of cells, or by continuous infusion of cells.

[0438] The cells and compositions can be administered using standard administration techniques, formulations and / or devices. The administration of cells can be autologous or allogeneic. For example, immunoreactive cells or progenitor cells can be obtained from a subject and administered to the same subject or different but compatible subjects. Peripheral blood-derived immune response cells or their progeny (e.g., in vivo, ex vivo or in vitro derived) can be administered by local injection, including catheter administration, systemic injection, local injection, intravenous injection or parenteral administration. When administering a therapeutic composition (e.g., a pharmaceutical composition containing genetically modified immunoreactive cells), it is usually formulated into a unit dose injectable form (solution, suspension, emulsion).

[0439] Formulations include those for oral, intravenous, intraperitoneal, subcutaneous, pulmonary, transdermal, intramuscular, intranasal, buccal, sublingual, or suppository administration. In some embodiments, the cell population is administered parenterally. As used herein, the term "parenteral" includes intravenous, intramuscular, subcutaneous, rectal, vaginal, and intraperitoneal administration. In some embodiments, the cells are administered to a subject using peripheral systemic delivery by intravenous, intraperitoneal, or subcutaneous injection.

[0440] In some embodiments, compositions are provided as sterile liquid preparations (for example, isotonic aqueous solutions, suspensions, emulsions, dispersions or viscous compositions), which can be buffered to the pH selected in some aspects.Liquid preparations are generally easier to prepare than gels, other viscous compositions and solid compositions. In addition, liquid compositions are slightly more convenient to give, particularly by injection. On the other hand, viscous compositions can be formulated in a suitable viscosity range, to provide a longer contact time with a particular tissue.Liquid or viscous compositions can include carriers, and the carriers can be solvents or dispersion media, and the solvents or dispersion media contain, for example, water, saline, phosphate buffered saline, polyols (for example, glycerol, propylene glycol, liquid polyethylene glycol) and suitable mixtures thereof.

[0441] Sterile injectable solutions can be prepared by incorporating cells into a solvent, such as mixing with a suitable carrier, diluent or excipient (such as sterile water, saline, glucose, dextrose, etc.). The composition may contain auxiliary substances, such as wetting agents, dispersants or emulsifiers (e.g., methylcellulose), pH buffers, gelling or viscosity enhancing additives, preservatives, flavoring agents and / or pigments, depending on the route of administration and the desired formulation. In some aspects, standard texts can be consulted to prepare suitable formulations.

[0442] Various additives that enhance the stability and sterility of the composition may be added, including antimicrobial preservatives, antioxidants, chelating agents, and buffers. Prevention of microbial action may be ensured by various antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, and sorbic acid). Prolonged absorption of injectable drug forms may be achieved by using agents that delay absorption (e.g., aluminum monostearate and gelatin).

[0443] Formulations for in vivo administration are generally sterile. Sterility can be readily achieved, for example, by filtration through sterile filtration membranes.

[0444] Adoptive cell therapy administration methods and uses

[0445] Provided are methods for giving cells, colonies and compositions as described herein, and purposes of such cells, colonies and compositions as described herein for treating or preventing diseases, disorders and obstacles (including cancer). In some embodiments, cells, colonies and compositions are administered to subjects or patients, and the subjects or patients suffer from specific diseases or disorders to be treated, for example, by adoptive cell therapy (such as adoptive T cell therapy). In some embodiments, cells and compositions prepared by the provided method (such as engineered compositions and production end compositions after incubation and / or other processing steps) are administered to subjects, such as subjects suffering from diseases or disorders or having the risk of suffering from diseases or disorders. In some aspects, the method thus treats the disease or disorder (for example, improving one or more symptoms thereof), for example, by reducing the tumor load in cancer expressing antigens recognized by engineered T cells for treatment.

[0446] Methods for administering cells for adoptive cell therapy are known and can be used with the provided methods and compositions. For example, adoptive T cell therapy methods are described in, for example, U.S. Patent Application Publication No. 2003 / 0170238 to Gruenberg et al.; U.S. Patent No. 4,690,915 to Rosenberg; Rosenberg (2011) Nat Rev Clin Oncol. 8(10): 577-85). See, for example, Themeli et al. (2013) Nat Biotechnol. 31(10): 928-933; Tsukahara et al. (2013) Biochem Biophys Res Commun 438(1): 84-9; Davila et al. (2013) PLoS ONE 8(4): e61338.

[0447] As used herein, a "subject" is a mammal, such as a human or other animal, and is typically a human. In some embodiments, the subject (e.g., patient) to which the cell, cell colony, or composition is administered is a mammal, typically a primate, such as a human. In some embodiments, the primate is a monkey or ape. The subject can be male or female, and can be any suitable age, including infants, young children, adolescents, adults, and elderly subjects. In some embodiments, the subject is a non-primate mammal, such as a rodent.

[0448] As used herein, "treatment" (and grammatical variants such as "treat" or "treating") refers to the complete or partial improvement or alleviation of a disease or condition or disorder, or a symptom, adverse effect, outcome, or phenotype associated therewith. Desired therapeutic effects include, but are not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or slowing the disease state, and alleviating or improving prognosis. The term does not imply a complete cure of the disease or complete elimination of any symptom or one or more effects on all symptoms or outcomes.

[0449] As used herein, "delaying the development of a disease" means postponing, hindering, slowing, delaying, stabilizing, inhibiting and / or postponing the development of a disease (such as cancer). This delay can be of varying lengths of time, depending on the medical history and / or the individual being treated. It will be clear to one skilled in the art that a sufficient or significant delay may actually encompass prevention, in that the individual will not develop the disease. For example, the onset of advanced cancers, such as metastases, may be delayed.

[0450] As used herein, "prevention" includes providing prevention of the occurrence or recurrence of a disease in a subject who may be susceptible to the disease but has not yet been diagnosed with the disease. In some embodiments, provided cells and compositions are used to delay the development of a disease or slow the progression of a disease.

[0451] As used herein, "inhibiting" a function or activity is reducing the function or activity when compared to otherwise identical conditions except for the target conditions or parameters, or when compared to another condition. For example, a cell that inhibits tumor growth reduces the growth rate of a tumor compared to the growth rate of the tumor in the absence of the cell.

[0452] In the context of administration, an "effective amount" of an agent (eg, a pharmaceutical formulation, cell, or composition) refers to an amount effective, at dosages / amounts and for periods of time necessary, to achieve the desired result (eg, a therapeutic or preventive result).

[0453] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical formulation or cell) refers to an amount that is effective to achieve a desired therapeutic outcome (e.g., treatment for a disease, condition, or disorder) and / or a pharmacokinetic or pharmacodynamic effect of treatment at a desired dosage and over a desired period of time. A therapeutically effective amount can vary depending on factors such as the disease state, age, sex, and weight of the subject, and the cell population administered. In some embodiments, provided methods involve administering cells and / or compositions in an effective amount (e.g., a therapeutically effective amount).

[0454] A "prophylactically effective amount" refers to an amount effective to achieve the desired prophylactic result at the necessary dosage and for the necessary time period. Typically, but not necessarily, because a prophylactic dose is used in a subject before or at an early stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. In the context of lower tumor burden, in some aspects, the prophylactically effective amount will be higher than the therapeutically effective amount.

[0455] In some embodiments, the subject has a persistent or recurrent disease, e.g., after treatment with another therapeutic intervention, including chemotherapy, radiation, and / or hematopoietic stem cell transplantation (HSCT), e.g., allogeneic HSCT. In some embodiments, the administering is effective to treat the subject despite the subject having developed resistance to another therapy.

[0456] Methods for administering cells for adoptive cell therapy are known and can be used with the provided methods and compositions. For example, adoptive T cell therapy methods are described in, for example, U.S. Patent Application Publication No. 2003 / 0170238 to Gruenberg et al.; U.S. Patent No. 4,690,915 to Rosenberg; Rosenberg (2011) Nat Rev Clin Oncol. 8(10): 577-85). See, for example, Themeli et al. (2013) Nat Biotechnol. 31(10): 928-933; Tsukahara et al. (2013) Biochem Biophys Res Commun 438(1): 84-9; Davila et al. (2013) PLoS ONE 8(4): e61338.

[0457] In some embodiments, the cell therapy (e.g., adoptive T cell therapy) is performed by autologous transfer, wherein the cells are isolated and / or otherwise prepared from a subject to be treated with the cell therapy or from a sample derived from the subject. Thus, in some aspects, the cells are derived from a subject in need of treatment (e.g., a patient), and after isolation and processing, the cells are administered to the same subject.

[0458] In some embodiments, the cell therapy (e.g., adoptive T cell therapy) is performed by allogeneic transfer, wherein the subject (e.g., first subject) is separated and / or otherwise prepared from a subject other than the subject who will receive or ultimately receive the cell therapy. In such embodiments, the cells are then administered to different subjects of the same species, such as a second subject. In some embodiments, the first and second subjects are genetically identical. In some embodiments, the first and second subjects are genetically similar. In some embodiments, the second subject expresses the same HLA class or supertype as the first subject.

[0459] In some embodiments, before giving cells or compositions containing cells, subjects have been treated with therapeutic agents for targeted diseases or conditions (such as tumors). In some aspects, subjects are difficult to treat or unresponsive for other therapeutic agents. In some embodiments, subjects, for example, suffer from a continuous or recurrent disease after being treated with another therapeutic intervention (including chemotherapy, radiation and / or hematopoietic stem cell transplantation (HSCT), such as allogeneic HSCT). In some embodiments, although subjects have developed resistance to another therapy, the subject is effectively treated by giving.

[0460] In some embodiments, the subject is responsive to another therapeutic agent, and treatment with the therapeutic agent reduces the disease load. In some respects, the subject is initially responsive to the therapeutic agent, but shows recurrence of the disease or condition over time. In some embodiments, the subject has not relapsed. In some such embodiments, it is determined that the subject has a risk of relapse, such as a high risk of relapse, and therefore cells are given prophylactically, for example to reduce the possibility of relapse or to prevent relapse.

[0461] In some aspects, the subject has not received prior treatment with another therapeutic agent.

[0462] Diseases, conditions and disorders for treatment with provided compositions, cells, methods and uses include tumors, including solid tumors, hematological malignancies and melanomas; and infectious diseases, such as infection with viruses or other pathogens (e.g., HIV, HCV, HBV, CMV); and parasitic diseases. In some embodiments, the disease or condition is a tumor, cancer, malignancy, neoplasm or other proliferative disease or disorder. Such diseases include, but are not limited to, leukemias, lymphomas, such as chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, refractory follicular lymphoma, mantle cell lymphoma, indolent B-cell lymphoma, B-cell malignancies, colon cancer, lung cancer, liver cancer, breast cancer, prostate cancer, ovarian cancer, skin cancer, melanoma, bone cancer and brain cancer, ovarian cancer, epithelial cancer, renal cell carcinoma, pancreatic adenocarcinoma, Hodgkin's lymphoma, cervical cancer, colorectal cancer, glioblastoma, neuroblastoma, Ewing's sarcoma, medulloblastoma, osteosarcoma, synovial sarcoma and / or mesothelioma.

[0463] In some embodiments, the disease or condition is an infectious disease or condition, such as, but not limited to, viral, retroviral, bacterial and protozoan infections, immunodeficiency, cytomegalovirus (CMV), Epstein-Barrvirus (EBV), adenovirus, BK polyomavirus. In some embodiments, the disease or condition is an autoimmune or inflammatory disease or condition, such as arthritis (e.g., rheumatoid arthritis (RA)), type I diabetes, systemic lupus erythematosus (SLE), inflammatory bowel disease, psoriasis, scleroderma, autoimmune thyroid disease, Graves' disease, Crohn's disease, multiple sclerosis, asthma, and / or a disease or condition associated with transplantation.

[0464] In some embodiments, the antigen associated with the disease, disorder or condition is selected from ROR1, B cell maturation antigen (BCMA), carbonic anhydrase 9 (CAIX), tEGFR, Her2 / neu (receptor tyrosine kinase erbB2), L1-CAM, CD19, CD20, CD22, mesothelin, CEA and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, epithelial glycoprotein 2 (EPG-2), epithelial glycoprotein 40 (EPG-40), EPHa2, erb-B2, erb-B3, erb-B4, erbB dimer, EGFR vIII, folate binding protein (FBP), FCRL5, FCRH5, fetal acetylcholine receptor, GD2, GD3, HMW-MAA, IL-22R-α, IL-13R-α2, kinase insert domain receptor (kdr), kappa light chain, Lewis Y, L1 cell adhesion molecule (L1-CAM), melanoma associated antigen (MAGE)-A1, MAGE-A3, MAGE-A6, melanoma preferentially expressed antigen (PRAME), survivin, TAG72, B7-H6, IL-13 receptor α2 (IL-13Ra2), CA9, GD3, HMW-MAA, CD171, G250 / CAIX, HLA-AI MAGE Al, HLA-A2NY-ESO-1, PSCA, folate receptor-a, CD44v6, CD44v7 / 8, avb6 integrin, 8H9, NCAM, VEGF receptor, 5T4, fetal AchR, NKG2D ligand, CD44v6, dual antigen, cancer-testis antigen, mesothelin, murine CMV, mucin 1 (MUC1), MUC16, PSCA, NKG2D, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, c-Met, GD-2, O-acetylated GD2 (OGD2), CE7, Wilms tumor 1 (WT-1), cyclins, cyclin A2, CCL-1, CD138, pathogen-specific antigens.

[0465] In some embodiments, the antigen associated with the disease or disorder is selected from orphan tyrosine kinase receptor ROR1, tEGFR, Her2, L1-CAM, CD19, CD20, CD22, mesothelin, CEA, and hepatitis B surface antigen, anti-folate receptor, CD23, CD24, CD30, CD33, CD38, CD44, EGFR, EGP-2, EGP-4, OEPHa2, ErbB2, 3 or 4, FBP, fetal acetylcholine e receptor, GD2, GD3, HMW-MAA, IL-22R- α, IL-13R-α2, kdr, kappa light chain, Lewis Y, L1 cell adhesion molecule, MAGE-A1, mesothelin, MUC1, MUC16, PSCA, NKG2D ligand, NY-ESO-1, MART-1, gp100, carcinoembryonic antigen, ROR1, TAG72, VEGF-R2, carcinoembryonic antigen (CEA), prostate specific antigen, PSMA, Her2 / neu, estrogen receptor, progesterone receptor, ephrin B2, CD123, CS-1, c-Met, GD-2 and MAGE A3 and / or biotinylated molecules, and / or molecules expressed by HIV, HCV, HBV or other pathogens.

[0466] In some embodiments, the cell is administered at a desired dose, which includes in some aspects the desired dose or number of cells or one or more cell types and / or the desired ratio of cell types. Therefore, in some embodiments, the cell dose is based on the total number of cells (or the number of cells per kg body weight) and the desired ratio of a separate population or subtype, such as the ratio of CD4+ to CD8+. In some embodiments, the cell dose is based on the total number of cells or a separate cell type (or the number of cells per kg body weight) in the desired separate population. In some embodiments, the dosage is based on a combination of such features, such as the total number of cells required, the desired ratio, and the total number of cells in the desired separate population.

[0467] In some embodiments, a population or subtype of cells, such as CD8 T cells, is administered at or within a tolerable difference of a desired dose of total cells (such as a desired dose of T cells). + and CD4 + T cells. In some aspects, the desired dose is the desired number of cells or the desired number of cells per unit body weight of the subject to whom the cells are administered, e.g., cells / kg. In some aspects, the desired dose is equal to or greater than the minimum number of cells or the minimum number of cells per unit body weight. In some aspects, the individual populations or subtypes are expressed at or near the desired output ratio (e.g., CD4+ / -1) of the total cells administered at the desired dose. + With CD8 + ratio) exists, for example within a certain tolerance difference or error of such ratio.

[0468] In some embodiments, cells are administered at or within the tolerance difference of the desired dose of one or more individual cell populations or subtypes (such as the desired dose of CD4+ cells and / or the desired dose of CD8+ cells). In some aspects, the desired dose is the number of cells of the desired subtype or population or the desired number of such cells per unit body weight of the subject to whom the cells are administered, e.g., cells / kg. In some aspects, the desired dose is equal to or greater than the minimum number of cells of a population or subtype or the minimum number of cells of the population or subtype per unit body weight.

[0469] Thus, in some embodiments, the dosage is based on a fixed dose of total cells desired and a desired ratio, and / or based on a fixed dose of one or more individual subtypes or subsets (e.g., each) desired. Thus, in some embodiments, the dosage is based on a fixed or minimum dose of T cells desired and a desired CD4 + With CD8 + ratio of cells, and / or based on the desired CD4 + and / or CD8 + Fixed or minimum dose of cells.

[0470] In certain embodiments, the cells, or individual subtype populations of cells, are administered to a subject in a range of about 1 million to about 100 billion cells, such as 1 million to about 50 billion cells (e.g., about 5 million cells, about 25 million cells, about 500 million cells, about 1 billion cells, about 5 billion cells, about 20 billion cells, about 30 billion cells, about 40 billion cells, or a range defined by any two of the foregoing values), such as about 10 million to about 100 billion cells (e.g., about 20 million cells, about 30 million cells, about 40 million cells, about 60 million cells, about 70 million cells, about 80 million cells, about 90 million cells, about 100 million cells, about 150 million cells, about 160 million cells, about 170 million cells, about 180 million cells, about 190 million cells, about 200 million cells, about 210 million cells, about 220 million cells, about 230 million cells, about 240 million cells, about 250 million cells, about 260 million cells, about 270 million cells, about 280 million cells, about 290 million cells, about 300 million cells, about 310 million cells, about 320 million cells, about 330 million cells, about 340 million cells, about 360 million cells, about 370 million cells, about 380 million cells, about 390 million cells, about 400 million cells, about 410 million cells, about 420 million cells, about 430 million cells, about 440 million cells, about 460 million cells, about 470 million cells, about 480 million cells, about 490 million cells, about 500 million cells, about 500 million cells, about In some embodiments, the present invention relates to a cell population having at least one nucleotide sequence of at least one nucleotide sequence and a plurality of nucleotide sequences. In some embodiments, the present invention relates to a cell population having at least one nucleotide sequence of at least one nucleotide sequence and a plurality of nucleotide sequences. In some embodiments, the present invention relates to a cell population having at least one nucleotide sequence of at least one nucleotide sequence and a plurality of nucleotide sequences. In some embodiments, the present invention relates to a cell population having at least one nucleotide sequence and a plurality of nucleotide sequences.

[0471] In some embodiments, the total cell dose and / or the dose of individual cell subpopulations is at or about 10 4 With at or about 10 9 cells / kg body weight, such as 105 with 10 6 cells / kg body weight, for example, at or about 1x10 5 cells / kg body weight, 1.5x 10 5 cells / kg body weight, 2x10 5 cells / kg body weight, or 1x 10 6 For example, in some embodiments, the cells are grown at or about 10 4 With at or about 10 9 T cells / kg body weight, such as about 10 5 with 10 6 T cells / kg body weight, for example, at or about 1 x 10 5 T cells / kg body weight, 1.5x 10 5 T cells / kg body weight, 2x 10 5 T cells / kg body weight, or 1x 10 6 T cells / kg body weight, or within a certain error range thereof.

[0472] In some embodiments, the cells are grown at or about 10 4 With or with about 10 9 CD4 + and / or CD8 + cells / kg body weight, such as 10 5 with 10 6 CD4 + and / or CD8 + cells / kg body weight, for example, or about 1 x 10 5 CD4 + and / or CD8 + cells / kg, 1.5x 10 5 CD4 + and / or CD8 + cells / kg, 2x 10 5 CD4 + and / or CD8 + cells / kg or 1x 10 6 CD4 + and / or CD8 + cells / kg body weight, or within a certain error range thereof.

[0473] In some embodiments, the cells are grown at a density of greater than and / or at least about 1 x 10 6 , about 2.5x 10 6 , about 5x 10 6 , about 7.5x 10 6, or about 9x 10 6 CD4 + cells, and / or at least about 1 x 10 6 , about 2.5x 10 6 , about 5x 10 6 , about 7.5x 10 6 , or about 9x 10 6 CD8+ cells, and / or at least about 1 x 10 6 , about 2.5x 10 6 , about 5x 10 6 , about 7.5x 10 6 , or about 9x10 6 In some embodiments, the cells are administered at about 10 8 with 10 12 T cells or about 10 10 with 10 11 T cells, about 10 8 with 10 12 CD4 + Between cells or about 10 10 with 10 11 CD4 + Between cells, and / or at about 10 8 with 10 12 CD8 + Between cells or about 10 10 with 10 11 CD8 + between cells, or within a certain error range thereof.

[0474] In some embodiments, the cells are administered at a desired output ratio of multiple cell populations or subtypes (e.g., CD4+ and CD8+ cells or subtypes), or within a tolerable range of the desired output ratio. In some aspects, the desired ratio can be a specific ratio or can be a range of ratios. For example, in some embodiments, a desired ratio (e.g., CD4+ and CD8+ cells or subtypes) is administered at a desired output ratio of multiple cell populations or subtypes (e.g., CD4+ and CD8+ cells or subtypes). + With CD8 +The ratio of cells) is between equal to or about 1:5 and equal to or about 5:1 (or greater than about 1:5 and less than about 5:1), or between equal to or about 1:3 and equal to or about 3:1 (or greater than about 1:3 and less than about 3:1), such as between equal to or about 2:1 and equal to or about 1:5 (or greater than about 1:5 and less than about 2:1), such as equal to or about 5:1, 4.5:1, 4:1, 3.5:1, 3:1, 2.5:1, 2 In some aspects, the tolerance difference is within about 1%, about 2%, about 3%, about 4%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50% of the desired ratio (including any values ​​between these ranges).

[0475] For the prevention or treatment of disease, the appropriate dosage may depend on the type of disease to be treated, the type of cell or recombinant receptor, the severity and course of the disease, whether the cells are administered for preventive or therapeutic purposes, previous treatments, the subject's clinical history and response to the cells, and the discretion of the attending physician. In some embodiments, the compositions and cells are administered to the subject once or over a series of treatments in an appropriate manner.

[0476] The cells may be administered by any suitable means, for example by bolus infusion, by injection (e.g., intravenous or subcutaneous, intraocular, periocular, subretinal, intravitreal, transseptal, subscleral, intrachoroidal, intracameral, subconjectval, subconjuntival, sub-Tenon, retrobulbar, periocular, or posterior juxtascleral delivery. In some embodiments, they are administered parenterally, intrapulmonary, and intranasally, and, if desired for local treatment, intralesionally. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, a given dose is administered by a single bolus administration of the cells. In some embodiments, a given dose is administered, for example, by multiple bolus administrations of the cells over a period of no more than 3 days, or by continuous infusion administration of the cells.

[0477] In some embodiments, cells are given as part of a combination therapy, such as being given simultaneously or sequentially in any order with another therapeutic intervention such as an antibody or engineered cell or receptor or other agent (such as a cytotoxic agent or therapeutic agent). Cells are co-administered in some embodiments with one or more additional therapeutic agents or in combination with another therapeutic intervention simultaneously or sequentially in any order. In some situations, cells are co-administered with another therapy, and their time is close enough so that the cell colony enhances the effect of one or more additional therapeutic agents, or vice versa. In some embodiments, cells are given before the one or more additional therapeutic agents. In some embodiments, cells are given after the one or more additional therapeutic agents. In some embodiments, the one or more additional agents include cytokines (such as IL-2) for example to enhance persistence. In some embodiments, the method includes administering a chemotherapeutic agent.

[0478] After the cells are given, the biological activity of the engineered cell colony is measured, for example, by any of many known methods in some embodiments. The parameters to be evaluated include the specific binding of engineered or natural T cells or other immune cells to antigens, which are evaluated in vivo, for example, by imaging, or in vitro, for example, by ELISA or flow cytometry. In certain embodiments, the ability of engineered cells to destroy target cells can be measured using any suitable method known in the art, such as described in the cytotoxicity assays in the following documents: Kochenderfer et al., J. Immunotherapy, 32 (7): 689-702 (2009), and Herman et al. J. Immunological Methods, 285 (1): 25-40 (2004). In certain embodiments, the biological activity of cells is measured by measuring the expression and / or secretion of one or more cytokines (such as CD 107a, IFNγ, IL-2 and TNF). In some aspects, biological activity is measured by evaluating clinical outcomes (such as the reduction of tumor load or burden).

[0479] In certain embodiments, the engineered cells are further modified in many ways so as to increase their therapeutic or preventive efficacy. For example, the engineered CAR or TCR expressed by the colony can be directly or indirectly conjugated to the targeting moiety through a joint. The practice of conjugating a compound (e.g., CAR or TCR) to a targeting moiety is known in the art. See, for example, Wadwa et al., J. Drug Targeting 3: 111 (1995) and U.S. Patent No. 5,087,616.

[0480] Example

[0481] The following examples are illustrative only and are not intended to limit the scope or content of the present invention in any way.

[0482] Example 1 - Preliminary screening of gRNA.

[0483] Guide RNAs were screened by complexing commercially synthesized gRNAs with Cas9 in vitro and delivering the gRNA / Cas9 ribonucleoprotein (RNP) to cells via electroporation.

[0484] Figure 1 The indel frequencies % of the tested gRNAs are depicted. Figure 2 The genome editing efficiencies of certain exemplary gRNA pairs are depicted.

[0485] Example 2 - Analysis of gRNA candidates against TGFBR2 in T cells.

[0486] The goal of CRISPR-Cas9 editing cells is to achieve the highest percentage of target gene knockout using the lowest possible concentration of gRNA / Cas9 complex and the least number of off-target cleavage events. To determine the best possible gRNA candidate for TGFBR2 gene editing, seven potential gRNAs were tested. T cells were transfected with different concentrations of gRNA / Cas9 RNP. Illumina miSeq analysis was then used to determine the indel frequency percentage. The results showed that the indel frequency percentages of different gRNAs ranged from 20% to 80%, and all gRNAs reached their highest indel frequency % ( 2 μM) at an RNP concentration of 2 μM. Figure 3 ). A 2 μM RNP concentration was subsequently used for all experiments.

[0487] The gRNA selected according to miSeq analysis was selected for further analysis in BCMACAR T cells. The gRNAs of SEQID NO:5050, 5052, 5093 and 5043 were used in RNP re-shearing assays to determine the editing % of the TGFBR2 gene. The dual gRNA method was also tested using the combination of SEQ ID NO:5043 / 5093. Although the individual gRNAs of SEQ ID NO:5043 and 5093 only achieved 20%-40% editing, it was found that the combination was more effective, producing an editing value of about 80% ( Figure 4A ).

[0488] High-throughput sequencing analysis was performed using the selected gRNAs to determine the indel frequency %. The gRNAs of SEQ ID NO: a and b and the dual gRNA combination of c / d were tested. Notably, an indel frequency of up to 95% was achieved from the selected gRNAs ( Figure 4B ).

[0489] Although the insertion and deletion frequency % is a useful measure of the effectiveness of the gRNA, some portion of the insertion and deletion produced may be in-frame insertions or deletions. Such in-frame insertions and deletions can produce modified genes whose protein products retain some activity. When trying to produce gene knockouts, out-of-frame insertions and deletions are preferred. In order to ensure that the gRNA tested actually produces the desired out-of-frame insertion and deletion, the specific types of insertions and deletions produced in the sequencing results were analyzed. The results showed that although SEQ ID NO: 5052 produced the highest insertion and deletion frequency %, SEQ ID NO: 5050 generated a higher out-of-frame insertion and deletion frequency % ( Figure 5 ).

[0490] Example 3 - In vitro efficacy of gene editing in primary and engineered T cells.

[0491] The inhibitory effect of TGFβ in primary T cells modified to express CAR targeting BCMA was analyzed. Anti-BCMACAR T cells were also modified to edit the TGFBR2 gene using the selected gRNA via the CRISPR-Cas9 system. The AAVS1 control for gene editing and T cells expressing anti-BCMA CAR with unedited TGFBR2 genes were used as controls. The cell line was co-cultured with the RPMI 8226 multiple myeloma cell line with or without 10ng / ml TGFβ. In the presence of excess TGFβ, primary T cells and anti-BCMACAR T cells exhibited the desired inhibitory effect, i.e., reduced interferon-γ (IFNγ) production. However, in gene-edited anti-BCMA CAR T cells, the inhibitory effect of TGFβ was rescued, thereby restoring the production of IFNγ to the level found when TGFβ was not added ( Figure 6 ).

[0492] Inhibition of T cell proliferation is one of the effects caused by TGFβ signaling (Tiemessen et al. Int. Immunol. 15: 1495-1504. 2003). To address the effect of TGFβ signaling on cell proliferation, anti-BCMA CAR T cell proliferation was monitored in the context of TGFBR2 gene editing using several gRNAs. In the case of editing the TGFBR2 gene, anti-BCMA CAR T cells were able to proliferate in the presence of excess TGFβ ( Figure 7 ).

[0493] T cell activity is influenced by the expression of various stimulatory and inhibitory receptors. CD25 expression in TGFBR2 gene-edited anti-BCMA CAR T cells was evaluated. When exposed to TGFβ, TGFBR2 gene editing resulted in higher CD25 expression levels compared to control cells ( Fig. 8A). The expression of the inhibitory receptor PD-1 was also assessed by measuring the % PD-1+ cells in the presence and absence of excess TGFβ. TGFBR2 gene-edited anti-BCMA CAR T cells showed a lower increase in PD-1 relative to control cells. Unexpectedly, gene-edited cells resulted in fewer PD-1+ cells ( Figure 8B ).

[0494] Activation of the TGFβ signaling pathway leads to phosphorylation of the Smad 2 / 3 complex, which in turn regulates many downstream processes of TGFβ signaling. For this reason, phosphorylated Smad 2 / 3 is often used as a measure of TGFβ signaling in cells. Phosphorylated Smad2 / 3 was detected in T cells transduced to express different CARs with or without TGFBR2 gene editing. T cells expressing CARs with (10ng / ml) or without TGFβ (including AAVS1 gene editing controls) were used as controls. Although excess TGFβ leads to the expected increase in Smad 2 / 3 phosphorylation in unedited cells, TGFBR2 gene-edited cells maintain the same level of Smad 2 / 3 phosphorylation ( Fig. 9 ). The results showed that the TGFBR2 CRISPR gene editing approach effectively silenced the TGFβ signaling pathway.

[0495] To further analyze the role of TGFBR2 gene editing in different CAR T cell contexts, GzmB levels were measured in the presence and absence of TGFβ. T cells expressing CAR (including AAVS1 gene editing control) in the presence (10 ng / ml) or absence of TGFβ were used as controls. The results of intracellular staining of GzmB revealed that TGFBR2 gene editing maintained GzmB expression in the presence of TGFβ ( Fig.10 ).

[0496] Cytokine detection assays were used in Fig.10 IFNγ production was analyzed in similar experiments as shown. Consistent with previous GzmB expression results, under conditions of excess TGFβ, IFNγ production was maintained or even increased in the TGFBR2 gene-edited background relative to controls ( Fig.11 ).

[0497] Using the Edu Click-It assay from ThermoFisher, Fig.10 and Fig.11 Cell proliferation was analyzed in a similar experiment as described. Under conditions of excess TGFβ, cell proliferation was maintained relative to controls in the context of TGFBR2 gene editing ( Fig.12).

[0498] The overall results of Example 3 demonstrate the advantages of using the CRISPR-Cas9 gene editing system to edit the TGFBR2 gene. Using single and dual gRNA approaches, the TGFβ signaling pathway can be effectively inhibited in the context of CAR T cells.

[0499] Example 4 - Comparison of TGFBR2 dominant negative method and CRISPR-Cas9 gene editing method.

[0500] An alternative approach to abrogate TGFβ signaling is to express a dominant negative form (DN) of TGFBR2. This form of TGFBR2 competes with wild-type TGFBR2 for binding to TGFβ, thereby minimizing the effective signaling response.

[0501] The inhibitory effect of TGFβ in primary T cells transduced to express anti-BCMA CAR was analyzed. In addition, T cells expressing anti-BCMA CAR were modified to express DN or edit the TGFBR2 gene via the CRISPR-Cas9 system. CRISPR-Cas9 edited cells were edited with dual gRNA of SEQ IDNO:5043 and 5093. The AAVS1 control for gene editing, T cells expressing anti-BCMA CAR with unedited TGFBR2 gene, and T cells expressing anti-BCMA CAR (including AAVS1 gene editing control) were used as controls. The cell line was co-cultured with the RPMI 8226 multiple myeloma cell line with or without 10ng / mlTGFβ. In the presence of excess TGFβ, primary T cells and anti-BCMA CAR T cells showed the desired inhibitory effect, i.e., reduced GzmB ( Fig.13A ) and IFNγ( Fig. 13B However, in DN or CRISPR-edited anti-BCMA CAR T cells, the inhibitory effects of TGFβ were rescued, restoring GzmB and IFNγ production to the levels found when no TGFβ was added.

[0502] To further demonstrate the utility of rescuing the inhibitory effects of TGFβ signaling, the killing activity of anti-BCMA CAR T cells in the context of DN or CRISPR editing was analyzed. Anti-BCMA CAR T cells expressing an unedited TGFBR2 gene were used as a control. Anti-BCMA CAR T cells were co-cultured with RPMI8226 cells at a ratio of 1 anti-BCMA CAR T cell to 4 RPMI cells with or without 10ng / ml TGFβ. In the presence of TGFβ, the lytic activity of anti-BCMA CAR T cells was maintained in both DN and CRISPR editing contexts. Unexpectedly, CRISPR-edited anti-BCMACAR T cells exhibited superior lytic activity compared to DN cells ( Fig.14 ). Even without the addition of excess TGFβ, the lytic activity of CRISPR-edited anti-BCMA CAR T cells was higher than that of control cells.

[0503] Repeated antigen stimulation of T cells (including CAR T cells) leads to reduced T cell persistence and can cause activation-induced cell death (AICD) (Gargett et al. Mol. Ther. 24: 1135-1149. 2016). Strategies to maintain T cell activity against specific antigens are very important for improving the efficacy of T cell-based therapies. The proliferation capacity of anti-BCMA CAR T cells in the context of DN or CRISPR editing in the presence of repeated stimulation with TGFβ was analyzed. Anti-BCMA CAR-expressing T cells with an unedited TGFBR2 gene were used as a control. Although unmodified anti-BCMA CAR T cells did not proliferate within days of TGFβ stimulation, TGBR2 DN or CRISPR-edited cells continued to proliferate over time in the presence of TGFβ ( FIG. 15A to FIG. 15C The percentage of anti-BCMA CAR T cells also did not decrease during repeated stimulation with TGFβ ( FIG. 15D to FIG. 15F ).

[0504] IFNγ production was analyzed again in the DN and gene editing context using a single rather than dual gRNA approach. An additional multiple myeloma cell line, OPM2, was used for comparison with the previously used RPMI 8226 cell line shown in Figure 13. Consistent with previous results, inhibition of TGFβ signaling effectively maintained IFNγ production in the presence of excess TGFβ. This was observed in RPMI ( Fig.16A ) and OPM2( Fig. 16B ) cell lines.

[0505] The expression of CD25 was also analyzed in DN and gene-edited contexts using a single gRNA approach. Fig.17A ) and OPM2( Fig. 17B ) cell line in the presence of excess TGFβ maintained CD25 expression. Unexpectedly, CD25 expression was increased in DN and gene-edited cells relative to unmodified T cells.

[0506] PD-1 expression was similarly examined in DN and gene-edited settings. In the presence of excess TGFβ, inhibition of TGFβ signaling by either approach effectively prevented the increase in PD-1 expression ( Fig.18A and Fig.18B ).

[0507] Previous experiments used TGFβ at a set dose of 10 ng / ml for stimulation. To better understand how TGFBR2 gene editing affects TGFβ signaling under physiological conditions, 0 to 100 ng / ml of TGFβ was used. This range is based on previous work that showed that TGFβ serum levels ranged from about 3 to 88 ng / ml (Aref et al. Hematological Oncology. 35: 51-57. 2017) and were about 3 to 10 ng / ml in multiple myeloma bone marrow (Bruns et al. Blood. 120: 2620-2630. 2012). Cell proliferation assays were used to determine the relative expansion times of cells in the context of DN and gene editing. Anti-BCMA CAR T cells were co-cultured with RPMI 8226 cells at a ratio of 1: 1. Unexpectedly, positive effects on cell proliferation can be seen at concentrations as low as 0.1 ng / ml TGFβ, which is far below physiological levels in normal or cancer environments ( Fig.19A This responsiveness was further demonstrated by increased IFNγ production ( Fig.19B ).

[0508] The same range of TGFβ concentrations was used to analyze PD-1 expression on CD4+ and CD8+ CAR T cells. Again, the TGFBR2DN and gene-edited backgrounds were able to maintain low PD-1 expression levels down to 0.1 ng / ml TGFβ ( Fig. 20A and Fig. 20B ).

[0509] The DN TGFBR2 strategy was used to achieve cell proliferation, granzyme B expression, and Smad 2 / 3 phosphorylation in T cells transduced to express three different CARs. DN TGFBR2 was able to rescue the antiproliferative effects of excess TGFβ in the context of the tested CAR T cells. In the context of the tested CAR T cells, DN was able to maintain granzyme B expression in the presence of excess TGFβ. Finally, DN was able to effectively inhibit TGFβ signaling in the presence of excess TGFβ, as measured by reduced Smad 2 / 3 phosphorylation in the context of the tested CAR T cells ( Fig. 22 ). Data are shown for only one of the three CAR T cell backgrounds, however similar results were observed for the other two CAR T cell backgrounds.

[0510] Example 5 - BCMA CAR in vivo Transcriptional profiling of T cells.

[0511] In order for the TGFBR2 gene editing strategy disclosed herein to form an effective therapy, the TGFβ immunosuppressive pathway must be present in the in vivo environment. If the TGFβ immunosuppressive pathway is present, the TGFBR2 gene editing strategy must effectively release T cells from the TGFβ immunosuppressive effect. In order to solve these two problems, the transcriptional profile of anti-BCMA CAR T cells was analyzed according to the anti-BCMA CAR T cells isolated from the tumor microenvironment of mice. The xenograft model was generated by implanting multiple myeloma RPMI 8226 cells into mice and propagating / forming tumors for 21 days. After 21 days of incubation, wild-type anti-BCMA CAR T cells, AAVS gene editing controls, TGFBR2DN or TGFBR2 gene editing backgrounds were injected into tumor-bearing mice. Tumor regression was allowed for 14 days, and then tumor-infiltrating leukocytes (TILs) and CAR T cells were isolated from tumors and spleens (non-cancerous negative control tissues). After separation, the cells were subjected to RNAseq analysis to determine the gene expression profiles of members of the TGFβ signaling pathway.

[0512] Results from transcriptional profiling revealed that TGFBR2 gene editing in CAR T cells successfully restricted the expression of several TGFβ signaling pathway members in tumors undergoing TGFβ inhibitory signaling ( Fig.21 ).like Fig.21As shown, members of the TGFβ signaling pathway are upregulated in T cells expressing anti-BCMA CAR isolated from tumors but not spleens. The data indicate that T cells expressing anti-BCMA CAR are exposed to a tumor microenvironment (TME) rich in TGFβ. In addition, T cells expressing anti-BCMA CAR with TGFBR2 DN or TGFBR2 gene editing background reversed the upregulation of TGFβ signaling members. The data indicate that the TGFβ signaling pathway is effectively eliminated.

[0513] Example 6 - Selective advantages of TGFBR2 gene editing strategy.

[0514] To determine whether TGFBR2 gene-edited CAR T cells have a selective proliferation advantage, anti-BCMA CART cells were gene-edited to produce different insertion and deletion frequencies. These individual insertion and deletion % CAR T cell populations were co-cultured with RPMI 8226 cells at a 1:1 ratio for stimulation in the presence or absence of 10ng / ml TGFβ. The cells were evaluated approximately every 7 days using high-throughput sequencing to determine which portion of the cells were gene-edited and which portion remained wild-type ( Fig.23 ). Cells were restimulated weekly with fresh RPMI cells and readjusted to a 1:1 ratio. The results showed that in an immunostimulatory setting, TGFBR2 gene editing confers a selective proliferation advantage over wild-type cells (see Fig.24 ).

[0515] Incorporated by Reference

[0516] All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. In the event of a conflict, the present application, including any definitions herein, will control.

[0517] Equivalent

[0518] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation many equivalents to the specific embodiments described herein. Such equivalents are intended to be encompassed by the following claims.

Claims

1. A genome editing system for altering the transforming growth factor beta receptor II TGFBR2 gene in T cells, the genome editing system comprising: A gRNA comprising a targeting domain complementary to a target sequence of the TGFBR2 gene; and RNA-guided nucleases, The sequence of the targeting domain is a nucleotide sequence identical to the nucleotide sequence of SEQ ID NO: 5050.

2. The genome editing system of claim 1, wherein the targeting domain is configured to form a double-strand break or a single-strand break within 500bp, 450bp, 400bp, 350bp, 300bp, 250bp, 200bp, 150bp, 100bp, 50bp, 25bp, or 10bp of the TGFBR2 target position, thereby altering the TGFBR2 gene.

3. The genome editing system of claim 2, wherein the TGFBR2 gene expression is knocked out or knocked down.

4. The genome editing system of claim 1, wherein the gRNA targets the coding region of the TGFBR2 gene.

5. The genome editing system of claim 4, wherein the coding region is exon 5.

6. The genome editing system according to claim 1, wherein: The RNA-guided nuclease is the Streptococcus pyogenes Cas9 nuclease.

7. The genome editing system according to claim 6, wherein: The Streptococcus pyogenes Cas9 nuclease recognizes the protospacer adjacent motif PAM of NGG; and The genome editing system targets TGFBR2.

8. The genome editing system of claim 1, wherein the RNA-guided nuclease is Staphylococcus aureus Cas9 nuclease.

9. The genome editing system of claim 8, wherein the Staphylococcus aureus Cas9 nuclease recognizes the PAM of NNNRRT or NNNRRV and the genome editing system targets TGFBR2.

10. The genome editing system of claim 1, wherein the RNA-guided nuclease is a mutant Cas9 nuclease.

11. The genome editing system of claim 1, wherein the gRNA is a modular gRNA or a chimeric gRNA.

12. The genome editing system of claim 1, comprising two, three or four gRNAs.

13. The genome editing system of claim 1, wherein the T cells are from a subject suffering from cancer.

14. The genome editing system of claim 1, wherein the expression of TGFBR2 is reduced by 30% or more relative to a baseline measurement.

15. The genome editing system of claim 14, wherein the expression of TGFBR2 protein is determined by Western blotting or indirect intracellular staining flow cytometry.

16. The genome editing system of claim 1, wherein a frameshift mutation is introduced into the TGFBR2 gene.

17. A genome editing system for altering the transforming growth factor beta receptor II TGFBR2 gene in T cells, the genome editing system comprising: a first and a second gRNA, each comprising a targeting domain complementary to a target sequence of a transforming growth factor beta receptor II TGFBR2 gene; and RNA-guided nuclease, wherein the first gRNA has a targeting domain as described below, and the sequence of the targeting domain is a nucleotide sequence identical to the nucleotide sequence of SEQ ID NO: 5050.

18. A composition comprising the gRNA as defined in any one of claims 1 to 17.

19. A vector comprising a polynucleotide encoding the gRNA defined in any one of claims 1 to 17.

20. The vector according to claim 19, wherein the vector is a viral vector.

21. The vector according to claim 20, wherein the viral vector is an adeno-associated virus (AAV) vector or a lentivirus (LV) vector.

22. Use of the gene editing system of any one of claims 1-17, the composition of claim 18, or the vector of any one of claims 19-21 for preparing a drug for altering TGFBR2 gene expression in T cells, wherein use of the drug comprises administering the gene editing system, composition or vector to the T cells.

23. The use according to claim 22, wherein the alteration comprises knocking out the expression of the TGFBR2 gene or knocking down the expression of the TGFBR2 gene.

24. The use according to claim 22, wherein the cell is from a subject suffering from cancer.

25. The use according to claim 22, wherein the gRNA and the RNA-guided nuclease comprise a ribonucleoprotein (RNP) complex.

26. The use according to claim 25, comprising administering to the cell two or more RNP complexes comprising gRNAs with different targeting domains.

27. The use according to claim 25, wherein the RNP complex comprises an enzymatically active Cas9eaCas9 nuclease.

28. The use according to claim 27, wherein the RNP complex comprises an eaCas9 nuclease that forms a double-strand break in a target nucleic acid or forms a single-strand break in a target nucleic acid.

29. The use according to claim 26, wherein two RNP complexes comprising different gRNAs are used to form offset single-strand breaks in the TGFBR2 gene in the cell.

30. A T cell comprising the genome editing system according to any one of claims 1-17, the composition according to claim 18, or the vector according to any one of claims 19-21.

31. The cell of claim 30, wherein the cell expresses TGFBR2.

32. The cell of claim 31, wherein the T cell comprises an engineered T cell receptor eTCR or a chimeric antigen receptor CAR.

33. Use of engineered T cells in the preparation of a medicament for treating cancer in a subject, wherein the engineered T cells have reduced TGFBR2 expression and optionally express an engineered T cell receptor eTCR or a chimeric antigen receptor CAR, wherein the engineered T cells have an insertion or deletion introduced by the gene editing system of any one of claims 1-17, the composition of claim 18, or the vector of any one of claims 19-21 at or near the target position of the TGFBR2 gene, wherein the insertion or deletion frequency is greater than or equal to 30%.

34. The use according to claim 33, wherein the eTCR or CAR has antigen specificity for cancer cells.

35. The use according to claim 33, wherein the cancer is selected from: leukemia, lymphoma, multiple myeloma, epithelial cancer, glioblastoma, neuroblastoma, Ewing sarcoma, medulloblastoma, osteosarcoma, synovial sarcoma, mesothelioma and / or any cancer type expressing TGF-β.

36. The use according to claim 33, wherein the cancer is selected from chronic lymphocytic leukemia CLL, acute lymphoblastic leukemia ALL and acute myeloid leukemia.

37. The use according to claim 33, wherein the cancer is selected from non-Hodgkin's lymphoma and Hodgkin's lymphoma.

38. The use according to claim 33, wherein the cancer is selected from refractory follicular lymphoma, mantle cell lymphoma and indolent B-cell lymphoma.

39. The use according to claim 33, wherein the cancer is selected from B-cell malignancies, colon cancer, lung cancer, liver cancer, breast cancer, prostate cancer, ovarian cancer, skin cancer, bone cancer and brain cancer.

40. The use according to claim 33, wherein the cancer is selected from renal cell carcinoma, pancreatic adenocarcinoma, cervical cancer, melanoma and colorectal cancer.

41. The use according to claim 33, wherein the engineered T cells are CD4+ and / or CD8+ T cells.

42. The use according to claim 33, wherein the engineered T cells maintain or have enhanced lytic activity against target cancer cells relative to non-engineered T cells.

43. The use according to claim 33, wherein in the presence of TGFβ, the engineered T cells maintain or have increased expression of granzyme B and / or interferon gamma relative to non-engineered T cells.

44. The use according to claim 33, wherein the engineered T cells maintain or have improved persistence to repeated antigenic stimulation relative to non-engineered T cells.

45. The use of claim 33, wherein the engineered T cells maintain or have increased CD25 expression relative to non-engineered T cells.

46. ​​The use according to claim 33, wherein the engineered T cells maintain or have reduced PD-1 expression relative to non-engineered T cells.

47. The use of claim 33, wherein the engineered T cells maintain or have increased proliferation relative to non-engineered T cells.

Citation Information

Patent Citations

  • Process for isolating rubbers

    EP0002015A1

  • Artificial antigen presenting cells and methods of use thereof

    US20020131960A1

  • Re-activated T-cells for adoptive immunotherapy

    US20030170238A1

  • Method of controlling administration of cancer antigen

    US20130149337A1

  • Use of Chimeric Antigen Receptor-Modified T-Cells to Treat Cancer

    US20130287748A1